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Peanut-specific IgE is necessary but not sufficient to elicit allergic reactions to peanut. Oral food 
challenge, the gold-standard for the diagnosis of peanut allergy, is indicated when tests based on 
the presence of IgE are equivocal; however, this is resource-intensive and carries the risk of an 
allergic reaction.  
My aims were to improve the diagnosis of peanut allergy and our understanding of the 
discrepancy between the presence of IgE (i.e. allergic sensitisation) and clinical allergy to peanut. 
Peanut allergic, peanut-sensitised but tolerant and non-sensitised non-allergic subjects were 
studied. Participants underwent clinical evaluation, skin prick testing, blood collection for serology 
and basophil and mast cell assays and oral food challenge to peanut, if clinically indicated. 
The basophil activation test had 97% accuracy to diagnose peanut allergy and reduced the need 
for oral food challenges by 66%. It proved to be particularly useful in cases in which conventional 
allergy tests failed to diagnose peanut allergy. The basophil activation test also estimated the 
severity and the threshold of allergic reactions to peanut.  
Peanut allergic patients had higher levels of peanut-specific IgE and were more likely to have IgE 
to peanut major allergens. Peanut-sensitised but tolerant patients showed a predominance of 
IgG4 over IgE. Their plasma inhibited peanut-induced activation of mast cells and basophils in 
vitro similar to plasma from patients submitted to peanut oral immunotherapy. The role of IgG4 in 
the inhibition of peanut-induced effector cell activation was confirmed by depletion of IgG4 from 
plasma samples of tolerant patients sensitised to major peanut allergens, which would otherwise 
be predictors of peanut allergy. 
In conclusion, the basophil activation test reproduced in vitro the clinical phenotype of peanut-
sensitised patients. Characteristics of IgE and the presence of IgG4 and possibly other blocking 
antibodies are two non-mutually exclusive explanations for the discrepancy between peanut 
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Chapter 1  Introduction 
 
1.1 Food allergy 
Food allergy is part of a larger spectra of clinical entities designated food hypersensitivity or 
adverse reactions to foods
2, 3
. An adverse reaction to food is considered food allergy when it is 
mediated by the immune system. Food allergies are classified based on the involvement of IgE 
antibodies in its pathogenesis in: IgE mediated, mixed IgE and non-IgE mediated and non-IgE 
mediated food allergies (Figure 1.1). IgE-mediated food allergies are also designated "immediate-
type food allergies" as symptoms develop usually within minutes up to one hour following 
exposure to the food allergens. The manifestations of the other two types of food allergies (non-
IgE-mediated and mixed IgE and non-IgE mediated) usually develop more than 2 hours after 
allergen exposure and/or manifest chronically. Non-immunological adverse reactions to foods are 
also designated food intolerances and can have a diversity of underlying aetiologies, such as 
metabolic (e.g. lactose intolerance, fructose intolerance, galactosemia), pharmacologic (e.g. 
mediated by histamine, tiramine, caffeine or teobromin), toxic (e.g. gastroenteritis, scombroid food 
poisoning) or other (e.g. pancreatic insufficiency, biliary conditions, hyatal hernia, gustatory 
rhinitis, auriculo-temporal or Frey syndrome, blepharochalasis).  
 
Figure 1.1 Classification of adverse reactions to foods 
 
The clinical presentation of food allergy depends on the underlying mechanism, not only with 
respect to timing after allergen exposure, but also to the type of symptoms that typically develop. 
The clinical manifestations of immediate-type food allergies can affect all organs and systems, 
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including: the skin (for example, pruritus, erythema, acute urticaria, angioedema, contact 
urticaria), the gastrointestinal tract (for example, vomiting, diarrhoea, abdominal pain, mild oral 
symptoms such as oral pruritus), the respiratory tract (for example, rhinorrhoea, nasal obstruction, 
sneezing, sometimes accompanied by lacrimation and ocular pruritus, laryngeal oedema and 
wheezing) and the cardiovascular system (for example, paleness, hypotension, tachycardia and 
shock). The most severe clinical presentation of food allergy is anaphylaxis. Anaphylaxis is 
defined in the new guidelines of the European Academy of Allergy and Clinical Immunology as a 
"severe, potentially life-threatening systemic hypersensitivity reaction characterized by being rapid 
in onset with life-threatening airway, breathing, or circulatory problems and is usually, although 
not always, associated with skin and mucosal changes"
4
. 
Theoretically, any food can cause allergies but in practice a small group of foods is responsible 
for more than 90% of immediate-type food allergies
5
. In children, the most common food allergies 
are allergy to peanut, cow's milk, egg, wheat, soya, tree nuts and seeds, fish and shellfish. In 
adults, the most common food allergies are: peanut and tree nut allergies, fish and shellfish 
allergies and allergies to fresh fruits.  
 
1.2 Oral tolerance 
Food allergies can be seen as disruption in the physiological process of oral tolerance. 
Immunologically, oral tolerance is an antigen-specific suppression of cellular and humoral 
responses to dietary antigens following exposure in the gastrointestinal tract. It is thought to be 
determined by a combination of factors, including physical factors, antigen dose and timing, 




1.2.1 Definition of oral tolerance 
There is considerable fluidity in the definition of oral tolerance in the literature, especially in the 
context of food allergy. Clinically, oral tolerance can be defined as the ability to eat the food 
without developing immunologically mediated symptoms irrespective of the frequency and the 
quantity of food that is consumed. It is conceivable that such a stringent definition of tolerance can 
only occur once clonal deletion (i.e. programmed cell death of T cells) or anergy (i.e. failure to 
activate T cells) has happened, whereas ongoing active suppression of an immune response to 
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food, for example by regulatory T cells, may require intermittent antigen exposure and thus 
regular consumption of the implicated food to maintain oral tolerance, but this is still under debate.  
 
1.2.2 Immunological mechanisms of oral tolerance 
The mucosal response to protein antigens in early life is typically Th2-skewed and IgE to foods 
can develop both in atopic and non-atopic infants. In non-allergic children, this IgE response is 
typically transient and the Th2 response is counterbalanced by a Th1 response leading to 
tolerance. In mouse models, the exposure to a high dose of antigen, even as a single dose, via 
the oral route, induced oral tolerance as reflected by the absence of hypersensitivity responses, T 
cell proliferation, and cytokine and antibody production
7
. It is possible that a similar phenomenon 
happens in humans during weaning and that early oral exposure to high dose of allergens 
induces oral tolerance. This is currently being investigated in randomised controlled trials, namely 
the LEAP study
8
. Such abrogation of response could either result from the absence of immune 
response (anergy) or from programmed cell death (deletion) of reactive T cell clones. Whether T 
cell clone anergy or deletion occurs depends on whether the interaction between the TCR and the 
MHC-class II on antigen presenting cells occurs in the presence of Fas-Fas-ligand interaction or 
in the absence of co-stimulation. Low dose exposure to the antigen, especially if repeated, 
induces T regulatory cells, such as CD4+ CD25+ Foxp3+ naturally occurring Tregs (which exerts 
its suppressive action via cell to cell contact and via the production of TGF-β) and inducible or 
adaptive Tregs (TR1 which produce IL-10 and Th3 which produce TGF-β). Cytokines produced by 
Tregs can influence B cells and lead to the production of IgG4 (induced by IL-10) and IgA 
(induced by TGF-β). Antibodies of an isotype other than IgE, such as IgG4 and IgA, can 
counteract the function of IgE either by competing for binding to the allergen or by intracellular 
inhibitory signalling possibly resulting from co-cross-linking of the FcεRI with ITIM-associated 
receptors such as FcγRIIB or FcαRI. Microbial stimulation provided by the enteric flora through 
innate immune receptors is critical for the development and organisation of mucosal and 
secondary gut-associated lymphoid tissue
9
 and may play an important role in the modulation of 
the immune response leading to oral tolerance.  
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1.3 Epidemiology of peanut allergy 
Food allergy affects about 8% of children and 2% of adults in Western countries. Reported food 
allergy is more common than food allergy diagnosed based on allergy tests alone, which in turn is 
more common than food allergy confirmed by oral food challenge. The overall prevalence of food 
allergy in children and adults has been estimated to affect about 12-13% of patients if only 
reported allergy is considered and about 3% of subjects if only challenge-proven food allergy is 
considered. The prevalence of food allergy is thought to be increasing and this is best described 
for peanut allergy
10, 11
. Apart from the recent increase in the prevalence of food allergy,  there has 
also been a change in the clinical spectra of this condition with food allergies manifesting from a 
very early age, to multiple unrelated foods, with severe manifestations, including anaphylaxis, and 
with persistence of the allergy until later in life
12
.  
Peanut allergy is one the most common food allergies in developed countries, particularly in the 
United Kingdom, the United States and Australia, where its prevalence ranges from 1 to 3%
11, 13-
15
. The prevalence of peanut allergy seems to be increasing. Although a report from birth cohort 
studies performed in the Isle of Wight suggested a recent stabilisation in the prevalence of peanut 
allergy, with 0.5% of 4-year-olds being affected in 1996, 1.4% of 3-year-olds being affected in 
2002 and 1.2% of 3-year-olds being affected in 2008
16
, recent figures from the Healthnuts study 
performed in Australia reported the highest prevalence of challenge-proven peanut allergy at 3% 
in 12-months old infants
15
, which suggests an increase in the prevalence of peanut allergy in the 
younger generations.  
The increase in the hospitalization rates for peanut-induced anaphylaxis seems to follow the 
increase in the prevalence of peanut allergy
17
. In a retrospective study performed in the United 
States using the New York State hospitalisation database between 1990 and 2006
17
, food 
anaphylaxis was the most frequent (67.4%) reason for anaphylaxis admissions after 1993, with 
peanut anaphylaxis constituting the largest proportion of cases (28.9% in 2006). The number of 
cases of peanut anaphylaxis increased more than the other food groups over time, with a 9-fold 
increase in the number of admissions from 1990 to 2006. Also in the United Kingdom, the number 
of hospital admissions for food-induced anaphylaxis from 1998 to 2012 has increased about 
106% overall and 137% in the age group from 0 to 14 years old
18
. Although the increase in the 
hospital admissions has fortunately not translated into increase in food anaphylaxis fatalities, 




1.4 The impact of peanut allergy 
Peanut allergy affects children at a very young age, with up to 80% of cases presenting after their 
first known exposure to peanut
21
. It is usually persistent, resolving for only 20% of young children 
by school age
22
. Peanut allergy is often responsible for severe allergic reactions and for a great 
proportion of food anaphylaxis fatalities
20
, being the commonest cause of life-threatening 
anaphylaxis in childhood
13, 23
. Patients can have a severe reaction on the first time they consume 
peanut
24
. Oral food challenges, the gold-standard for the diagnosis of peanut allergy, can also 
cause severe reactions in a significant proportion of cases
25
. 
There is no curative treatment for peanut allergy and the mainstay of its management currently is 
strict avoidance of peanut-containing foods and the implementation of an emergency plan to treat 
accidental allergic reactions, which includes adrenaline auto-injectors in the severe cases. Since 
peanut is a ubiquitous food and affected patients often react to small doses, avoidance is difficult 
and accidental allergic reactions are common26, 27. Therefore, peanut allergic children and their 
families and carers experience a poorer quality of life due to food and social restrictions and to the 
potentially life-threatening nature of this allergy
28
. The quality of life of children with peanut allergy 
has been found to be more impaired than the quality of life of children with insulin-dependent 
diabetes
29
, for example. Recent studies suggest that peanut allergy can also have a significant 
psychological impact on the lives of the patients and their families with fear of eating, anti-social 




1.5 Peanut allergens 
Twelve different allergens have been identified in peanut (Table 1.1). Ara h 1
31
, Ara h 2
32
 and Ara 
h 3
33
 are peanut major allergens. These 3 storage proteins are stable to temperature, acidity and 
proteolytic digestion and thus are potent allergens, able to induce primary allergic responses to 
peanut and severe systemic symptoms in allergic individuals. Ara h 4, previously registered as a 
separate allergen, is currently considered an isoform of Ara h 3 and has been renamed to Ara h 
3.02. Belonging to the same protein family as Ara h 2, Ara h 6 and Ara h 7 are also considered 
“true peanut allergens” and particularly Ara h 6 has been reported as being able to cause severe 
systemic allergic reactions and as being a major allergen in populations of peanut allergic patients 
in Europe
32, 34-36
. On the contrary, Ara h 5, a profilin
32




involved in pollen-food syndromes due to cross-reactivity of antibodies primarily directed to pollen 
allergens, such as grass pollen profilin and birch pollen Bet v 1 respectively, but are not usually 
responsible for systemic allergic reactions to peanut. Ara h 9, a lipid transfer protein, appears to 
have different clinical relevance depending on the geographical location, eliciting systemic 
reactions in Southern European countries
38-40
. Ara h 10 and Ara h 11 are oleosins
41
, which are 
hydrophobic proteins intimately related to lipid structures and can cause severe allergic reactions. 
Finally, Ara h 12 and Ara h 13 are defensins and are also very stable proteins.  
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Table 1.1 Peanut allergens grouped by protein family.                                                                              
Abbreviations: MW, molecular weight; pI, isoelectric point; PR, pathogenesis related protein. 
Protein Family Allergens     MW (KDa) pI 
Cupin 
(Vicillin-type, 7S globulin) 
Ara h 1.0101 68.8 6.4 
Cupin 
(Legumin-type, 11S globulin) 
Ara h 3.0101 58.3 5.7 
Ara h 3.0201 61.0 5.5 
Conglutin 
(2S albumin) 
Ara h 2.0101 18.0 5.5 
Ara h 2.0201 17.7 5.3 
Ara h 6.0101 14.8 5.5 
Ara h 7.0101 16.3 5.6 
Ara h 7.0201 17.4 7.5 
Profilin Ara h 5.0101 14.1 4.6 
PR-10 
Ara h 8.0101 17.0 5.0 
Ara h 8.0201 16.4 5.1 
Nonspecific Lipid-transfer protein 1 
Ara h 9.0101 9.1 9.5 
Ara h 9.0201 9.1 9.3 
Oleosin 
Ara h 10.0101 17.8 9.6 
Ara h 10.0201 15.5 9.4 
Ara h 11.0101 14.3 10.1 
Defensin 
Ara h 12.0101 7.9 7.7 




Ara h 1, Ara h 2, Ara h 3 and Ara h 6 are the allergens most commonly recognised by peanut 
allergic patients’ IgE, except for Southern European countries, such as Spain, where Ara h 9 
gains more importance
35, 39, 42
. Ara h 2 has shown to be the best discriminator of peanut allergic 
patients
43-45





1.6 Immunologic mechanisms of peanut allergy 
The immunologic mechanism underlying peanut allergy is type I hypersensitivity. Following 
allergic sensitisation, where peanut allergens are presented to T cells and a Th2-skewed immune 
response commits B cells to IgE production, peanut-specific IgE binds to the high affinity IgE 
receptors (FcRI) on the surface of mast cells and basophils. In allergic individuals, on 
subsequent exposure to peanut, multivalent allergens bind to receptor-bound allergen-specific IgE 
on the surface of mast cells and basophils which leads to cross-linking of IgE molecules and 
aggregation of FcεRI receptors. These initiate complex intracellular signalling cascades which 
culminate in mast cell and basophil activation and degranulation with the release of pre-formed 
mediators and de novo synthesis of leukotrienes and cytokines, all of which contribute to allergic 





1.6.1 Intracellular signalling cascade 
Following IgE cross-linking by allergen, the signalling cascade downstream of FcεRI
50-55
 starts 
with activation of Lyn, possibly due to de-phosphorylation of its regulatory site by tyrosine 
phosphatase CD45. Activated Lyn phosphorylates tyrosine residues of the immunoreceptor 
tyrosine-based activation motifs (ITAMs) of the β and γ chains of FcεRI. Phosphorylated ITAMs 
serve as docking sites for spleen tyrosine kinase (Syk). Activation of Syk leads to auto-
phosphorylation and phosphorylation of downstream proteins, such as the linker for activation of T 
cells (LAT), Bruton's tyrosine kinase (BTK) and the phosphoinositide 3-kinase (PI3K) pathway 
(Figure 1.2). Activated phospholipase C hydrolyses phosphatidylinositol 4,5-biphosphate (PIP2) 
present in the plasma membrane to produce second messengers, including inositol triphosphate 
(IP3), which leads to an increase in intracellular calcium, and DAG, which activates protein kinase 
C (PKC). A number of other intracellular signals are thought to play a role in subsequent events, 
namely: activation of small GTPases (e.g. Rac, Ras and Rho) leading to activation of extracellular 
signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and p38-mitogen-activated protein 
kinase (p38-MAPK), which function as mediators between the cytosol and the nucleus and 
regulate transcription factors; granular fusion and release of mediators; activation of calcineurin, 
which de-phosphorylates nuclear factor of activated T-cells (NFAT) leading to the transcription of 
cytokine genes; phosphorylation and degradation of the inhibitor iKB, which leads to the release 
34 
and nuclear translocation of NF-KB (nuclear-factor kB) proteins and consequent transcription of 
pro-inflammatory mediators; and, finally, PKC and MAPK action on phospholipase A2 which 
releases arachidonic acid and leads to prostaglandin and leukotriene production.  
FcεRI receptor aggregation also activates negative regulators which limit the intensity and 
duration of positive signals
56-59
. For example, SH2-containing inositol 5-phosphatase (SHIP) is 
recruited to the plasma membrane and hydrolyses PIP3 products, the main activator of PI3K 
signalling. SH2-containing protein tyrosine phosphatases, SHP-1 and SHP-2, de-phosphorylate 
other signalling molecules such as tyrosine kinases.   
 
 
Figure 1.2 Simplified schematic representation of the signalling cascade downstream the high-affinity IgE 
receptor, FcεRI.  
FcεRI is composed of 4 chains: one α chain, one β chain and two γ chains. An allergen cross-linking two IgE molecules, 
with their Fab and Fc regions, are represented. Syk, spleen tyrosine kinase; PI3K, Phosphoinositide 3-kinase; PLC, 
phospholipase C; DAG, diacylglycerol; IP3,  inositol triphosphate; PKC, Protein kinase C; ERK, extracellular signal-
regulated kinases; MAPK, mitogen-activated protein kinases; JNK, c-Jun N-terminal kinase; NFAT, Nuclear factor of 
activated T-cells; NFkB, nuclear-factor kB; SHIP, SH2-containing inositol 5-phosphatase; SHP, SH2-containing protein 




1.6.2 Activation and mediator release by basophils and mast cells 
Mast cells and basophils can differ in the substances that can elicit cell activation and in the 




Table 1.2 Examples of stimulants of and mediators released by basophils and by mast cells.  
*Catepsin G exists in mast cells localised to the skin, submucosae, perivascular tissue and conjunctiva (MCTC) but not in 
alveolar or epithelial mast cells (MCT). Abbreviations: fMLP, formyl-methionyl-leucyl-phenylalanine; PAF, platelet 
activating factor; LT, leukotrien; PG, prostaglandin; IL, interleukin; TNF, tumour necrosis factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; MCP-1, monocyte chemoattractant protein-1; MIP-1, macrophage inflammatory 
protein. 
 Basophils  Mast cells 
Stimulants 




 Ionomycin  
 IgE cross-linking 
 (allergens, anti-IgE) 
 Morphine and codeine 










 Chondroitin sulphate 
 Heparin 
 Chymase 
 Carboxipeptidase A3  









 IL-4, IL-13 
 IL-5, IL-6, IL-8, IL-16, TNF-α, 
GM-CSF, MCP-1, MIP-1-α 
 
 
1.7 The basophil activation test 
IgE-mediated allergic reactions can be reproduced in vitro using mast cells and basophils. 
Basophils have the advantage of being easily available as they can be readily isolated from 
peripheral blood. Traditionally, functional in vitro tests based on allergen-induced activation of 
IgE-bearing mast cells and basophils were based on the measurement of mediators released by 




during degranulation, together with the release of vasoactive mediators, basophils up-regulate the 
expression of different activation markers on their surface - Figure 1.3. The expression of these 
markers, particularly of CD63, correlates with histamine release
62, 63
.  
The basophil activation test (BAT) is a flow cytometry-based assay where the expression of 
activation markers is measured on the surface of basophils following stimulation with allergen
60, 64
. 
A positive basophil activation test can be seen as an in vitro surrogate of an acute allergic 
reaction in vivo. In a study of patients allergic to hymenoptera venom, up-regulation of basophil 
activation markers was observed both in vitro following stimulation with yellow jacket or honey 
bee venom and in vivo following a positive sting challenge. In the same study, there was a 
general agreement between the clinical presentation (systemic reaction versus large local 
reaction) and the results of BAT, suggesting that the BAT is a potential biomarker of anaphylaxis.   
 
 
Figure 1.3 Basophil activation markers  
Basophil activation markers seem to form two distinct groups that are up-regulated concomitantly: CD63, CD107a and 
CD107b (in yellow) and CD203c, CD13 and CD164 (in blue). Abbreviations: ITAM, immunoreceptor tyrosine-based 
activation motif 
 
1.7.1 Basophil identification markers 
Different cell-surface markers can be used to identify basophils in whole blood, including IgE, 
CD123, CCR3, CRTH2, or CD203c
64




Table 1.3 Basophil identification markers 
Marker IgE CD123 CCR3 CRTH2 CD203c 
































































 HLA-DR is expressed on monocytes and dendritic cells allowing the distinction from basophils and eosinophils. The latter 
two types of cells have different size and granularity and can thus be distinguished using forward scatter and side scatter 
characteristics.  
2
CD3 is expressed on T cells and therefore allows the exclusion of this cell type when using CCR3 or CRTH2. The 
distinction between basophils and eosinophils can be done by size and granularity using forward scatter and side scatter.  
3
CD203c is specific for basophils and therefore can be used to identify basophils without other markers.  
Abbreviations: CCR3, C-C chemokine receptor type 3; CRTH2, chemoattractant receptor-homologous molecule 




In peripheral blood, IgE is detected on basophils, dendritic cells, eosinophils, monocytes, 
macrophages, B cells and platelets. The expression of IgE on the surface of basophils varies with 
the atopic status, being higher in atopic individuals. Labelling basophils with an anti-IgE antibody 
can activate the cells. This undesired effect can be reduced by fixing, cooling and adding EDTA-
containing buffer to the cells before staining.  
38 
CD123 is the low affinity (α) subunit of the IL-3 receptor. It is expressed in high levels on 
plasmacytoid dendritic cells and basophils and in low levels on monocytes, eosinophils, myeloid 
dendritic cells and subsets of haematologic progenitor cells. Additional staining with HLA-DR 
discriminates between HLA-DR-negative basophils and HLA-DR-positive dendritic cells and 
monocytes. One of the advantages of identifying basophils with CD123 and HLA-DR is that their 
expression is not influenced by the allergic status of the donor.  
CCR3 is the receptor for C-C type chemokines (e.g. eotaxin, MCP and RANTES). It is highly 
expressed on basophils and eosinophils but also on Th1 and Th2 cells. Thus, an anti-CD3 marker 
should be used in combination with CCR3 to exclude the CD3 positive T cells. Side scatter allows 
distinguishing basophils from eosinophils. Haussmann et al
66
 have compared the mentioned three 
basophil identification methods (IgE, CD123/HLA-DR and CCR3) and showed that CD123/HLA-
DR and CCR3 are the most reliable. CCR3 has the advantages of being stable with the atopic 
background of the patient and of allowing the identification of basophils with a single marker; 
however, CCR3 has the disadvantage of being down-regulated after basophil activation
66
.   
CRTH2 is another marker that is expressed by basophils, eosinophils and T cells, and thus 
requires a T cell marker, such as CD3, to distinguish basophils from T cells. CD203c is 
constitutively and specifically expressed on basophils and therefore can be used as a single 
identification marker.  
 
1.7.2 Basophil activation markers 







(Table 1.4). CD63 is a lysosomal-
associated membrane protein (LAMP), which is not expressed on the surface of resting basophils 
but only on the membrane of the granules inside the cells
62
. When the granules fuse with the 
plasmatic membrane of the basophils during degranulation, CD63 becomes expressed on the 
surface of basophils
68
. CD203c is an enzyme that cleaves phosphodiester and phosphosulphate 
bonds, hydrolytically removing 5'-nucleotides successively from the 3'-hydroxy-termini of 
oligonucleotides. It is exclusively and constitutively expressed in low levels on the surface of 
basophils and mast cells and its expression increases with cell activation.  
39 
Table 1.4 Main basophil activation markers.  
Abbreviation: LAMP, lysosomal associated membrane protein. 
 
Basophil activation markers seem to form two distinct groups of markers that are up-regulated 
concomitantly: one including CD63, CD107a and CD107b and another including CD203c, CD13 
and CD164
65 
(Figure 1.3). These markers behave differently in their up-regulation profiles
69, 70
. 
The increase in their expression in response to specific activators and inhibitors follows different 
kinetics and seems to be directed through distinct signal transduction pathways. For example, 
Marker CD203c CD63 
Synonym 
neural cell surface differentiation 
antigen 
gp53, lysosomal associated 








glycosylated type II 
transmembrane molecule 
secretory granule-associated 






exclusively and constitutively 
expressed on basophils 
basophils, neutrophils, 






can also be used as an 
identification marker 
anchored to the intracellular 
granules and barely expressed 





levels of CD203c rapidly increase 
 
unimodal expression 
up-regulated on the surface as 
a result of fusion between the 
granule and the plasma 
membrane 
bimodal expression 










CD203c is expressed in resting basophils that have not been primed with IL-3 and increases after 
activation in the whole basophil population, whereas CD63 is not expressed in resting cells and its 
up-regulation is bimodal, with only a subgroup of basophils expressing it. The expression of 
CD203c is higher on the surface of basophils of atopic when compared with non-atopic patients 
and also in patients with chronic urticaria
71
. This in vivo priming reflects ongoing basophil 
activation. Interestingly, basal expression of CD203c has shown to be increased in patients with 
uncontrolled asthma and frequent asthma exacerbations
72
. Dose-response curves with different 
agonists and inhibitors show dissociation between the two activation markers: CD203c is 
associated with the low-dose events of chemotaxis and CD63 is associated with degranulation
65
. 
Different studies have suggested that CD63 may reflect anaphylactic degranulation whereas 
CD203c may reflect piecemeal degranulation. MacGlashan
73
 hypothesised that this may be the 
reason why neither CD203c nor CD63 strictly reflect the exact amount of histamine released. 
Histamine release measured in the cell supernatant is an average of what occurs in a 
heterogeneous population of basophils, being a result of the sum between the two pathways of 
basophil activation. This reflects an advantage of using flow cytometry to study basophil activation 
compared to measuring histamine release as it gives more complete and detailed information 
about the behaviour of individual cells following stimulation with allergen.  
 
1.7.3 Practical aspects of the basophil activation test 
The laboratory procedure of the BAT consists of three stages: cell stimulation, cell staining and 
flow cytometry. The primary source of cells is preferentially whole blood, but dextran- or Ficoll-
isolated leukocytes can also be used. When collecting the blood for BAT, a syringe or tube 
containing anticoagulant should be used and the anticoagulant can vary depending on the 
adopted laboratory protocol. Blood should be processed as soon as possible, after blood 
collection, but studies have been performed with samples stored at +4ºC up to 24h
74
. A volume of 
75 to 250µl of whole blood is used per condition with equal volume of the stimulants. Crude 
allergen extracts or purified or recombinant allergens may be used for cell stimulation. Different 
allergen concentrations should be tested, as the sensitivity of the basophils to specific allergen 
stimulation varies among patients. With regards to the positive controls, anti-IgE or anti-FcɛRI are 
used to test the integrity of the IgE-mediated pathway and formyl-methionyl-leucyl-phenylalanine 
(fMLP), a chemotactic agent, to test for the ability of basophils to degranulate through an IgE-
41 
independent mechanism. As a negative control, cells are stimulated with stimulation buffer alone. 
A short incubation with IL-3 may increase the sensitivity of the assay and has been used in some 
studies
75
. IL-3 increases the expression of CD203c but not CD63; however, it may cause false 
positive results
76
. If IL-3 is used, a negative control with IL-3 in stimulation buffer should be added 
to the experimental plan.  
 
1.7.4 Expressing the results of the basophil activation test 
The results of BAT can be determined in terms of percentage of basophils expressing the defined 
activation marker or in terms of mean fluorescence intensity (MFI) by calculating the stimulation 
index, i.e. the ratio between the MFI of the selected condition and the MFI of the negative control. 
The former is usually used for CD63 as CD63 is not expressed in resting cells and its expression 
after activation is bimodal. The latter is usually used for CD203c which is already expressed in 
resting cells and its increase following allergen stimulation is unimodal (Figure 1.4).   
42 
 
Figure 1.4 Dot plots and histograms showing the expression of CD63 and CD203c on the surface of 
basophils in different conditions.  
Unstimulated cells (negative control) and cells stimulated with peanut or with anti-IgE are represented. The expression of 
CD63 is represented as the percentage of positive basophils (left panel) and the expression of CD203c is represented as 
the stimulation index (SI), i.e. the ratio of the mean fluorescence intensity of stimulated cells and the negative control (right 
panel). 
 
In allergic patients, allergen-induced basophil activation typically results in a bell-shaped dose-
response curve, with increasing concentrations of the allergen (usually 5 to 6 log difference) 
leading to a progressive increase in the expression of the basophil activation markers until 
reaching a plateau - Figure 1.5. Sub and supra-optimal concentrations can be identified in the 
dose-response curve. In the example given in Figure 1.5, for the dose-response coloured in blue 
100 ng/ml is the optimal concentration of peanut extract and 10 ng/ml and 1000 ng/ml are the 
sub-optimal and the supra-optimal concentrations, respectively. 
43 
 
Figure 1.5 Basophil reactivity and basophil sensitivity.  
Two examples of dose-response curves of basophil activation following stimulation with various concentrations of allergen 
are represented. The proportion of CD63+ positive cells is a measure of basophil reactivity and EC50, the effective 
concentration at 50% of the maximal activation, is a measure of basophil sensitivity. 
 
There is a large degree of variability in the basophil response to allergen between individuals 
(Figure 1.5). In order to express this heterogeneity and to compare basophil responses between 
different patients, various parameters can be determined based on the dose-response curve, 
such as CD-max and EC50 or CDsens. CD-max is the maximal activation and corresponds to the 
maximum proportion of activated basophils at any concentration of allergen. EC50 is the effective 
dose at 50% of the maximal activation, i.e. 50% effective dose, and can also be represented as 
CDsens. First described by Johansson
77
, CDsens is the inverse of the half-maximal effective 
concentration, i.e. the concentration at which basophil activation is half of the maximum 
activation, times 100 and can be calculated using the formula: CDsens=1/EC50x100.  
CDmax and CDsens are measures of basophil reactivity and of basophil sensitivity, respectively. 
Basophil reactivity can be defined as the degree of basophil activation, i.e. the proportion of 
activated basophils, and can also be measured as the percentage of CD63-positive basophils at 
different allergen concentrations or as the ratio of the percentage of CD63-positive after 
stimulation with allergen and with anti-IgE. Basophil sensitivity refers to the concentration of 
allergen at which basophils become activated and can be expressed as a percentage of the 
maximal effective dose (e.g. EC5, EC10) apart from EC50 and CDsens, previously mentioned. Figure 
44 
1.5 represents the basophil response of two different individuals, one with higher basophil 
reactivity and sensitivity (blue) and the other with lower basophil reactivity and sensitivity (red), i.e. 
responding to higher concentrations of the allergen with a smaller proportion of basophils 
becoming activated. Shreffler and Patil
78
 have recently proposed a novel parameter to measure 
basophil responses, the area under the dose-response curve, which has the advantage of 
combining basophil reactivity and basophil sensitivity. 
 
1.7.5 Non-responder basophils 
In about 5-20% of individuals, basophils do not respond to allergen or to any IgE-mediated 
stimulants but only to non-IgE-mediated stimulants, such as fMLP - these are the so-called "non-
responders". In terms of assessing the individual's response to the allergen for diagnostic 
purposes, in such patients the result of BAT is uninterpretable. From an immunologic perspective, 
the non-responder phenotype raises fascinating questions, namely whether this phenomenon 
could explain the absence of clinical symptoms in sensitised individuals. Although the expression 
of FcεRI, the amount of IgE bound to FcεRI, the structure of FcεRI and their ability to aggregate 
following IgE cross-linking seems to be conserved, there is no increase in intracellular calcium 
and no release of pre-formed or any other type of mediators from non-responder basophils
79
. 
Defects in Syk, which is present in the early phase of the intracellular signalling pathway leading 
to basophil degranulation, have been described in these individuals
79-81
. Interestingly, deficiency 
in Syk does not seem to be present in other types of leukocytes (including B cells, eosinophils, 
and neutrophils) from the same donors. mRNA levels of Syk are similar between responders and 
non-responders, suggesting a translational or a post-translational mechanism. Furthermore, this 
Syk deficiency seems to be reversible following culture of basophils in the presence of IL-3
80
. 
Unravelling the mechanisms by which non-responder basophils do not become activated 
following exposure to allergen to which the patient is sensitised to may lead to potential novel 
treatments for allergic disease.  
 
1.7.6 Assessing basophil intracellular signalling using flow cytometry 
The molecular mechanisms governing basophil activation are complex and not completely 
understood. Traditionally, analysis of cell signalling has been performed using western blot and 
45 
ELISA techniques, whose results are an average of the total cell population, which can be 
heterogeneous
56
. Recently, a proof of concept study demonstrated that flow cytometry can be 
used to quantify phosphorylation of p38-MAPK in basophils at the same time that the expression 
of basophil activation markers is evaluated on the surface
82
. Similar methods may be used to 
evaluate consecutive phosphorylation of other proteins involved in the signalling cascade, similar 
to what has been done for other cell signalling pathways
83
.  
Flow cytometry offers advantages over the traditional techniques. It allows identification of cells 
with heterogeneity in response to activation, it combines surface with intracellular staining and 
integrates immunophenotyping of individual cells. Flow cytometry enables the study of cells in 
their natural environment, avoiding basophil purification and potential interference from additional 
manipulations. Furthermore, flow cytometry significantly shortens the time of analysis from days 
to hours and reduces the sampling volume considerably, rendering it more accessible for clinical 
and research applications. This is particularly important in young children, from whom limited 
volume of blood can be collected. 
 
1.8 Allergic sensitisation and clinical allergy 
Sensitisation is the first stage of the development of IgE-mediated food allergy. Clinically, it is 
demonstrated by a positive skin prick test (SPT) or detectable allergen-specific IgE antibodies in 
the serum. However, allergic sensitisation does not always lead to clinical allergy. In fact, the 
majority of individuals with detectable food-specific IgE do not develop any allergic symptoms 
when consuming the food
8, 43
. In other words, allergen-specific IgE is necessary but not sufficient 
for the development of immediate-type food allergy.  
 
1.8.1 Phenotypes of allergic sensitisation 
There are different phenotypes of food tolerant children. Firstly, there are tolerant children with no 
IgE to foods (i.e. no allergic sensitisation) and these account for the majority of individuals in the 
general population. For example, in the Healthnuts study, in a population of 5300 infants, 80% 
had no IgE antibodies to peanut, sesame, egg or cow's milk and were tolerant to all foods 
tested
84
.  Non-sensitised non-allergic patients have variable levels of IgG and lymphocyte 
46 
proliferative responses to the food in question. Some individuals will develop IgE to foods but only 
a minority of these will develop food allergy. In other words, IgE sensitisation is more common 
than clinical food allergy
15, 43
. Thus, there are phenotypes of clinically tolerant children who 
paradoxically show evidence of allergic sensitisation to the food in the absence of clinical 
reactivity. In this group, five subgroups can be recognised: antenatal sensitisation; stable 
sensitisation; pre-allergic sensitisation; post-allergic sensitisation; and desensitisation (Table 1.5). 
It is possible that different phenotypes of allergic sensitisation have different underlying 
immunological mechanisms and that in some phenotypes different mechanisms coexist.  
 
Table 1.5 Clinical phenotypes of allergic sensitisation.  
Clinical phenotypes of allergic sensitisation 
 Antenatal sensitisation 
 Stable sensitisation 
 Pre-allergic sensitisation 




Allergic sensitisation may develop in utero and be present at birth. Studies have shown detection 
of allergen-specific IgE in cord blood to various antigens. Antenatal IgE can be of maternal origin 
or less commonly of foetal origin
85, 86
. It is unclear whether IgE sensitisation persists through 
childhood. The clinical relevance of prenatal IgE and a mechanism relating it to the development 
of allergy are unclear
87
.  
In the majority of cases, IgE develops post-natally
85, 87, 88
. In the case of stable sensitisation, 
children can develop IgE for many years and never develop symptoms of allergy. This is best 
described in respiratory allergy and has also been reported in food allergy
89-91
. IgE sensitised 
patients who never develop allergic symptoms following food allergen exposure during their life-
time may have IgE antibodies of different specificity. For example, some clinically irrelevant 
sensitisation to foods may be secondary to the development of pollen allergy and the cross-
reactivity of IgE antibodies. In a recently published study performed in the Isle of Wight
92
, the high 
prevalence of peanut sensitisation at 18 years of age that was not accompanied by a 
47 
corresponding increase in peanut allergy was due to the development of grass or tree pollen 
allergy and sensitisation to the profilin Ara h 5 or the Bet v 1-homologue Ara h 8 (Table 1.1). 
Other patients may be sensitised to "true food allergens" but IgE binds to a different part of the 
allergen that is clinically irrelevant as it is not able to induce effector cell activation and clinical 
symptoms. Furthermore, IgE can be of lower affinity (i.e. strength of antibody binding to the 
allergen) compared with the IgE antibodies of patients who are sensitised and develop allergic 
symptoms. An additional explanation for the absence of allergic symptoms in IgE sensitised 
individuals is the presence of blocking antibodies that could competitively inhibit the function of 
IgE, such as IgG4
93
.  
Latent sensitisation has been described where IgE antibodies to foods are present in clinically 
non-reactive patients who subsequently become allergic to that specific food - this can be called 
pre-allergic sensitisation. A number of studies have evaluated the prospective association 
between asymptomatic allergen sensitisation and the later development of allergic symptoms in 
children and adults. For example, in the LISA birth cohort, about 10% of children sensitised to 
foods at the age of 2 years developed new-onset food allergy at 6 years and early food 
sensitisation was identified as a strong risk factor for food allergy at the age of 6 (OR= 4.7; 95%CI 
2.0-11.2)
91
. In another birth cohort study, early sensitisation to foods was a strong predictor of the 
later development of allergic disease, including allergic rhinitis and asthma
94
.In sensitised patients 
who become allergic later in life there may be an increase in the levels and a modification of the 
qualitative features of IgE, namely the development of additional IgE specificities, i.e. the 
progressive appearance of IgE binding one part of the allergen to IgE binding additional parts of 
the allergens (so-called "epitope spreading"), and the increase in the affinity of antibody for the 
allergens, as a result of somatic hypermutation
90
.  
Food allergy can spontaneously resolve. Depending on the allergen, food allergy can be outgrown 
in childhood (common in children with cow’s milk or egg allergy) 
95-99
 or tend to persist into 
adulthood (common in patients with peanut and tree nut allergies) 
97, 100
. Although the acquisition 
of tolerance is usually preceded by a decrease in food-specific IgE levels, IgE can remain 
detectable after oral tolerance is established - this can be designated post-allergic 
sensitisation. The typical decrease in food-specific IgE levels that accompanies the resolution of 
food allergies is used in clinic as an indicator of when to perform oral food challenges to assess 
the acquisition of tolerance
101
. The decrease in food-specific IgE is often accompanied by an 
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increase in allergen-specific IgG antibodies, in particular of the IgG4 isotype
102, 103
.In patients who 
outgrow their food allergy, possible underlying mechanisms include: reduced T cell proliferation 
and elimination of reactive T cell clones, a change in the IgE epitope recognition pattern and/or 
IgE affinity, and the induction of regulatory T cells leading to the production of blocking antibodies 
such as IgG4 that are able to interfere with IgE and to inhibit allergen-induced activation of 
basophils and mast cells, reducing cell reactivity. Allergen-specific basophil suppression can also 
be a consequence of the changes in the characteristics of IgE. Some of these mechanisms have 
been described in patients who are in the process of outgrowing milk and egg allergy and tolerate 




In patients submitted to allergen-specific immunotherapy, such as subcutaneous immunotherapy 
to respiratory allergens
108, 109
 and oral or sublingual immunotherapy to foods
110-114
a transient 
increase is followed by a decrease in allergen-specific IgE levels
110, 111
 - so called 
“desensitisation". The decrease in allergen-specific IgE is usually accompanied by an increase 
in IgG4, IgG1 and IgA antibodies. Unfortunately, for the majority of patients desensitisation is 
transient and only lasts for a few years
115
. The typical clinical outcome of allergen-specific 
immunotherapy to date has been an increase in the threshold of reactivity rather than the 
establishment of absolute long-term tolerance. It is debatable whether this should be designated 
oral tolerance or transient desensitisation. In allergic patients submitted to oral immunotherapy 
(OIT) to egg or peanut, after cessation of treatment, within weeks or months, clinical improvement 
is often lost
111, 116, 117
. In contrast, in children with post-allergic sensitisation, who have outgrown 
their food allergy, it is extremely unusual for the symptoms to recur. The clinical effects of 
immunotherapy may result from the direct effect of low dose continuous exposure to the allergen 
on mast cells and basophils (which can result in the activation of inhibitory intracellular signalling 
molecules such as SHIP followed by progressive loss of activatory intracellular signalling 
molecules such as Syk and loss of the high affinity IgE receptor FcεRI on the surface of the 
cells
59
) and/or from the action of blocking antibodies as a result of the induction of regulatory T 
cells. There is typically no evidence of changes in IgE epitope binding or affinity and some 
evidence of regulatory T cell changes
117
. In desensitised patients, a good response is usually 
maintained for as long as the food is consumed and treatment withdrawal is typically followed by 




. From an immunological point of view, the reverse of the mechanisms previously described 
for desensitisation would occur with a progressive restoration of the high affinity IgE receptor 
FcεRI on the surface of mast cells and basophils and of the activatory component Syk and 
suppression of SHIP phosphorylation inside these cells and with a progressive loss of the 
regulatory T cell response, possibly as a consequence of changes in the methylation patterns of 
transcription factors such as Fox p 3 (the master Treg switch)
117
. These changes overall would 
result in an increase in effector cell reactivity to the allergen and in the development of allergic 
symptoms. In true oral tolerance, the absence of clinical (and effector cell) reactivity would remain 
regardless of whether the food is consumed or not, probably because T cell clone anergy and 
deletion are irreversible processes.  
 
1.8.2 Discrepancy between allergic sensitisation and clinical allergy to peanut 
Clinically, allergic sensitisation to peanut is demonstrated by the presence of allergen-specific 
IgE, as evidenced by a positive skin prick test to peanut or detectable peanut-specific IgE 
antibodies in the serum. Allergic sensitisation is far more common than clinical allergy. This is one 
of the pillars of the practice of the specialty of allergy and clinical immunology and is well 
documented in various research studies for different types of allergic conditions, including food 
allergy.  
The higher prevalence of allergic sensitisation compared to challenge-proven peanut allergy has 
been documented across the globe. For example, in the United Kingdom, in the 8-year review of 
the Manchester Asthma and Allergy Study (MAAS), the prevalence of challenge-proven peanut 
allergy among peanut-sensitised school-age children was approximately 10% 
43
. This number 
increased to 22.4% if patients with definite peanut allergy that were not challenged were included. 
In the United States, 10% of children are sensitised to peanut
10
, but only 1.4% are clinically 
allergic to peanut
23
. In Australia, Allen et al
15
 recently reported a higher prevalence of peanut 
allergy in 12-month-old participants in the Healthnuts study at 3% whereas sensitisation to peanut 
was 3-times higher, i.e. was present in 9% of infants.  
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1.9 Diagnosis of peanut allergy 
The gold-standard for the diagnosis of peanut allergy is oral food challenge
3, 118
. In clinical 
practice, most centres use open oral food challenges for diagnostic purposes. In the research 
setting, double-blind-placebo-controlled-food-challenges (DBPCFC) are required to ensure an 
unbiased outcome
119
. The gold-standard for the diagnosis of food tolerance is an open oral food 
challenge; thus, a negative DBPCFC should be followed by an open food challenge. However, 
oral food challenges are time-consuming, labour intensive, expensive and carry the risk of 
causing an acute allergic reaction, which is potentially severe
25
. Furthermore, with increasing 
prevalence and awareness about food allergies there has been an increasing number of requests 
and Allergy services have some difficulty in responding to demand. Moreover, albeit the gold-
standard, oral food challenges may result in indeterminate (2-9%), false negative (3%) or false 
positive (3%) outcomes
120-125
. Therefore, in clinical practice, whenever possible, the diagnosis of 
peanut allergy is based on the combination of a history of an immediate-type allergic reaction to 
peanut and in vivo or in vitro measurement of IgE sensitisation
126
. Some clinics use peanut-
specific IgE alone, others use peanut-skin prick test (SPT) alone and some use the combination 
of these tests. No clear consensus exists as to which is the best approach. The diagnosis of 
peanut allergy can be particularly difficult in cases where there is no clear history of peanut 
consumption. With increasing awareness about food allergy and the fact that many families avoid 
peanut in the first few years of life, peanut-sensitised children with no history of oral exposure to 
peanut constitute a considerable proportion of patients seen in Allergy clinics. Thus, a test that 
could accurately diagnose peanut allergy reducing the need for oral food challenge is desirable 
and would change clinical practice.  
Given that the likelihood of clinical peanut allergy increases as the weal diameter on SPT to 
peanut or serum peanut-specific IgE level increase, diagnostic decision points based on these 
determinations have been defined to try to improve the utility of SPT and specific IgE to peanut 
and to reduce the need for oral food challenge
127-131
. Using a mixed population, partly from a 
specialised outpatients' clinic and partly birth cohort in the United Kingdom, Roberts et al
129
 
determined that a SPT to peanut ≥8 mm and a serum peanut-specific IgE ≥15 KUA/l have a 95% 
positive predictive value for peanut allergy as confirmed by oral food challenge, similar to the cut-
offs previously determined  in the United States
127, 128
. Cut-offs have been determined in other 
populations in other parts of the world
130, 131
. These cut-offs vary in different studies with the type 
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of oral food challenge performed (e.g. open or double-blind placebo controlled food challenge), 
the oral food challenge protocol (e.g. the criteria to select patients for oral food challenge, 
consideration of immediate as well as delayed allergic reactions, and subjective symptoms as well 
as objective signs as a positive oral food challenge, the criteria for stopping the challenge), the 
study design (e.g. retrospective or prospective) and the statistical analysis performed
127, 128, 130, 131
. 
Using the same research methodology, these cut-offs may also be influenced by the prevalence 
of peanut allergy in the studied population and by the age of the child
131, 132
. Furthermore, these 
cut-off values used alone can misdiagnose a considerable proportion of children with detectable 
peanut-specific IgE. For example, in the birth-cohort-based Manchester Asthma and Allergy Study 
(MAAS), only about 55% of peanut allergic patients had peanut-specific IgE levels above 15 
KUA/l
43
. In another UK study in a population partly birth cohort and partly recruited at a specialised 
Paediatric Allergy clinic, 74% of peanut allergic had peanut-specific IgE levels below the 95% 
PPV cut-off
129
. Thus, in a large proportion of peanut-sensitised children, peanut-specific IgE levels 
or SPT results fall below these cut-offs in non-diagnostic values (the so-called immunological grey 
area
133
 - Figure 1.6) and oral food challenges are required to confirm or rule out the diagnosis of 
peanut allergy
5, 129
. There are also a proportion of patients who are tolerant and have specific IgE 
levels above the 95% PPV and patients who are allergic and have specific IgE levels below the 
95% NPV. Moreover, the levels of peanut-specific IgE do not necessarily reflect clinical allergic 





Figure 1.6 Immunological grey area of different allergy tests: specific IgE to peanut, skin prick test and 
specific IgE to Ara h 2. 
Abbreviations: SIgE, specific IgE; SPT, skin prick test.  
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The determination of specific IgE to peanut components can help distinguishing primary from 
secondary peanut sensitisation
43, 45, 134
. Ara h 1, Ara h 2 and Ara h 3 are major peanut allergens, 
usually able to induce systemic reactions in peanut-sensitised patients, whereas Ara h 8 is 
involved in phenomena of cross-reactivity, causing false positive results on SPT and specific IgE 
to peanut. Ara h 2 seems to be a dominant allergen and has proved to be particularly useful for 
diagnosis
44, 134
; however, peanut allergy can develop in patients with undetectable specific IgE to 




1.10 Management of peanut allergy 
There is no curative treatment for peanut allergy. Current recommendations for the management 
of food allergy and anaphylaxis are based on expert opinion more than evidence-based 
randomised controlled trials
4, 136, 137
. The mainstay of the management of peanut allergy currently 
is strict avoidance of peanut-containing foods and the implementation of an emergency plan to 
treat accidental allergic reactions, which includes adrenaline auto-injectors in the severe cases.  
Various clinical factors have been identified as conferring a greater risk for severe food allergic 
reactions
24
, some related to the food (e.g. the allergen involved, peanut being a risk factor for 
anaphylaxis; the quantity consumed, the type of food processing), some related to the patient 
(namely the age, with adolescents and young adults being at greatest risk; a previous history of 
anaphylaxis and the co-existence of uncontrolled asthma) and other related to the circumstances 
in which the reaction occurs (for example, the absence of cutaneous symptoms, the presence of 
co-factors such as exercise, alcohol and NSAIDs, delay in administration of adrenaline, 
concomitant medication that may interfere with treatment such as beta-blockers and angiotensin-
converting enzyme inhibitors). However, in studies looking at fatal or near-fatal anaphylaxis, not 
all patients had such risk factors. For example, the majority who experienced food-related fatal 
anaphylaxis had previously only had mild allergic reactions
138, 139
.  
Determination of peanut threshold doses and of whether a patient is likely to react to lowamounts 
of the allergen is an important aspect of the management of peanut allergy. Individual peanut 
thresholds could help define the stringency of allergen avoidance measures and population 
peanut thresholds would be useful for public health authorities and the food industry to establish 
regulatory measures to protect food allergic patients and to institute allergen control measures 
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and labelling policies. Thus far, no reliable biomarkers of severity or threshold of acute allergic 
reactions to peanut or to other food allergens have been identified. The gold-standard to 
determine the severity of allergic reactions and the threshold dose at which the patients react to is 
oral food challenge.  
 
1.11 Statement of the problems 
More common than developing allergy to peanut is developing peanut-specific IgE, i.e. 
sensitisation to peanut. In the United Kingdom, 10% of 8-year old children are sensitised to 
peanut but only 2% have peanut allergy
43
. This means that considering IgE levels alone for the 
diagnosis of peanut allergy, specific IgE testing will be inaccurate in 4 out of 5 cases. The 
diagnosis is particularly challenging in the cases where peanut-specific IgE falls in non-diagnostic 
levels and/or there is no history of oral exposure to peanut or there is a discrepancy between the 
clinical history and allergy test results, which constitute a considerable proportion of patients seen 
in Allergy clinics. Moreover, some children have high levels of peanut-specific IgE and tolerate 





1.11.1 Diagnosis of peanut allergy 
The determination of peanut-specific IgE either by serology or skin prick test carries a significant 
number of false-positive results. The use of these tests in the clinic requires the capacity to 
perform oral food challenges to clarify the equivocal cases. The increase in demand has been 
significant over the recent years. Furthermore, oral food challenges are resource-intensive and 
carry the risk of causing acute allergic reactions. Thus, a test that could accurately diagnose 
peanut allergy and reduce the number of oral food challenges could change clinical practice.  
 
1.11.2 Estimating the severity and threshold of allergic reactions to peanut 
In the cases where peanut allergy is confirmed, the severity and threshold of allergic reactions is 
a common concern of patients and their families. The current gold-standard to determine the 
severity of allergic reactions and the threshold doses at which the patients react to peanut is a 
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graded double-blind-placebo-controlled-peanut-challenge in patients known to be peanut 
allergic
140
. This is logistically and technically demanding and carries significant risk; therefore, an 
ex vivo objective biomarker that could reflect the likelihood of experiencing severe allergic 
reactions for individual patients and estimate threshold levels without the need for DBPCPC 
would be very valuable to the management of peanut allergy. Determination of thresholds is also 
useful for the Public Health Authorities and for the Food Industry. 
 
1.11.3 Discrepancy between allergic sensitisation and clinical allergy 
Apart from diagnostic difficulties, the discrepancy between allergic sensitisation and clinical 
allergy to peanut constitutes a gap in our knowledge about the mechanisms of allergy versus 
tolerance. The presence of IgE is necessary but not sufficient to elicit an acute allergic reaction to 
peanut. This is an intriguing and still unsolved problem in the field of Allergology that has not been 
sufficiently explored since the discovery of IgE by Johansson
141
 and of its capability of inducing 





The two main objectives of the present research project were: 
1. To develop a new biomarker for peanut allergy, improving the diagnosis of peanut allergy and 
reducing the need for oral food challenges to peanut; 
2. To understand the discrepancy between allergic sensitisation and clinical allergy to peanut.  
 
1.13 Hypotheses 
IgE-mediated allergic reactions have been reproduced in vitro, where basophil activation markers 
are analysed by flow cytometry following stimulation with allergen
64, 69, 143
. With respect to the first 
objective, I hypothesised that the basophil activation test could become a new biomarker for 
peanut allergy, improving the diagnosis of peanut allergy and reducing the number of oral food 
challenges. I also hypothesised that the basophil activation test could reflect the severity and 
threshold of allergic reactions to peanut; and that patients with severe reactions would show 
55 
greater basophil reactivity and that patients who react to lower doses of peanut allergen would 
show greater basophil sensitivity.   
With respect to the second objective, I addressed two non-mutually exclusive hypotheses to 
explain the discrepancy between clinical allergy and allergic sensitisation to peanut: 
1. The first hypothesis was that allergen-specific IgE is different in allergic and in sensitised but 
tolerant patients.  
2. The second hypothesis was that sensitised but tolerant patients have an inhibitor that blocks 
the function of allergen-specific IgE.  
Given that natural tolerance to food allergens is allergen-specific and long-lasting, the IgE inhibitor 
is likely to be a food-specific antibody of an isotype other than IgE, such as IgG4. IgG4 has been 
shown to increase in patients who naturally outgrow IgE-mediated food allergy, such as cow's 
milk allergy
102, 103
, and in patients who are submitted to food oral immunotherapy
110, 112
 and 
immunotherapy to respiratory allergens
108, 109
. IgG4 is produced as part of a Th2-type immune 
response, induced mainly by the tolerogenic cytokine IL-10
144
, and was therefore the main 
suspect of being the IgE inhibitor in peanut-sensitised but tolerant patients in this study.  
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Chapter 2 Material and methods 
 
2.1 Study populations 
Within the scope of the present doctoral thesis, three cohorts of patients were studied:  
- a population recruited from two specialised Paediatric Allergy outpatients’ clinics, the 
Paediatric Allergy Clinic at St Thomas' Hospital and the Paediatric Allergy Clinic at the 
Portland Hospital, both in London (BAT Study); 
- participants in the Peanut Allergy and Sensitisation study (PAS Study), who are patients 
excluded from a clinical trial on the prevention of peanut allergy, the Learning Early About 
Peanut Allergy (LEAP) study; and  
- participants in a study of peanut oral immunotherapy at Addenbrooke’s Hospital in 
Cambridge (STOP I Study). 
 
2.1.1 BAT Study 
Peanut allergic, peanut sensitised but tolerant and non-sensitised non-allergic children 
consecutively attending the Paediatric Allergy clinic at St Thomas’ Hospital and at the Portland 
Hospital, in London, were invited to participate in the study. The allergic status to peanut was 
determined by oral food challenge, except for: (a) children with a convincing history of systemic 
reaction(s) to peanut within one year of their visit and (i) a wheal size on skin prick test to peanut 
greater or equal to 8 mm
129
 and/or (ii) peanut-specific IgE greater or equal to 15 KUA/l
129
, who 
were considered peanut allergic; and (b) children who were able to eat 4 grams or more of peanut 
protein twice a week (as assessed by a validated peanut consumption questionnaire
145
) without 
developing allergic symptoms, who were considered peanut tolerant. Peanut sensitisation was 
defined by a weal diameter on skin prick test to peanut greater or equal to 1 mm and/or a serum 
peanut-specific IgE greater or equal to 0.10 KUA/l. Children clinically unwell, who had significant 
chronic illness or were unwilling to participate in the study were excluded. 
All children received standard clinical care, including clinical evaluation, skin prick testing (Section 
2.2.1), determination of serum specific IgE to peanut and to peanut components (Section 2.3.1.) 
and oral food challenge (Section 2.2.3.1.), if clinically indicated. A sample of blood for the 
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research study was collected at the same time and in addition to the blood collected for diagnostic 
purposes (Section 2.2.2.).  
The study was reviewed and approved by the South East London Research Ethics Committee 2 
(10/H0802/44) and by the Research & Development Offices of Guy’s and St Thomas’ Hospital 
NHS Foundation Trust (RJ110/N300) and of the Portland Hospital (CTO/10/054). Written 
informed consent was obtained from parents of all children before any study procedures.  
 
2.1.2 PAS Study 
The Peanut Allergy and Sensitisation (PAS) study included children that were screened but 
excluded from the Learning Early About Peanut Allergy (LEAP) study 
(http://www.leapstudy.co.uk/). The LEAP study is a randomised controlled trial, registered at 
http://ClinicalTrials.gov with identification number NCT00329784, in which infants at high risk for 
peanut allergy, as demonstrated by eczema, egg allergy, or both, were enrolled. Participants were 
stratified based on the results of skin prick test to peanut into those with a weal diameter of 0 mm 
(SPT-negative stratum or Group II), and those with a weal diameter of 1, 2, 3, or 4 mm (SPT-
positive or Group III)
8
. Participants in each stratum were randomly assigned to introduce peanut in 
the diet or to avoid peanut until 60 months of age. The group assigned to receive a peanut-
containing snack or peanut butter ate a minimum of 2 g of peanut protein three times per week. 
The prevalence of peanut allergy was compared between the peanut consumption and the 
avoidance groups by oral food challenge at the age of 60 months. At the end of this period, 
participants were invited to enrol in the LEAP-On study in which participants in both arms of the 
LEAP study avoid peanut for 12 months. The prevalence of peanut allergy will be re-assessed by 
oral food challenge at the age of 72 months.  
The PAS Study included patients in groups I and IV of the LEAP screening study, i.e. included 
patients who had to be excluded from the LEAP study either because they did not meet the 
inclusion criteria (Group I, for example, did not have severe enough eczema) or because they 
were considered to have already developed peanut allergy as determined by a skin prick test of 5 
mm or more in the first year of life (Group IV). These patients were not followed up for the 
duration of the LEAP study and were invited to participate in the PAS Study at the time of what 
would have been their last LEAP visit if they had entered the LEAP study. Participants of the PAS 
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Study underwent the exact same assessments as the LEAP study participants at the end of the 
LEAP study, namely clinical evaluation, skin prick testing, determination of specific IgE to peanut 
and to peanut components, oral food challenge and basophil activation test to peanut.  
Only data regarding participants in the PAS study, and not data regarding participants in the 
LEAP and LEAP-On studies, are included in this doctoral thesis.  
 
2.1.3 STOP I Study 
The Study of Tolerance to Oral Peanut (STOP I), registered at http://ClinicalTrials.gov with 
identification number NCT01259804, is an uncontrolled clinical trial of 22 peanut allergic children, 
aged from 4 to 18 years old, treated with high dose oral immunotherapy (OIT) to peanut
146
. The 
diagnosis of peanut allergy was established based on a positive oral peanut challenge and the 
presence of serum peanut-specific IgE. Exclusion criteria were major immunodeficiency and 
inability to adhere to the OIT protocol. An up-dosing phase with 2 weekly increments to the 
maximum tolerated dose aiming at 800 mg of peanut protein a day (corresponding to 5 peanuts) 
over 8 to 38 week-period was followed by a 30 week maintenance phase, where 800mg of peanut 
protein were taken daily. After 6 and 30 weeks of the maintenance phase, children underwent an 
open peanut challenge with roasted peanuts.  
Dr Andrew Clark, principal investigator of the STOP I study, kindly provided plasma samples from 
19 patients included in the study, 14 paired pre and post OIT samples and 5 unpaired post-OIT 
samples. The post-OIT samples were from the 24-month (5 paired and 3 unpaired samples), 18-
month (3 paired samples), 12-month (4 paired and 1 unpaired) or 6-month (2 paired and 1 
unpaired) visits. 
 
2.2 Clinical procedures  
The clinical procedures for participants in the BAT and in the PAS studies were similar and are 
described in this section. The clinical assessments of participants in the STOP I study were 
performed at Addenbroke's Hospital in Cambridge by the research team led by Dr Andrew Clark.  
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2.2.1 Skin prick testing  
Skin prick testing was performed on the volar surface of the non-dominant forearm or on the back 
of the child using a single-head lancet (ALK-Abelló, Denmark), a positive control (10 mg/ml 
histamine dihydrochloride, Stallergenes, France), a negative control (50% glycerol and 50% 
buffered saline, Stallergenes, France) and peanut extract (ALK-Abelló, Denmark). Skin reactions 
were recorded after 15 minutes. The size of the weal was determined as the mean of two 
perpendicular diameters including the longest one. 
 
2.2.2 Collection of blood samples 
Blood samples were collected simultaneously, i.e. in the same blood draw, for serology, whole 
blood basophil activation assays and plasma separation for later use in passive sensitisation 
basophil and mast cell assays. For whole blood basophil activation assays, blood was collected in 
lithium heparin (BD Vacutainer®). For serology, blood was collected in spray-coated silica tube 
with a polymer gel (BD Vacutainer® SST™), which was centrifuged; the serum was then collected 
with a pipette into cryovials and stored at -80°C for later use. For obtaining plasma, blood was 
collected in citrate-dextrose solution (Sigma-Aldrich, Poole, UK) in a 1 in 10 dilution; the tubes 
were centrifuged and the plasma was collected with a pipette into cryovials and stored at -80°C 
for later use.  
 
2.2.3 Oral food challenges 
2.2.3.1 Oral food challenge protocol 
For the oral food challenges, US high oleic runner variety of peanut were used to produce 12% fat 
light roast peanut flour by the Golden Peanut Company. Nutritional information was supplied by 
Golden Peanut Company. When preparing the challenge recipes, muffins and biscuits were 
weighed individually to ensure consistent size. Protein level was not tested in the final challenge 
foods. The challenge was blinded using fruit biscuit or chocolate muffin recipe. In terms of the 
food matrix employed, the fruit biscuit recipe contained plain wheat flour, bicarbonate of soda, 
rapeseed oil, dark brown sugar, vanilla extract, mashed very ripe bananas, mixed dried fruit, 
mixed peel and orange juice; and the chocolate muffin contained plain wheat flour, cocoa powder, 
baking powder, bicarbonate of soda, soft brown sugar, rapeseed oil, prunes in fruit juice pureed, 
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oatly milk and vanilla extract. For the open challenges, peanut butter, Bamba or whole peanuts 
(for children 5 years of age or older) were used. Occasionally, if the participant disliked these, 
other products were used, such as Reese's peanut butter cups, Peanut M & M's or peanut biscuit.  
At the start of the challenge, each child was examined (including temperature, blood pressure, 
respiratory rate, oxygen saturation, auscultation of the chest, peak expiratory flow (if the child was 
older than 5 years), capillary refill, height and weight) and fitness for challenge was confirmed. 
Children with active infection, fever, flairs of asthma, eczema or hay fever in the past 2 weeks, 
had their challenge postponed. Children must had stopped short acting antihistamines for 48 
hours, long acting antihistamines for 1 week, leukotriene receptor antagonists for 24 hours, long-
acting Agonists for 48 hours, before the challenge.  If children became unwell with the 
interruption of their medication for this length of time, they also had their challenge postponed."  
Prior to the administration of each meal, the child was evaluated for signs of an allergic reaction 
and vital signs (temperature, pulse, respiratory rate, blood pressure, oxygen saturation, and peak 
expiratory flow rate) were monitored. The meals were blinded by a computer-generated random 
code known only to the dietician. A blinded dose may have been repeated if any of the following 
occurred: abdominal pain, nausea, chest tightness or pain, abnormal oropharyngeal sensation, or 
unexplained behavioural change. 
Double-blind placebo-controlled food challenges consisted of 6 verum doses and 3 placebo doses 
randomly interspersed with verum doses up to a cumulative dose of 9.35 g of peanut protein 
(Table 2.1). Children of 1 to 3 years were given one placebo and 5 verum doses up to a 
cumulative dose of 4.35 g of peanut protein. The last dose was administered in an unblinded 
fashion. In infants (aged 1 year or less), the oral food challenges were open up to a cumulative 
dose of 4.35 g of peanut protein. High-risk patients (i.e. patients with suspected peanut allergy, 
history of life-threatening food-induced anaphylaxis or SPT ≥7 mm) received an additional lower 
starting active dose of 0.033g of peanut protein. Some older children received an open oral food 
challenge for logistical reasons. The open challenges followed the same sequence doses of 




Table 2.1 Doses of peanut protein in the oral food challenge protocol.  
Placebo doses were randomly interspersed with verum doses. 









2.2.3.2 Criteria for a positive oral food challenge 
After each dose, the child was observed for 20 minutes and the examination was repeated. The 
results of the examinations were recorded in specific tables and the symptoms recorded as free 
text in the case report form. A system of consensus, where all attending nurses and doctors 
observed and discussed the symptoms and signs, minimised observer bias. A table with the 
major and minor criteria for a positive challenge that needed to be ticked at the end of the 
challenge ensured that the criteria for a positive challenge were met. Oral food challenges were 
considered negative when all doses were tolerated. If an allergic reaction developed at any stage 
following a verum dose, the oral food challenge was considered positive (Table 2.2) and the 
symptoms treated according to local guidelines. If a reaction followed a placebo dose, the patient 







Table 2.2 Criteria for positive oral food challenge to peanut.  
A positive oral food challenge was defined by the presence of either ≥1 major criteria or ≥2 minor criteria. An indeterminate 
oral food challenge was defined as one minor criterion. A negative oral food challenge was defined by the absence of 
major or minor criteria. 
Major criteria 
Confluent erythematous pruritic rash 
Wheezing 
Stridor 
Dysphonia / Aphonia 
≥ 3 urticarial lesions 
≥ 1 site of angioedema 
Hypotension for age not related to vasovagal episode 




Persistent rubbing of eyes that last ≥3 minutes 
Persistent rhinorrhoea that lasts ≥3 minutes 




2.2.3.3 Classification of the severity of allergic reactions to peanut 
Allergic reactions to peanut on DBPCPC were attributed a symptom score varying between 1 and 
5 and the severity was classified into mild (symptom score of 1 or 2), moderate (symptom score of 
3) or severe (symptom score of 4 or 5), using published criteria
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. Patients were grouped 




Table 2.3 Classification of the severity of allergic reactions to peanut 
Symptom score Severity classification 
1 
Localised cutaneous erythema 
Localised  urticaria 
Localised  angioedema 


















2.2.3.4 Determination of the peanut threshold dose 
The threshold dose on oral food challenge was defined as the cumulative threshold dose of 
peanut protein at the time of reaction as opposed to discrete threshold dose. Patients were 
grouped according to the cumulative threshold dose at the time of reaction into low (≤0.1g of 
peanut protein) versus high (>0.1g of peanut protein) threshold. Discrete threshold doses, i.e. the 




2.3 Laboratory procedures 
2.3.1 Measurement of serum immunoglobulins 
2.3.1.1 Total IgE and specific IgE to peanut and peanut components 
Total and allergen-specific IgE were measured by using an immunoenzymatic assay 
(ImmunoCAP, Phadia AB, Uppsala, Sweden). Total IgE ImmunoCAP had a measuring range 
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from 2 to 5000 KUA/l. Regarding allergen-specific IgE, serum samples were analysed for IgE to 
peanut as well as IgE to the recombinant peanut allergens Ara h 1, Ara h 2, Ara h 3, Ara h 8 and 
Ara h 9. The allergen-specific IgE assay had a lower detection limit of 0.01 KUA/l and an upper 
detection limit of 100 KUA/l. For allergen-specific IgE levels above 100 KUA/l, serial dilutions were 
performed to determine the exact serum allergen-specific IgE level.  
 
2.3.1.2 Specific IgG4 to peanut and peanut components 
Serum specific IgG4 to peanut and to Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9 were 
measured using the Phadia ImmunoCAP 100. The peanut-specific IgG4 assay had a lower 
detection limit of 70 μg/l and an upper detection limit of 30 mg/l.  
 
2.3.1.3 Specific IgA to peanut 
Serum specific IgA to peanut was measured using the Phadia ImmunoCAP 100. The peanut-
specific IgA assay had a lower detection limit of 1 mg/l and an upper detection limit of 100 mg/l. 
 
2.3.1.4 Ratios of allergen-specific IgG4 to IgE 
The ratios of IgG4 to IgE to peanut and peanut components were determined following 
conversion of the IgE levels from KUA/l to ng/ml
150
 and conversion of the IgG4 levels from mg/l to 
ng/ml, using the formula: 
IgG4/IgE ratio = (IgG4 x 1000)/(IgE x 2.4) 
 
2.3.2 Antibody depletion 
2.3.2.1 IgG4 depletion 
IgG1 anti-IgG4 antibodies (clone MH164-4, Sanquin, Netherlands) were coupled to CNBr-
activated sepharose (GE Healthcare, Hertfordshire, UK) during an overnight incubation at 4°C. 
Remaining reactive groups were blocked with 1M ethanolamine followed by three cycles of 
washes in alternating pH using 0.1 M acetic acid/sodium acetate at pH 4.0 and 0.1M Tris-HCl at 
pH 8.0. Mock-coupled sepharose beads were processed in parallel with anti-IgG4 coupled beads. 
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Plasma samples were filtered and diluted 1:10 in PBS-AT (0.3% BSA, 0.1% Tween 20 and 0.05% 
NaN3 in PBS). Diluted plasma samples were incubated with anti-IgG4- or mocked-coupled 
sepharose beads in a total volume of 500 μl overnight at room temperature with continuous end-
over-end rotation. Anti-IgG4 depleted and mock-depleted samples were collected by means of 
centrifugation. Total IgG4 plasma levels were measured by ELISA in IgG4-depleted and mock-
depleted samples, as described below in section 2.3.2.2.
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. In the same samples, peanut-specific 
IgG4 levels were determined using ImmunoCAP, as described above in section 2.3.1.2.  
 
2.3.2.2 IgG4 ELISA 
ELISA plates (Nunc Immunoplate Maxisorp, Thermoscientific) were coated with 100 µl per well of 
purified mouse anti-human IgG4 antibody (clone JDC-14, BD Biosciences) diluted in carbonate 
buffer (4 nM, pH 9.2) to 2 μg/ml and incubated overnight at 4C. Following removal of the coating 
antibody, plates were blocked with 200 μl per well of 1% BSA/PBS and incubated for 1 hour at 
room temperature. Plates were then washed four times with 0.05% Tween 20 in PBS using a 
squeezy bottle and 50 µl of serum samples or controls were incubated for 16 hours at 4°C. 
Following four washing steps, plates were incubated with 100 µl per well of 1 μg/ml biotin-
conjugated anti-human IgG4 (clone G17-4, BD Biosciences), followed by washing steps and 
incubation for 30 minutes at room temperature with 100 µl per well of 5 l/ml streptavidin–
horseradish peroxidase (R&D Systems, Minneapolis, Minn). The plates were washed and 50 µl of 
the substrate solution, 3,3'-5,5'-tetramethylbenzidine (TMB), was added to each well. The plates 
were incubated in the dark for 15 minutes and the reaction was stopped with 50 μl per well of 3M 
sulphuric acid. IgG4 was detected with TMB (R&D Systems) by measuring absorbance at 450 
nm. Human IgG4 (Sigma-Aldrich) was used to generate a standard curve from which the 
concentrations of test samples were extrapolated. 
 
2.3.2.3 IgG depletion 
In the collaborative project described in Section 6.2. (entitled "Auto-anti-IgE antibodies"), to 
deplete total IgG from the sera, 500 µL of serum samples were incubated with an equal volume of 
protein G Sepharose (Sigma-Aldrich) at 48°C overnight in a mini Bio-Spin chromatography 
column (Bio-Rad, Hercules, Calif). The flow-through was recovered and re-incubated with fresh 
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protein G Sepharose at 4°C overnight. IgG was measured in the final recovered flow-through by 
ELISA, as described in Section 2.3.2.4. 
For the affinity experiments described in section 2.3.4., to deplete IgG from plasma, protein G 
spin columns (GE healthcare, 28-9031-34) were used following the manufacturer's instructions. 
 
2.3.2.4 IgG ELISA 
To assess the efficiency of the IgG depletion, total IgG was measured by ELISA. Nunc Maxisorp 
plates were coated with 100 µl per well of goat anti-human IgG (Oxford Biotech 204001) in 
carbonate buffer (110 ml Na2CO3 (0.2 M), 140 ml NaHCO3 (0.2 M), 500 ml distilled H2O, pH 9.2) 
and incubated overnight at 4C. Following four consecutive washes with PBS/0.05% Tween, 
plates were blocked with 200 µL per well PBS/Tween/2% marvel for 1 hour at room temperature 
on a plate shaker. After another four consecutive washes with PBS/0.05% Tween, 50 µL per well 
of test samples, IgG standard curve (Sigma I4506 in NaCl) or buffer alone (blank) were added to 
different wells in duplicate, diluted 1:2 from 200 ng/ml in PBS/Tween/1% marvel. The plates were 
incubated overnight at 4C. Following another four washing steps, 100 µL of anti-IgG-HRP 
(Sigma A0170) in PBS/Tween/1% marvel were added per well and the plates were incubated for 
2 hours at 37C. After another four washing steps, 50 µl per well of TMB substrate was added 
and the reaction was stopped with 50 µL of 1 M sulphuric acid. IgG was detected by measuring 
absorbance at 450 nm.  
 
2.3.3 Depletion and purification of IgE-binding proteins 
In the collaborative project described in Section 6.2. (entitled "Auto-anti-IgE antibodies"), to 
deplete IgE-binding proteins, IgE was cross-linked to cyanogen bromide (CNBr)–activated 
Sepharose 4B (Sigma-Aldrich) according to the manufacturer’s instructions. Briefly, 100 mg of 
recombinant IgE anti-NP-BSA (manufactured in-house) were mixed with 100 ml of 1 mM HCl-
swollen CNBr-activated Sepharose in coupling buffer (0.1 M NaHCO3 buffer containing 0.5 M 
NaCl) at 4°C overnight in a mini Bio-Spin chromatography column, then washed with coupling 
buffer. Unconjugated sites were blocked with 0.2 M glycine buffer pH 8.0 for 2 hours at room 
temperature. After extensive washing with 5 cycles of the coupling buffer and 0.1 M acetate buffer 
pH 4, the IgE-coupled Sepharose was ready to be used. IgE-coupled Sepharose (50 ml) was 
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mixed with 3 ml of subjects’ sera at 4°C overnight. The eluate containing non-IgE binding 
antibodies was stored at -20°C for later analysis. Proteins bound to the IgE-coupled Sepharose 
were then eluted with 100 ml of 0.2 M glycine pH 2.5 into an equal volume of 100 mM Tris buffer 
pH 8.0. The eluted solutions were dialyzed in PBS at 4°C overnight, and then mixed with protein 
G Sepharose one-to-one at 4°C overnight to capture IgG antibodies. The IgG anti-IgE antibodies 
were eluted off the protein G Sepharose with glycine, dialyzed with PBS as above, then quantified 
by ELISA and run on 10% SDS-PAGE under non-reducing conditions compared with recombinant 
IgE and IgG (Sigma-Aldrich). No contaminating IgE was found in purified antibodies. 
 
2.3.4 Peanut extract and purified peanut allergens 
The peanut extract (Batch EC-B044) used in the basophil activation assay was prepared at ALK 
Abelló, in Horsholm, Denmark, and kindly provided by Dr Henning Løwenstein. Raw peanut was 
extracted in cold isotonic phosphate buffer pH 6.5 at 100 mg/ml and magnetically stirred for 
90  15 minutes at 2-8°C. The extract was centrifuged at 20,000xg for 30  5 minutes at 2-8 °C 
then clarified by filtration through glass-fibre filters or 0.5 μm membrane filters. The pH was 
adjusted to 6.5  0.5. The extract was sterilised by filtering it twice through 0.2 μm filters then filled 
at 1 ml per vial into sterilised glass vials and freeze dried. The frozen lyophilised extract was 
gradually brought to room temperature and reconstituted with 1 ml of PBS at 20 mg of protein per 
millilitre before use. The extract concentrations are expressed as mass of protein per unit of 
volume throughout the thesis. 
The concentration of protein in the peanut extract was determined at ALK-Abelló as being 20 
mg/ml. Stability studies were performed where chemical, biochemical and microbiological 
parameters were tested after 24 months of storage at 2-8°C, after 6 months of storage at 25°C, 
after 15 days of storage at 37°C and after 6 months of storage at 2-8°C, under in-use conditions. 
In all these conditions, the extract showed to be stable and maintained its protein profile as 
assessed by SDS-PAGE electrophoresis and its allergenic activity as assessed by RAST 
inhibition with an in-house reference.  
The presence of Ara h 1, Ara h 2 and Ara h 3 in the peanut extract was confirmed by western 
blotting. The concentration of the major peanut allergens Ara h 1 (5.5 mg/ml), Ara h 2 (1.6 mg/ml) 
and Ara h 3 (4 mg/ml) in the crude peanut extract was measured by SDS-PAGE and densitometry 
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(Figure 2.1) by Dr Soheila Maleki (Agriculture Research service, Southern Region Research 
Center, New Orleans, Louisiana, USA).  
Dr Maleki also kindly provided purified native peanut proteins, namely Ara h 1, Ara h 2, Ara h 3 





Figure 2.1 Quantification of Ara h 1, Ara h 2 and Ara h 3 using SDS-PAGE and densitometry.   
  Abbreviations: A3, purified Ara h 3; A2, purified Ara h 2; A1, purified Ara h 1; ALK, peanut extract from ALK-Abelló; CPP, 
crude peanut protein; MW, molecular weight marker. Courtesy of Dr Soheila Maleki. 
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2.3.5 Surface plasmon resonance 
Surface Plasmon resonance experiments were performed using a Biacore T200 instrument. All 
experiments were performed at 25C. A fusion protein mimicking the high affinity IgE receptor 
formed by the soluble fragment of the high-affinity IgE receptor α-chain fused to the Fc region of 
IgG4
154
, designated IgG4-Fc(sFcεRIα)2, kindly provided by Dr Tihomir Dodev and Dr Andrew 
Beavil, was used to capture IgE. Purified native Ara h 2 was injected over the sensor chip 
containing IgE bound to the fusion protein to measure IgE affinity for the peanut allergen.  
The aim was to compare the IgE affinity for peanut allergen Ara h 2 between peanut allergic and 
peanut sensitised but tolerant patients. However, peanut sensitised but tolerant patients tended to 
have lower levels of IgE to peanut and to peanut allergens and lower proportion of IgE that was 
allergen-specific. Furthermore, most of the peanut tolerant patients with IgE to the major peanut 
allergens were infants and young children and the volume of plasma samples collected from 
these study participants was limited. To assess the feasibility of the experiments and the 
experimental design, pilot experiments using recombinant grass pollen allergen Phl p 7 and 
plasma from a non-atopic patient spiked with recombinant monoclonal IgE antibody directed to 
Phl p 7 were performed before testing samples of PA and PS patients.  
 
2.3.5.1 Immobilisation of IgG4-Fc(sFcεRIα)2 fusion protein to the sensor chip 
The IgG4-Fc(sFcεRIα)2 fusion protein was diluted to 10 g/ml in sodium acetate buffer (pH 4.5) 
and immobilised on the surface of a CM5 chip flow cell (Biacore, Uppsala, Sweden) by amine 
coupling: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) were injected to activate the flow cell followed by injection of IgG4-
Fc(sFcεRIα)2 fusion protein. Following this, the flow cell was deactivated with 1 M ethanolamine-
HCl (pH=8.5) to prevent further non-specific binding. A second control flow cell was prepared in 
parallel in which the surface was activated and deactivated in the absence of IgG4-Fc(sFcεRIα)2 
fusion protein. IgE-containing plasma and allergen were flown over both a blank surface with no 
protein immobilised (flow cell 3) and a surface where IgG4-Fc(sFcεRIα)2 was immobilised (flow 
cell 4).  
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2.3.5.2 Pilot experiments using monoclonal anti-Phl p 7 IgE and recombinant Phl p 7 
Pilot experiments using a single recombinant grass pollen allergen Phl p 7 (kindly provided by Dr 
Louisa James and Professor Hannah Gould) and plasma from a non-atopic patient spiked with 
recombinant monoclonal IgE antibody anti-Phl p 7 (also provided by Dr Louisa James and 
Professor Hannah Gould) were performed to test the experimental design before testing samples 
of PA and PS patients. The aims were to test firstly whether it was possible to capture IgE from 
plasma using the IgG4-Fc(sFcεRIα)2 fusion chip and secondly whether it was possible to measure 
allergen-IgE interactions in samples with a low proportion of allergen-specific IgE using a small 
volume of plasma.  
Plasma from a non-atopic adult volunteer was spiked with a mixture of recombinant monoclonal 
IgE antibody specific for the grass pollen allergen Phl p 7 and polyclonal non-specific IgE (WHO 
reference standard). The concentration of allergen-specific IgE was adjusted to 100 g/ml and 
mixed with non-specific IgE in the following proportions: 100%, 30%, 10%, 3%, 1%, 0.3% and 
0.1%. A plasma sample from a non-atopic adult volunteer was applied to a protein G spin column 
(GE healthcare, 28-9031-34) to deplete IgG. The IgE mixtures were added to the non-atopic 
plasma at 2.5 g/ml.  
The IgE-spiked plasma samples were injected in series over the IgG4-Fc(sFcεRIα)2 and control 
flow cell surfaces for 600 s at a flow rate of 5 L/min. Binding of IgE to the IgG4-Fc(sFcεRIα)2 
protein was detected as indicated in Figure 2.2. After a 120s stabilization period, recombinant Phl 
p 7 (1 M) was injected for 300 s and binding of IgE and of allergen was detected as indicated in 
Figure 2.2. Between cycles the surface of IgG4-Fc(sFcεRIα)2 was regenerated with glycine (pH 
2.5). Binding of allergen was detected when specific IgE was present at 100%, 30% and 10% of 




Figure 2.2 Surface plasmon resonance following capture of plasma IgE (including Phl p 7-specific IgE) by 
IgG4-Fc(sFcεRIα)2 and subsequent flow of recombinant allergen Phl p 7.  
A. IgE capture and allergen binding expressed in response units and not corrected for background. B. Allergen binding 
shown as response units for flow cell 4 (surface where IgG4-Fc(sFcεRIα)2 was immobilised), with background control data 
from flow cell 3 (blank surface with no protein immobilised) subtracted. 
 
2.3.5.3 Experiments using plasma of peanut allergic and peanut sensitised but tolerant 
patients and purified Ara h 2  
Using the same IgG4-Fc(sFcεRIα)2  immobilised sensor chip as described in Section 2.3.4.2, 
plasma samples of PA and PS patients (Table 2.4), previously depleted of IgG using protein G 
spin columns (GE healthcare, 28-9031-34) according to the manufacturer's instructions, were 
injected for 600s at 5 L/minute to capture IgE. Purified peanut protein Ara h 2 was then injected 
for 300s at 5 l/minute at increasing concentration (1nm to 1μM) to detect binding to Ara h 2-
specific IgE captured on the sensor chip. The kinetics of binding was analysed using the 
BIAevaluation software. Between cycles the surface of the sensor chip was regenerated with 
glycine, pH 2.5.  
Unidentified proteins specifically present within plasma from atopic patients bound to both the 
IgG4-Fc(sFcεRIα)2  and to the control surface leading to a high background that was not 
completely removed by glycine regeneration. Each injection of plasma resulted in an increase in 
the baseline response until the sensor surface became saturated. Under these conditions it was 
not possible to detect binding of allergens to IgE. Alternative regeneration conditions (high pH) 
and the addition of high salt concentrations to the samples were attempted to prevent the 
observed non-specific binding of plasma proteins to the IgG4-Fc(sFcεRIα)2 surface without 
success. In light of these technical challenges, the planned affinity measurements of IgE present 
in the plasma for purified peanut allergens were not achieved.  
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Table 2.4 Examples of plasma samples of peanut allergic and peanut sensitised but tolerant patients 
selected to measure affinity of IgE for Ara h 2 using surface plasmon resonance.  
The samples were selected on the basis of Ara h 2 ≥0.10 KU/L and ratio of Ara h 2-specific IgE to total IgE ≥0.3% and 
paired between peanut allergic and peanut sensitised but tolerant for the ratio of Ara h 2-specific IgE to total IgE. 





















AS057 16 483 5.21 5.27 1.09% 
AS040 8 42 0.46 0.34 0.81% 
AS163 10 105 21.6 4.42 4.21% 
PAS8301 10 250 5.81 5.41 2.16% 
PAS8726 8 33 2.45 0.38 1.15% 
AS012 7 40 0.39 0.68 1.70% 





AS079 10 8132 97.1 82.30 1.01% 
AS120 2 13 0.05 0.11 0.85% 
AS136 4 6 0.56 0.24 4.00% 
AS140 2 45 0.14 0.17 0.38% 
AS151 5 13 0.71 0.28 2.15% 
AS175 7 305 0.41 0.12 1.20% 
AS182 7 7 0.07 0.13 1.86% 
 
 
2.3.6 Basophil assays 
2.3.6.1 Whole blood basophil activation assay 
2.3.6.1.1 Laboratory procedure 
Peripheral venous blood was collected in lithium heparin tubes (BD Vacutainer®, Plymouth, UK) 
and tested within four hours of collection. Whole blood (100 µl) was stimulated for 30 minutes at 
37˚C with an equal volume of peanut extract (ALK Abelló, Horsholm, Denmark) diluted in 
Rosewell Park Memorial Institute medium (RPMI, GIBCO, Paisley, UK) at serial 10-fold dilutions 
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from 10 µg/ml to 0.1 ng/ml. Polyclonal goat anti-human IgE (1 µg/ml, Sigma-Aldrich, Poole, UK), 
monoclonal mouse anti-human FcɛRI (2.5 µg/ml, eBioscience, San Diego, CA, USA), formyl-
methionyl-leucyl-phenylalanine (fMLP, 1 µM, Sigma-Aldrich, Poole, UK) or RPMI alone were used 
as controls. The reaction was stopped by adding cold ethylenediaminetetraacetic acid (EDTA) at 
a final concentration of 20 mM. Cells were stained for 30 minutes at 4˚C with the following 
fluorochrome-conjugated monoclonal antibodies: CD123-fluorescein isothiocyanate (clone 6H6, 
eBioscience, San Diego, CA, USA), CD203c-phycoerythrin (clone NP4D6, Biolegend, San Diego, 
CA, USA), HLA-DR-peridinin chlorophyll protein (clone L243, Biolegend, San Diego, CA, USA) 
and CD63-allophycocyanin (clone MEM259, Biolegend, San Diego, CA, USA). Red blood cells 
were lysed with BD Pharmlyse lysing buffer (BD Immunocytometry Systems, San Jose, CA, 
USA). Basophils were gated as side scatter (SSC)
low
/CD203c+/CD123+/HLADR- unless 
otherwise indicated, and surface expression of CD63 and CD203c was analysed using FACS 
Canto II with FACSDiva software (BD Biosciences, San Jose, CA, USA). A minimum of 1000 
SSC
low
 CD203c+ CD123+ HLADR- events were acquired.  
 
2.3.6.1.2 Data analyses 
BAT data was analysed using FlowJo software version 7.6.1. (TreeStar, Ashland, Ore, USA). 
Basophil activation was expressed as the percentage of CD63-positive basophils with the 
background activation (i.e. the percentage of CD63-positive basophils in the negative control) 
subtracted. Basophil activation was also expressed as the stimulation index of CD203c (SI 
CD203c), i.e. the ratio of the mean fluorescence intensity of CD203c-PE for each condition and 
the mean fluorescence intensity of CD203c-PE for the negative control. Other parameters were 
constructed based on the percentage of CD63-positive basophils or the SI CD203c, namely: 
- Mean CD63 Peanut 10-100 - average of the percentage of CD63-positive basophils at 10 
and 100 ng/ml of peanut extract; 
- Mean CD203c 10-100 - average of the stimulation index of CD203 on basophils at 10 and 
100 ng/ml of peanut extract; 
- Mean CD63 Peanut 100-1000 - average of the percentage of CD63-positive basophils at 
100 and 1000 ng/ml of peanut extract; 
- Mean CD203c 100-1000 - average of the stimulation index of CD203 on basophils at 100 
and 1000 ng/ml of peanut extract; 
74 
- AUC CD63 - area under the dose-response curve for the basophil activation expressed 
as percentage of CD63-positive basophils using a logarithmic scale for the peanut extract 
concentrations; 
- AUC CD203c - area under the dose-response curve for the basophil activation expressed 
as stimulation index of CD203c on basophils using a logarithmic scale for the peanut 
extract concentrations; 
- Maximal %CD63 Peanut or CDmax - the maximal percentage of CD63-positive basophils, 
i.e. the percentage of CD63-positive basophils at the optimal peanut extract 
concentration; 
- Maximal SI CD203c Peanut - the maximal stimulation index of CD203c on basophils, i.e. 
the stimulation index of CD203c on basophils at the optimal peanut extract concentration; 
- %CD63+ Peanut 100/aIgE - the ratio of the percentage of CD63-positive basophils 
following stimulation with 100 ng/ml of peanut extract and the percentage of CD63-
positive basophils following stimulation with anti-IgE; 
- %CD63+ Peanut 100/aFcεRI - the ratio of the percentage of CD63-positive basophils 
following stimulation with 100 ng/ml of peanut extract and the percentage of CD63-
positive basophils following stimulation with aFcɛRI; 
- EC50 CD63 - half-maximal effective concentration determined using the CD63 dose-
response curve; 
- EC50 CD203c - half-maximal effective concentration determined using the CD203c dose-
response curve; 
- CDsens CD63 - the inverse of EC50 times 100 determined using the CD63 dose-response 
curve; 
- CDsens CD203c - the inverse of EC50 times 100 determined using the CD203c dose-
response curve. 
 
2.3.6.2 Basophil activation test to determine biological activity of peanut-containing dust 
samples 
Six extracted dust samples containing high (19.3-43.5 µg/ml, n=3) or low (0.01-0.015 µg/ml, n=3) 
levels of peanut protein were used to stimulate basophils of 3 peanut monoallergic and 3 non-
allergic children, resulting in 5 pairs of dust sample–patient experiments. The extracted dust 
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samples with high peanut content were diluted to a maximum concentration of 10 µg/ml and then 
serially diluted to compare dose-responses obtained with the extracted dust samples and the 
peanut standard across experiments. The low peanut dust samples were prepared using the 
same dilution factor to control for other potential components of the dust extract that could 
activate basophils independently of peanut protein. In this group of patients, peanut allergy was 
diagnosed based on a combination of a recent history of an immediate allergic reaction to peanut 
and peanut skin prick test responses of 8 mm or greater (Stallergenes, Antony, France) and 
serum peanut-specific IgE levels of 15 KUA/l or greater (ImmunoCAP; ThermoFisher Scientific, 
Uppsala, Sweden)
129
. Non allergic patients were eating peanuts regularly and had negative skin 
prick test results and negative serum specific IgE levels to peanut and to common food and 
airborne allergens. Apart from skin prick testing to peanut and to common food and airborne 
allergens and from specific IgE to peanut, patients were also tested for specific IgE to peanut 
components Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9. Whole blood basophil activation test 
using the extracted dust samples, the peanut extract and the appropriate negative (RPMI alone) 
and positive (anti-IgE and fMLP) controls, as described in section 2.3.6.1. 
 
2.3.6.3 Basophil activation test to determine the ability of serum from asthmatics to 
activate basophils 
Citrate-dextrose anticoagulated blood was obtained from a single atopic non-asthmatic donor with 
total serum IgE >150 KUA/l and sensitised to house dust mite as determined by skin prick testing. 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient separation using 
Histopaque-1077 (Sigma-Aldrich, Poole, UK) and resuspended to a final concentration of 2 x 10
7
 
cells/ml. For each condition, 1 x 10
6
 cells (50 µL) were incubated with 50 µL of test sera diluted 
1:2 with BAT buffer  (HBSS with 2 mM CaCl2) for 30 minutes at 37°C and degranulation stopped 
by adding 2 ml of FACS buffer containing 2 mM EDTA on ice. Autologous serum or BAT buffer 
were used as negative controls. Polyclonal goat anti-human IgE, monoclonal mouse anti-human 
FcεRI or fMLP were used as positive controls. PBMC were stained with anti-CD203c-
phycoerythrin (Clone NP4D6; BioLegend, San Diego, Calif) and anti-CD63-allophycocyanin 
(Clone MEM-259; BioLegend) and analysed by flow cytometry, as previously described. 
Basophils were gated as SSC
low
 CD203c+ cells and basophil activation was defined as the 
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percentage basophils expressing the activation marker CD63 compared with the BAT buffer 
negative control. 
 
2.3.6.4 Basophil intracellular signalling 
To assess intracellular signalling during IgE-mediated basophil activation, BD Phosflow™(BD 
Biosciences, San Jose, California) reagents were used. Blood collection and preparation of 
stimulants were performed as described in section 2.3.6.1. Whole blood and stimulants were 
incubated with the following surface-staining antibodies for 30 minutes (unless indicated 
otherwise) at 37°C (5% CO2) in an incubator: CD123-allophycocyanin (clone 7G3, BD 
Biosciences, San Jose, CA, USA), HLA-DR-peridinin chlorophyll protein (clone L243, Biolegend, 
San Diego, CA, USA) and CD63-phycoerythrin-Cy7 (clone H5C6, Biolegend, San Diego, CA, 
USA). 20 μl of cold (4°C) 20 mM EDTA (in PBS) was added to each tube to stop degranulation. 
Cells were fixed and lysed with pre-warmed BD Lyse/Fix Buffer and incubated at 37°C for 10 min. 
Following washing, cells were permeabilised with BD Perm/Wash Buffer I. Cells were washed and 
resuspended in Perm/Wash Buffer I and stained with BD Phosflow antibodies: Syk-Alexa Fluor 
488 or phycoerythrin (clone I120-722 (pY348), BD Biosciences, San Jose, CA, USA), SHP-2-
phycoerythrin (clone L99-921 (pY542), BD Biosciences, San Jose, CA, USA) and p38-MAPK-
pacific blue or phycoerythrin (clone 36/p38 (pT180/pY182), BD Biosciences, San Jose, CA, USA), 
depending on the colour panel used. Cells were incubated at room temperature for 60 minutes 
protected from light, washed and resuspended in BD Perm/Wash Buffer I prior to flow cytometric 
analysis.  
 
2.3.6.5 Passive sensitisation basophil activation and inhibition assays 
Peripheral blood mononuclear cells (PBMC) were isolated from citrate-dextrose anticoagulated 
blood of atopic non-peanut allergic non-peanut sensitised adult volunteers by density gradient 
separation using Histopaque-1077 (Sigma-Aldrich, Poole, UK). For stripping of membrane-bound 
IgE, PBMC were resuspended in lactic acid (13.4 mmol/l lactate, 140 mmol/l NaCl, 5 mmol/l KCl, 
pH 3.9) and incubated at 4˚C for 5 minutes
155
. Human serum albumin (HSA) 0.5% in RPMI was 
added and the solution neutralised with 12% Tris. After washing with 0.5% HSA, the cell pellet 
was resuspended in 1:100 of the original blood volume in 0.5% HSA. The cell suspension was 
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incubated for 60 minutes at 37˚C with the same volume of individual plasma from study 
participants. After washing, resensitised PBMC were stimulated with peanut extract or purified 
peanut proteins, stained and analysed by flow cytometry, as described in section 2.3.6.1. 
For inhibition experiments, 20 µL of plasma from a reference PA patient was incubated with 20 µL 
of plasma from PS or NA patients and 10 µL of allergen (concentration as indicated) before the 
addition of 1x10
6
 (50 µL) IgE-stripped PBMC to the allergen-plasma mixture. The reference PA 
plasma contained 172 KUA/l of specific IgE to peanut, 74.1 KUA/l of specific IgE to Ara h 1, 77.6 
KUA/l of specific IgE to Ara h 2 and 33.6 KUA/l of specific IgE to Ara h 3. The same reference PA 
plasma was used in all basophil inhibition experiments. The results were expressed as 
percentage of inhibition and calculated using the formula: 
% inhibition = (%CD63+ of cells sensitised with PA plasma-%CD63+ of cells sensitised with PA 
plasma in presence of test plasma)/%CD63+ of cells sensitised with PA plasma. 
 
2.3.6.6 Optimisation of basophil assays 
The described basophil assays were developed specifically for this research project.  
 
2.3.6.6.1 Anti-IgE dose response 
PBMC were isolated from citrate-dextrose anticoagulated blood of atopic adult volunteers by 
density gradient separation using Histopaque-1077 (Sigma-Aldrich, Poole, UK) and stimulated 
with 0.5% HSA in RPMI, 1 µM fMLP or anti-IgE serially diluted in 0.5% HSA RPMI at different 
concentrations ranging from 0.01 to 100 µg/ml to identify the optimal anti-IgE concentration to be 
used in future experiments.  
Expression of CD63 and CD203c on the surface of basophils followed a bell-shaped dose-
response curve (Figure 2.3). 
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Figure 2.3 Dose-response curve of CD63 expression on the surface of basophils following stimulation with 
different concentrations of goat polyclonal anti-human IgE. 
 
The optimal concentration of anti-IgE was 0.1 µg/ml or 1 µg/ml in replicate experiments (n=2). 
Taking into account the variability in basophil reactivity between donors and the reported optimal 
concentration of anti-IgE (1 to 100µg/ml
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), the concentration of anti-IgE of 1 µg/ml was adopted 
for all subsequent experiments unless otherwise indicated. 
 
2.3.6.6.2 Allergen dose-response 
Following passive sensitisation of basophils with plasma from peanut allergic patients, stimulation 
with different concentrations of peanut extract ranging from 0.001 to 10,000 ng/ml was performed. 
The expression of CD63 and CD203c was detected after stimulation with increasing 
concentrations of peanut extract, resulting in a bell-shaped dose-response curve. Figure 2.4 
illustrates a representative experiment where basophils were sensitised with plasma from a 
peanut allergic patient with high specific IgE to peanut (172 KUA/l) and to peanut major allergens, 
Ara h 1 (74.1 KUA/l), Ara h 2 (77.6 KUA/l) and Ara h 3 (33.6 KUA/l). Prior to passive sensitisation, 
native and IgE-stripped basophils from the basophil donor did not respond to peanut extract but 
only to the positive controls, 1 µg/ml anti-IgE and 1 µM fMLP. 
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Figure 2.4 Dose-response curve of CD63 expression on the surface of basophils following stimulation with 
different concentrations of peanut extract.  
Basophils were sensitised with plasma from a peanut allergic patient prior to stimulation with peanut extract. Anti-IgE and 
fMLP were used as positive controls. Abbreviations: aIgE, anti-IgE; fMLP, formyl-methionyl-leucyl-phenylalanine. 
 
In the whole blood basophil activation assay, a range of concentrations of peanut extract from 
0.01 to 10,000 ng/ml was initially tested but since no peanut allergic patient tested reacted at 0.01 
ng/ml the range was reduced to 0.1 to 10,000 ng/ml in the final protocol. 
 
2.3.6.6.3 Stimulation with purified peanut allergens 
Passive sensitisation experiments were performed in which basophils sensitised with plasma from 
a peanut allergic patient were stimulated with purified peanut allergens, namely Ara h 1, Ara h 2, 
Ara h 3 and Ara h 6. Purified natural peanut allergens were individually able to activate basophils 




Figure 2.5 Purified native peanut allergens were able to individually induce basophil activation.  
Upper right quadrants (Q2) show the percentage of CD63-positive basophils sensitised with plasma from a peanut allergic 
patient (with high levels of specific IgE to Ara h 1, Ara h 2 and Ara h 3) after stimulation with (A) 100 pM Ara h 1, (B) 50 pM 
Ara h 2, (C) 1 nM Ara h 3 and (D)1 nM Ara h 6. 
 
 
2.3.6.6.4 IgE dependency 
In a passive sensitisation basophil activation assay, basophils were separately sensitised with 
different dilutions (50%, 1%, 0.5% and 0.1%) of plasma from a peanut allergic patient in 0.5% 
HSA/RPMI. The concentration of peanut-specific IgE in undiluted plasma was 172 KUA/l. 
Allergen-induced basophil activation occurred in a plasma dilution-dependent manner, possibly 
depending on the concentration of peanut-specific IgE – Figure 2.6. 
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Figure 2.6 Peanut-induced CD63 expression on the surface of basophils sensitised with different 
concentrations of the same plasma sample of a peanut allergic patient (PA plasma).  
Basophils were separately sensitised with undiluted plasma (100%) and serial dilutions (50%, 1%, 0.5% and 0.1%) of the 
same PA plasma and stimulated with 10 ng/ml peanut extract.  
 
 
2.3.6.6.5 Donor dependency 
2.3.6.6.5.1 Atopic versus non-atopic donors  
Passive sensitisation experiments were performed using basophils from atopic and non-atopic 
donors sensitised with plasma from the same peanut allergic patient with high levels of peanut-




Figure 2.7 Peanut-induced CD63 expression of basophils from atopic and non-atopic donors sensitised with 
the same plasma sample of a peanut allergic patient.  
Results for the atopic donor are presented in red and results for the non-atopic donor are presented in blue. Anti-IgE and 
fMLP were used as positive controls. Abbreviations: aIgE, anti-IgE; fMLP, formyl-methionyl-leucyl-phenylalanine. 
 
 
Although sensitivity of basophils to peanut extract was similar, as evaluated by EC50 
(approximately 0.01 ng/ml), there was lower basophil reactivity from the non-atopic donor, 
reaching a plateau at peanut extract concentrations ranging from 0.1 ng/ml to 10,000 ng/ml. This 
could be due to the lower density of FcɛRI receptors on the surface of non-atopic donors’ 
basophils
156
. Since the expression of FcɛRI on the surface of basophils could be a limiting factor 
in passive sensitisation experiments, atopic (non-peanut allergic) volunteers were preferred as 
donors of cells for all subsequent passive sensitisation basophil experiments. 
 
2.3.6.6.5.2 Variability in basophil responses among cell donors 
In every passive sensitisation experiment, a set of cells was sensitised with plasma from the 
same peanut allergic patient (peanut-specific IgE of 172 KUA/l, specific IgE to Ara h 1 of 74.1 
KUA/l, specific IgE to Ara h 2 of 77.6 KUA/l and specific IgE to Ara h 3 of 33.6 KUA/l), as an internal 
inter-assay control. 
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Figure 2.8 illustrates the heterogeneous response of basophils from different non-peanut allergic 
donors sensitised with the same plasma sample from a peanut allergic patient and stimulated with 
an optimal (10 ng/ml) and a suboptimal (0.1 ng/ml) concentration of peanut extract, as well as 
with anti-IgE (1 µg/ml).  
 
Figure 2.8 Variability of peanut-induced CD63 expression by basophils from different donors  
Results are presented for basophils from 9 donors sensitised with the same plasma sample of a peanut allergic patient. 
Quartiles, maximum and minimum are represented. Abbreviations: PE, peanut extract.  
 
 
2.3.7 Mast cell assays 
To try to overcome the variability when using primary human basophils' from different blood 
donors and in view of obtaining a standardised in vitro passive sensitisation assay to investigate 
serological determinants of allergy and tolerance, mast cell assays were developed using the 
LAD2 mast cell line
157
, kindly provided by Dr Dean Metcalfe at the Laboratory of Allergic Diseases 
in the NIH. The aim was to develop functional mast cell activation and inhibition flow cytometry-
based assays to assess the functionality of peanut-specific IgE and other antibody isotypes in 
relation to peanut allergy versus tolerance.These assays had the additional advantage of allowing 
studying mast cells, which are the other main effector cells of IgE-mediated peanut allergy and 
anaphylaxis, apart from basophils. 
LAD2 cells have been previously used in mediator release assays, where the concentration of 
mediators such as β-hexosaminidase is measured in the cell supernatant, and protocols have 
been published
158
. The result obtained is an average of the mediator released by single mast 






















the single cell level. Lysosomal associated membrane proteins have been detected in human skin 
mast cells isolated from circumcision cutaneous tissue
159
. I hypothesised that LAD2 cells are able 
to bind IgE present in human plasma and to reproduce clinical reactivity (or tolerance) to peanut 
allergens by up-regulating (or not) the expression of these activation markers on their surface 
during degranulation measured by flow cytometry. 
In pilot experiments, LAD2 cells expressed the high affinity IgE receptor and selected IgG 
receptors on their surface (Figure 2.9).  
Figure 2.9 Expression of selected IgE and IgG receptors on the surface of LAD2 cells. 
(A) high affinity IgE receptor, (B) CD64 or FcγRI, (C) CD16 or FcγRIII and (D) CD32 or FcγRII Histograms in red represent 
the mean fluorescent intensity compared to the isotype control in grey. The percentage of positive cells is represented.   
 
 
LAD2 cells were sensitised with IgE from human plasma or myeloma (Figure 2.10) and up-










Figure 2.10 Expression of IgE on the surface of LAD2 cells 
LAD2 cells were sensitised with plasma (red), human IgE purified from myeloma (blue) and buffer alone (grey). 
Histograms and percentage of positive cells are indicated. 
 
 
Figure 2.11 LAD2 cells up-regulate the expression of lysosomal-associated membrane proteins and CD203c 
following activation with ionomycin.  
A. LAMP-1; B. LAMP-2; C. LAMP-3 or CD63; D.CD203c. Cells were stimulated with 1μg/ml ionomycin (red) or buffer alone 
(blue). Isotype control is shown in grey. Histograms and percentage of positive cells are indicated. Abbreviation: LAMP, 
lysosomal-associated membrane protein. 
 
The mast cell activation assay consisted of a sensitisation phase, in which LAD2 cells were 
cultured in the presence of human plasma, and a stimulation phase, in which LAD2 cells 
sensitised with plasma were stimulated with peanut proteins and other IgE and non-IgE-mediated 
stimulants, as controls. Staining with IgE-PECy7 was used to control for sensitisation, i.e. for IgE 
binding. The changes in the expression of activation markers on the cell surface following 
stimulation were then evaluated using flow cytometry.  
Up-regulation of LAMP-1 and LAMP-3 (CD63) - but not LAMP-2 - was observed on the surface of 
LAD2 cells that were previously sensitised with plasma from a peanut allergic patient following 
stimulation with peanut extract.  
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Sensitising LAD2 cells with same plasma sample from a PA patient resulted in consistent peanut-
induced mast cell activation (Figure 2.12). This same plasma sample was used in all mast cell 
inhibition experiments as the reference plasma to assess the ability of test plasma to inhibit 
peanut-induced mast cell activation.  
 
Figure 2.12 Dose-response of CD63 expression on the surface of mast cells sensitised with the same 
plasma sample of a peanut allergic patient following stimulation with different concentrations of peanut 
extract.  
Results of 3 independent experiments are presented. A. Individual dose-response curves are represented. B. Mean and 
standard error are represented by dots and error bars, respectively.  
 
2.3.7.1 Mast cell activation assay 
LAD2 cells were cultured with rIL-4 for 5 days before overnight sensitisation with patients' plasma 
in a 1:10 dilution with culture media. Sensitised cells were stimulated with different concentrations 
ranging from 0.1 to 1000 ng/ml of peanut extract, 1 µg/ml of anti-IgE, 1 µg/ml of ionomycin in 
RPMI/BSA or 0.04% BSA RPMI for 30 minutes at 37˚C and stained with viability dye eFluor 450 
(eBioscience, San Diego, CA, USA) and CD107b fluorescein isothiocyanate (clone ABL-93, 
eBioscience, San Diego, CA, USA), CD203c-phycoerythrin (clone NP4D6, Biolegend, San Diego, 
CA, USA), CD107a-peridinin chlorophyll protein-Cy5.5 (clone H4A3, Biolegend, San Diego, CA, 
USA), CD63-allophycocyanin (clone MEM259, Biolegend, San Diego, CA, USA) and IgE- 
phycoerythrin-Cy7 (clone NHE-18, Biolegend, San Diego, CA, USA) and analysed by flow 
cytometry. LAD2 cells were gated as CD203c+ viable cells. Mast cell activation was expressed as 
%CD107a+ or %CD63+ cells. Flow cytometry was performed on a FACS Canto II with FACSDiva 




2.3.7.2 Inhibition of mast cell activation assay 
For inhibition experiments, 20 µL of plasma from PS or NA patients or stimulation buffer was 
incubated with an equal volume of stimulation buffer and 10 µL of allergen (concentrations as 
indicated) at 37˚C for one hour. LAD2 cells sensitised overnight with 100µL of plasma from a PA 
patient (as described for the mast cell activation assay above), were washed and then added to 
the allergen-plasma mixture. The same PA plasma was used in all mast cell inhibition 
experiments. This plasma had similar IgE levels and patterns of sensitisation to peanut allergens 
(i.e. positive to Ara h 1, Ara h 2 and Ara h 3) to the plasma used in the basophil inhibition 
experiments: peanut-specific IgE of 255 KUA/l, specific IgE to Ara h 1 of 84.4 KUA/l, specific IgE to 
Ara h 2 of 125 KUA/l, specific IgE to Ara h 3 of 1.8 KUA/l.  
 
2.3.7.3 Degranulation assay using RBP-SX38 cells 
Cells of the RBL-SX38 rat basophilic cell line, which stably express human FcεRI
160
, were used in 
the collaborative project described in Section 6.2. Cells were cultured in RPMI-1640 medium 
(Sigma-Aldrich) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich), 1% Penicillin-
Streptomycin-Glutamine (Life Technologies, Carlsbad, Calif) and 1 mg/ml Genticin (Life 
Technologies). RBL-SX38 cells were harvested and resuspended in BAT buffer (HBSS with 2 mM 
CaCl2) at 2x10
7
 cells/ml, then incubated with Phl p 7–specific IgE at a concentration of 0.5 mg/ml 
in 50 µl BAT buffer for 30 minutes at 37°C. Aliquots of 10
6
 cells were washed with HBSS and 
incubated with 50 µl aliquots of the sera (diluted 1:2 in BAT buffer) for 30 minutes at 37°C. After 
further washing with HBSS, the cells were resuspended and incubated with 50 µl of 1 µg/ml of in-
house produced, freshly biotinylated Phl p 7 diluted in BAT buffer for 30 minutes at 37°C. Surface-
bound IgE was detected using anti-IgE-FITC (Vector Laboratories, Burlingame, Calif) and Phl p 7 




2.4 Statistical analyses 
Statistical analyses were performed with SPSS 20.0 and STATA 12.1 for Windows, unless 
otherwise indicated. Significance was determined using a two-sided α level of 0.05.  
 
2.4.1 Power calculation 
The study to assess the performance of the basophil activation test to diagnose peanut allergy 
was undertaken in a specialised tertiary allergy referral centre where the anticipated prevalence of 
peanut allergy is around 50%. Based on a previous study
143
, the expected sensitivity and 
specificity of BAT is 95%. Our desired precision in estimating 95% confidence intervals was 6.5%. 
To achieve this precision for sensitivity and specificity, we need a total sample size of 89 
patients
161
. Taking into account that BAT non-responders cannot be analysed and that the rate of 
BAT non-responders is usually between 7.5-10%, this resulted in a final sample size estimation of 
100 patients.  
 
2.4.2 Comparison of groups 
Qualitative variables were expressed as number and percentage and compared between PA and 
PS using the Fisher’s Exact test or the Chi-Square test. Quantitative continuous variables were 
expressed as median and interquartile range and compared using the Mann-Whitney U test or the 
Kruskall-Wallis test. For comparison of paired samples, the Wilcoxon Signed Ranks Test was 
used.  
 
2.4.3 Diagnostic study 
The diagnostic performance of the whole blood basophil activation test to peanut was assessed 
and diagnostic cut-offs were determined. The utility of the basophil activation test in combination 
with other diagnostic tests was also assessed.  
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2.4.3.1 ROC curve analyses 
The performance of allergy tests in predicting the allergic status was examined using ROC curve 
analyses. The cut-offs to predict peanut allergy and peanut tolerance for BAT and the various 
allergy tests with optimal accuracy were determined according to the Youden index and validated. 
Internal validation was performed using repeated random sub-sampling validation (bootstrap) and 
"leave-one-out" methodologies
162
. Both methodologies produced similar results in estimating the 
optimal cut-points and the former methodology is reported. The 95% confidence interval was 
constructed using bootstrapping methodology with 1000 replications to reflect on the 
reproducibility
163
. An external validation study was also conducted using a new cohort of 65 
subjects (25 PA, 24 PS and 16 NA) mainly recruited from the PAS (Peanut Allergy Sensitisation) 
study, a group of patients from all over the country that were excluded from the LEAP study
8
, and 
from a private Paediatric Allergy clinic in London. The cut-offs previously determined in the 
primary study population were applied to this validation study population and sensitivity, 
specificity, predictive values, likelihood ratios and accuracy were calculated. 
 
2.4.3.2 Agreement analyses 
Three Paediatric Allergy specialists were asked to classify 44 equivocal cases from the primary 
study population as peanut allergic or tolerant based on the history and results of SPT, peanut-
specific IgE and specific IgE to Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9. The agreement 




2.4.3.3 Combination of the basophil activation test with other diagnostic tests 
In the primary study population, following ROC curve analyses, the performance of BAT with SPT, 
peanut-specific IgE and Ara h 2-specific IgE was compared using conventional cut-offs, indicated 
in Figure 1.6. For skin prick test, 8 mm and 3 mm were used as positive and negative cut-offs, 
respectively
129
. For specific IgE to peanut, 15 KUA/L and 0.35 KUA/L were used as positive and 
negative cut-offs, respectively
128, 129
. For specific IgE to Ara h 2, 1 KUA/L and 0.10 KUA/L were 
used as positive and negative cut-offs, respectively
44
. For BAT, the cut-off for the mean of 
percentage of CD63-positive basophils at 10 and 100 ng/ml of peanut extract was used as both 
positive and negative cut-off. The diagnostic utility of BAT was further assessed when considered 
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in combination with other allergy tests, i.e. considering the results of different tests 
simultaneously, and when considered as a second or third step in the diagnostic process, i.e. 
performed in selected patients where the results of single or of combinations of tests were 
equivocal.  
When interpreted individually, the results of standard allergy tests were considered diagnostic of 
allergy when ≥95% PPV cut-off, diagnostic of tolerance when <95% negative predictive value 
(NPV) cut-off and equivocal when between the positive and the negative cut-offs (Figure 1.6). 
BAT was considered equivocal in the case of "non-responders" (defined as <5% CD63-positive 
basophils to IgE-mediated controls and ≥5% CD63%+ basophils to fMLP). 
The combination of allergy tests were interpreted as equivocal if one test result was ≥95% PPV 
cut-off and another test result was <95% NPV cut-off or when all tests gave equivocal results (as 
defined above) or a combination of equivocal results and results <95%NPV.  
In these simulations, oral food challenges were deemed necessary when the interpretation of 
tests was equivocal. The combination of SPT and peanut-specific IgE was the clinical reference-
point against which the change in the number of oral food challenge required was determined.  
 
2.4.4 Severity and threshold study 
Since BAT was shown to discriminate between peanut allergic and peanut tolerant patients with 
high diagnostic accuracy
165
, I hypothesised that BAT may also indicate the severity and the 
threshold of allergic reactions to peanut in allergic patients.  
 
2.4.4.1 Logistic regression analyses 
Allergy test parameters noted to have differences (p value <0.2) in the comparison of groups (i.e. 
severe versus non-severe reactors and low versus high threshold) were further tested as 
independent variables in logistic regression analyses using severity or threshold dichotomised 
groups as dependent variables. Since several (correlated) BAT parameters distinguished 
between severity and threshold groups, only the best performing BAT parameter (based on the 
lowest p value) was tested in the logistic regression analysis. For severity this parameter was the 
ratio of the percentage of CD63-positive basophils at 100 ng/ml of peanut to the percentage of 
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CD63-positive basophils following stimulation with anti-IgE (CD63 peanut/anti-IgE). For threshold 
this parameter was CDsens determined using CD63. Independent associations between severity or 
threshold and allergy test parameters were further investigated by forward multivariable logistic 
regression analyses and only variables significantly contributing to the model (p<0.05) were 
retained. 
 
2.4.4.2 BAT cut-offs for severity and for threshold of allergic reactions  
In order to quantify the differences in basophil activation between severity and threshold groups, 
patients were dichotomised based on the 75th percentile of CD63 peanut/anti-IgE or CDsens and 
the proportion of patients with severe reactions or low threshold were compared between those 
falling above and below the 75th percentile.  
BAT cut-offs for severity and threshold were also determined by ROC curve analyses, using the 
software MedCalc 13.3 (MedCalc Software, Ostend, Belgium). The Youden index was the criteria 
adopted to select the optimal cut-offs. Bias-corrected and accelerated bootstrapped 95% 
confidence intervals were calculated for sensitivity, specificity and predictive values. 
 
2.4.4.3 Correlation between severity and threshold 
The correlation between the clinical and the BAT parameters for severity and threshold were 
assessed using Spearman correlation.  
 
2.4.5 IgG4 study 
Apart from the analyses for comparison of groups, described in section 2.4.2. above, in the work 
described in chapter 7 referred to here as "IgG4 study", additional statistical methods were used, 
including analysis of covariance using ranks and multivariate logistic regression analysis. 
 
2.4.5.1 Analysis of covariance using ranks  
In order to confirm whether the peanut allergic status in PA and PS patients could be explained by 
differences in the peanut-specific IgG4/IgE ratio or differences in peanut-specific IgE, the peanut-
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2.4.5.2 Multivariate logistic regression model 
To clarify the contribution of peanut-specific IgE and of peanut-specific IgG4 to the clinical 
outcome in PA and PS patients, a multivariate logistic regression model with log base 10 
transformed peanut-specific IgG4 and peanut-specific IgE as well as a relative importance 
analysis were performed using JMP® Pro 11.2.1 for Windows. 
 
2.4.5.3 Correlation analyses 
To study the relationship between the ratio of peanut-specific IgG4 to IgE and basophil activation, 
the Spearman correlation coefficient was calculated and the corresponding p value determined.  
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Chapter 3 Gating strategy for the whole blood basophil 
activation test 
Different cell-surface markers can be used for the identification of basophils in whole blood, 
including the combination of CD123 and HLA-DR
64, 69
. CD123 is the low affinity (α) subunit of the 
IL-3 receptor and is highly expressed on plasmacytoid dendritic cells and basophils, and in low 
levels on monocytes, eosinophils, myeloid dendritic cells and haematologic progenitor cells. While 
eosinophils can be excluded by side-scatter, additional staining with HLA-DR is required to 
discriminate between HLA-DR-negative basophils and HLA-DR-positive dendritic cells and 
monocytes. In previous studies, the expression of CD123 and HLA-DR were shown to be stable 
with the atopic status of patients and following basophil activation
66, 69
. However, stimulation of the 
IL-3 receptor by IL-3 can increase the baseline expression of CD203c and possibly CD63 and 
maximise the up-regulation of CD63 upon basophil activation
70, 167
. Therefore, I hypothesised that 
CD123 expression could change in response to basophil activation. With increasing attention 
given to basophils in the coordination of adaptive immune responses and their possible role in 
antigen presentation
168-170
, I hypothesised that there could be an increase in the expression of 
HLA-DR by basophils following activation by allergen or by other stimulants. Given the important 
implications for the gating strategy to be adopted for BAT in future studies, I sought to determine 
whether the expression of CD123 and HLA-DR remained unchanged with basophil activation and 
to select the best gating strategy using these markers.  
 
3.1 Summary of methodology 
Basophil activation test to peanut was performed in children aged from 5 months to 17 years, as 
described in Section 2.3.6.1. Basophil activation was expressed as the proportion of CD63-
positive basophils, corrected for the negative control, and as a ratio of the MFI of CD203c-PE of 
stimulated to unstimulated basophils, the stimulation index of CD203c (SI CD203c). The variation 
of CD123 was defined as the proportion of the difference between the MFI of CD123-FITC of the 
negative control and of the stimulated cells and the MFI of CD123-FITC of the negative control 
and calculated using the formula:  
Variation of CD123-FITC = (MFI CD123-FITC pre-stimulation - MFI CD123-FITC post-
stimulation)/MFI CD123-FITC pre-stimulation.  
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All patients tested (n=116) responded to fMLP; therefore, when assessing basophil activation 
induced by fMLP all patients were considered (n=116). When assessing basophil activation 
induced by anti-IgE (n=104), patients with non-responder basophils, i.e. basophils which did not 
respond to any IgE-mediated stimulants but only to fMLP, were excluded. When evaluating the 
response to peanut, peanut allergic patients (as defined in Section 2.1) with responding-basophils 
were considered (n=42). For data analysis, when only one concentration of peanut extract was 
used, the optimal concentration of 100 ng/ml was selected. 
Qualitative variables were represented as numbers of patients and percentage (taking into 
account the missing values) and groups were compared using the Fisher’s Exact test or Chi-
Square test, as appropriate. Continuous variables were represented as median and range and 
were compared using the Mann-Whitney U test or the Kruskall-Wallis test, as appropriate. 
Wilcoxon-signed rank test was used to compare samples before and after stimulation. For 
receiver-operating characteristic (ROC) curve analysis, the performance of the average 
percentage of CD63-positive basophils at 10 and 100 ng/ml of peanut extract determined using 
different gating strategies was evaluated against the patients' allergic status to peanut, i.e. in 
relation to allergy versus tolerance. All statistical analyses were performed with SPSS 20.0 for 
Windows. Significance was determined using a two-sided α level of 0.05.  
 
3.2 Gating on basophils using CD123 and HLA-DR led to the loss-to-
analysis of cells 
Identifying basophils with CD123 and HLA-DR led to the loss to analysis of cells particularly in 
conditions where basophils were activated. The baseline number of unstimulated basophils was 
variable (median=1721, IQR=1225-2184) but comparable between atopic and non-atopic patients 
(p=0.444) and between peanut allergic and peanut tolerant children (p=0.739). Following basophil 
stimulation with fMLP (p=0.012) and anti-IgE (p=0.005), the number of basophils was significantly 
reduced compared to baseline (Table 3.1). Of note, if only patients with non-responder basophils 
were considered (n=12), the change in basophil number was significant after fMLP stimulation 
(p=0.004) but not after anti-IgE stimulation (p=0.099), suggesting that the reduction in cell number 
was dependent on basophil activation.  
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Table 3.1. Number of basophils (gated as SSC
low
 CD123+ HLA-DR- cells) in different stimulation conditions.  
Median and interquartile range are represented. p value refers to the comparison of post-stimulation conditions with the 
negative control. Significant p values are marked in bold. 
Stimulant n Pre-stimulation Post-stimulation p value 
fMLP 116 1722 (1226, 2184) 1572 (1037, 2100) 0.012 
Anti-IgE 104 1722 (1221, 2191) 1414 (972, 1995) 0.005 
Peanut extract 42 1732 (1212, 2174) 1514 (914, 2041) 0.134 
 
 
Considering anti-IgE stimulation, 14% of patients showed more than 25% decrease in the number 
of basophils compared to the negative control (Figure 3.1). In 27% of patients, this number 
decreased to below 1000 basophils. Selecting peanut allergic patients, a trend was seen toward a 
reduction in the basophil number after stimulation with peanut extract compared to the negative 
control (n=42, p=0.081). As the starting volume of blood, and thus the starting number of cells, 
was similar in all experimental conditions, I hypothesised that the expression of the identification 
markers, CD123 and/or HLA-DR, changed with basophil activation. 
 
 
Figure 3.1 Variation in the number of basophils following stimulation with anti-IgE compared to unstimulated 
basophils.  





3.3 CD123 is down-regulated with basophil activation 
To evaluate the changes in the expression of CD123 and HLA-DR on the surface of basophils, I 
used CD203c to gate on the basophil population (Figure 3.2).  
 
Figure 3.2 Preferred gating strategy for the basophil activation test.  
Basophils were identified in whole blood in the lymphocyte-monocyte area (A) as SSC
low
/CD203c+ (B) and CD123+/HLA-
DR- (C). Figures D and E show CD63 and CD203c expression in unstimulated basophils (D) and basophils stimulated with 
100 ng/ml of peanut extract (E). In figure F, histograms show the changes in the mean fluorescence intensity of CD203c-
PE following stimulation with peanut extract. 
 
The baseline MFI of CD123-FITC was variable between patients (median=1082, interquartile 
range=98-1549) but comparable between atopic and non-atopic children (p=0.153) and between 
peanut allergic and peanut tolerant patients (p=0.826). Down-regulation of CD123 by basophils 
was seen following stimulation with fMLP (n=116, p<0.001), anti-IgE (n=104, p<0.001) and peanut 
extract (n=42 peanut allergic patients, p<0.001) - Table 3.2, Figure 3.3.A. and Figure 3.4.A. In 
92.3% of patients, anti-IgE stimulation led to a decrease in the MFI of CD123-FITC compared to 
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the negative control: in 38.5% less than 25% decrease, in 26.9% between 25 and 50% decrease, 
in 13.5 % between 50 and 75% decrease and in 13.5% greater than 75% decrease (Figure 
3.4.B). The down-regulation of CD123 expression on the surface of basophils stimulated by fMLP 
and by anti-IgE was correlated (rs=0.723, p<0.001), suggesting this phenomenon happened in the 
same patients with different stimulants. The decrease in CD123 expression with anti-IgE 
stimulation was similar between atopic and non-atopic (p=0.828) and between peanut allergic and 
peanut tolerant children (p=0.431). The expression of CD123 was stable when basophils were not 
activated - for example, after stimulation with peanut in peanut tolerant patients (p=0.658) or after 
stimulation with anti-IgE in non-responders' basophils (p=0.083), while down-regulation was still 
observed in this subgroup after stimulation with fMLP (p=0.006).  
 
Table 3.2 Expression of CD123 on the surface of basophils (gated as SSC
low 
CD203c+ cells) as measured 
by MFI of CD123-FITC in different stimulation conditions.  
Median and interquartile range are represented. p value refers to the comparison of post-stimulation conditions with the 
negative control. 
Stimulant n Pre-stimulation Post-stimulation p value 
fMLP 116 1082 (98, 1549) 514 (75, 1020) <0.001 
Anti-IgE 104 1081 (95, 1549) 495 (60, 1111) <0.001 






Figure 3.3 Changes in the MFI of CD123-FITC and of CD203c-PE following stimulation with peanut extract. 
A. MFI of CD123-FITC; B. MFI of CD203c-PE; in unstimulated basophils (blue) and following stimulation with 100 ng/ml of 






Figure 3.4 Down-regulation of CD123 expression with basophil activation. 
A. Histogram of MFI of CD123-FITC before and after anti-IgE stimulation; B. Change in the MFI of CD123-FITC on the 
surface of basophils following anti-IgE stimulation; C. Correlation between the decrease in CD123 and the up-regulation of 
CD63 on the surface of basophils; D. Relationship between CD63 and CD123 on CD203c+ cells at rest and with activation 
from a donor demonstrating the loss of CD123 expression phenotype in activated cells.  
 
 
Basophils were HLA-DR-negative and were distinct from the CD123+ HLA-DR+ population 
probably constituted by plasmacytoid dendritic cells. Following basophil activation, the HLA-DR 
expression did not increase and remained distinct from HLA-DR-positive cells.  
 
3.4 Decrease in CD123 correlates with the up-regulation of CD63 and 
CD203c  
Taken together the previous observations indicate that the down-regulation of CD123 by 
basophils is an activation-dependent phenomenon. A significant correlation was observed 
between the decrease in the MFI of CD123 and the up-regulation of basophil activation markers 
after stimulation with anti-IgE (Figure 3.4.C) as measured by the stimulation index of CD203c (rs=-
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0.35, p<0.001) or by the percentage of CD63-positive basophils (rs=-0.31, p<0.001), suggesting 
that the basophils that down-regulate CD123 the most are also the ones that express more CD63 
and CD203c. The correlations between changes in the MFI of CD123-FITC and in the percentage 
of CD63-positive basophils or the SI of CD203c following stimulation with fMLP (-0.191, p=0.04 
and -0.223, p=0.016, respectively) and following stimulation with peanut extract (-0.229, p=0.145 
and -0.31, p=0.051, respectively) were less strong. 
 
3.5 Additional use of CD203c prevented the loss-to-analysis of 
activated basophils 
The down-regulation of CD123 with basophil activation has important implications in gating 
strategies that depend on the marker CD123. Identifying basophils using CD123 and HLA-DR led 
to the loss-to-analysis of basophils, particularly of the ones with higher expression of the 
activation markers CD63 and CD203c, and thus leading to an underestimation of basophil 
activation (Table 3.3 and Figure 3.5.A). Adding CD203c as an identification marker maintained 
the cell number, regardless of the basophil activation status. Thus, the basophils that were most 
highly activated were included in the analysis, improving the value of the test (Table 3.3 and 
Figure 3.5.B). The expression of CD203c remained stable or increased following basophil 
activation, allowing a distinct separation from the remaining blood cells (Figure 3.3.B.). 
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Table 3.3 Comparison of different gating strategies to identify basophils.  
Median and inter-quartile range are represented. Medians were compared between 3 groups using Kruskall-Wallis test and between 2 groups using Mann-Whitney U test: 
1
CD123+ HLA-DR- versus CD203c+; 
2
CD203c+ versus CD203c+ HLA-DR-, 
3
CD123+ HLA-DR- versus CD203c+ HLA-DR-. 
a 
n=116 (whole population), 
b 
n=104 (non-responders were excluded), 
c 
n= 42 (peanut allergic). Abbreviations: MFI, mean 
fluorescence intensity; SI, stimulation index; fMLP, formyl-methionyl-leucyl-phenylalanine. 

















 1722 (1226, 2184) 1782 (1334-2239) 1697 (1268-2134) 0.635 0.390 0.436 0.908 
Anti-IgE
b
 1414 (972-1995) 2156 (1620-3097) 1939 (1452-2877) <0.001 <0.001 0.06 <0.001 
fMLP
a
 1572 (1037, 2100) 2146 (1684-2940) 1891 (1447-2715) <0.001 <0.001 0.084 <0.001 
Peanut extract
c





 24.8 (10.7, 42.5) 29.4 (17.3-48.9) 32.0 (17.1-53.9) 0.021 0.020 0.809 0.013 
fMLP
a
 28.2 (15.9, 42.3) 41.1 (26.3-53.4) 41.4 (26.9-56.9) <0.001 <0.001 0.644 <0.001 
Peanut extract
c





 104.0 (26.3-195.2) 148 (36, 345) 159.3 (45.4-350.8) 0.019 0.029 0.611 0.009 
fMLP
a
 139 (37, 284) 285 (76, 683) 307 (81, 708) <0.001 <0.001 0.678 <0.001 
Peanut extract
c




 2.4 (1.5-3.8) 2.9 (2.0-4.2) 3.2 (2.0-4.6) 0.004 0.028 0.191 0.002 
fMLP
a
 2.3 (1.7-3.1) 2.6 (2.2-3.7) 2.8 (2.2-4.1) <0.001 0.001 0.280 <0.001 
Peanut extract
c






 2331 (197-5633) 4833 (254, 9020) 5013 (29-9161) 0.008 0.011 0.677 0.005 
fMLP
a
 2763 (216-5139) 4549 (279, 7961) 4908 (334-8270) 0.001 0.002 0.813 0.001 
Peanut extract
c





Figure 3.5 Gating with CD123/HLA-DR led to the loss-to-analysis of basophils and underestimation of basophil activation. 
In a representative experiment, basophils were gated as SSClow CD123+ HLA-DR- (A) or SSClow CD203c+ HLA-DR- (B). The percentage of CD63+ basophils is represented in different conditions: negative 





3.6 Selecting the optimal gating strategy using CD203c 
In a subset of patients (16%), gating solely on SSC
low
 CD203c+ cells included a population of 
cells that were HLA-DR+, which in selected experiments were identified as CD14+. To overcome 
this, three identification markers were combined to gate on basophils in subsequent experiments: 
SSC
low
 CD203c+ cells were first selected and then gated on CD123/HLA-DR following the contour 
of the cell population of interest, including CD123
low
 as well as CD123
high
 cells, all HLA-DR-. 
The gating strategy using CD203c+ HLA-DR- proved superior to CD123+ HLA-DR-, similar to 
what was observed for gating on CD203c+ cells alone (Table 3.3).  The combination of the three 
markers was superior to CD203c+ in the subgroup of peanut allergic patients improving the 
detection of basophil activation (Table 3.3, borderline non-significant p values for the percentage 
of CD63-positive basophils, SI CD203c and MFI of CD203c) and in patients with a subset of 
CD203c+ HLA-DR+ cells mentioned above thus avoiding contamination with HLA-DR+ cells.  
Markers for other immune cells (anti-CD14, anti-CD3, anti-CD19, anti-CD41 and in six of these 
experiments also anti-CD56) were included in selected experiments (n=10) to exclude potential 
cell contamination within the adopted basophil gate (Figure 3.6). The results were similar using 







/lineage-negative/CD203c+/HLA-DR- (Figure 3.6.A); however, using all the 
markers (Figure 3.6.A) a "cleaner" population was obtained. None of the other cell populations 
(CD14+, CD3+, CD19+, CD41+, CD56+) expressed simultaneously both markers CD203c or 
CD63 (Figure 3.6.D and E). Given the higher cost and longer time involved in the use of multiple 








Figure 3.6 Representative experiment of basophil activation performed with additional staining for CD3+, 
CD19+, CD41+, CD56+ and CD14+ using antibodies labelled with pacific blue (PB) to exclude possible cell 
contamination within the adopted basophil gating strategy.  
Histograms represent unstained cells (grey) and cell stimulated with buffer alone (blue), 1000 ng/ml of peanut extract 
(orange), 1 µg/ml of anti-IgE (red) or 1 µM of fMLP (green).  
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3.7 Gating strategy of BAT has important diagnostic implications 
The diagnostic performance of BAT gating on SSC
low
/CD203c+/HLA-DR- was superior to the one 
using SSC
low
/CD123+/HLA-DR- with a larger area under the ROC curve (Figure 3.7). The optimal 
cut-off based on the ROC curve generated using the latter gating strategy resulted in a 91% 
diagnostic accuracy with 5% false-negatives and 3% false positives (Table 3.4). Adopting the 
SSC
low
/CD203c+/HLA-DR- gating strategy resulted in a diagnostic accuracy of 97%, with 1% 
false-negatives and 2% false-positives
165
. Unusually, this methodological improvement resulted in 
both enhanced sensitivity and specificity. Figure 3.5 shows an example of a patient that would be 
considered false negative if gating was confined to CD123+/HLADR- cells. Furthermore, using 
this gating strategy, 15% of patients had less than 500 basophils in at least one condition and 
thus BAT would be uninterpretable. 
 
Table 3.4 Diagnostic accuracy of the basophil activation test to peanut using different gating strategies.  
The optimal cut-off was determined for the percentage of CD63-positive basophils following stimulation with 100 ng/ml of 
peanut extract according to the Youden index. Abbreviations: AUC ROC, area under the receiver operating characteristic 




CD123+ HLADR- CD203c+ HLADR- 
Optimal cut-off 6.8 7.3 
AUC ROC for the cut-off 0.91 0.97 
Accuracy 91% 97% 
Sensitivity 88% 98% 
Specificity 94% 96% 
PPV 93% 95% 
NPV 90% 98% 
%True positives 40% 45% 
%False positives 3% 2% 
%True negatives 51% 52% 
%False negatives 5% 1% 
LR+ 14.7 24.4 






Figure 3.7 Receiver operating characteristic curves of the average percentage of CD63-positive basophils at 
10 and 100ng/ml of peanut extract using two different gating strategies to identify basophils.  
 SSC
low
 CD203c+ HLA-DR- (red), SSC
low







Basophils down-regulate CD123 with activation in a subset of patients and this can have 
significant deleterious implications in the diagnosis of allergic disease. While performing the BAT, 
the use of gating strategies that depend on CD123 may lead to loss-to-analysis of basophils, in 
particular basophils that highly express CD63 and CD203c, resulting in a false-negative outcome 
for the test. To overcome this limitation, the additional use of CD203c, both as an identification 
and activation marker, prevents the loss-to-analysis of activated basophils and allows accurate 
assessment of basophil activation and, consequently, a more accurate diagnosis of allergy.  
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Chapter 4 Basophil activation test discriminates between allergy 
and tolerance in peanut-sensitised children 
Published in Santos A.F., et al. J Allergy Clin Immunol 2014;134(3):645-52 (open-access).   
The basophil activation test (BAT) to peanut is an in vitro assay where the expression of 
activation markers on the surface of basophils is evaluated by flow cytometry following stimulation 
with peanut allergens
64, 69
. It can be seen as a surrogate of oral food challenges, where instead of 
feeding patients peanut in vivo, blood basophils are exposed to peanut in vitro. With a view to 
improve the diagnosis of peanut allergy, I sought to assess the performance of BAT to diagnose 
peanut allergy and to compare it to that of diagnostic tests that are currently available in clinical 
practice, namely skin prick test to peanut, specific IgE to peanut and specific IgE to peanut 
components, such as Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9.  
 
4.1 Diagnostic study population 
One hundred and nine children, 76% boys, aged from 5 months to 17 years (median 5 years), 
participated in this diagnostic study. Eighty-four children had suspected peanut allergy and twenty 
were tested only for research purposes. Patients had different pre-test probability of peanut 
allergy. Figure 4.1 shows the main reasons for suspecting of peanut allergy which justified the 
allergy testing. Sixty-six oral food challenges to peanut were performed, 52 DBPCFC and 14 open 
oral food challenges. Twenty challenges were positive, 41 were negative and 5 were 
indeterminate (3 patients refused to eat and 2 showed subjective symptoms in the absence of 
objective signs). These 5 patients with indeterminate outcome in the oral food challenge were 
excluded from the study. Four patients who passed the peanut challenge (4% of the total 
population and 11% of PS patients) had previously reacted to peanut or been diagnosed with 
peanut allergy and were considered to have outgrown peanut allergy. The study population 
included 104 participants, 43 peanut allergic (PA) and 61 peanut-tolerant, of which 36 were 
peanut-sensitised but tolerant (PS) and 25 were non-sensitised non-allergic (NA), as shown in 
Figure 4.2. Demographic and clinical features of the study population are represented in Table 4.1 




Figure 4.1 Indications for testing for peanut allergy in the study population.  
*The asterisk indicates the twenty five children who were assigned to the total non-allergic (NA) group studied. 




Figure 4.2 Study population.  




13 positive oral food challenge, 4 negative oral food challenge, 2 indeterminate oral food 
challenge; 
2
6 positive oral food challenge, 23 negative oral food challenge, 3 equivocal oral food challenge; 
3
10 negative oral food challenge. Abbreviations: SPT, skin prick test to peanut; sIgE, specific IgE to 
peanut; OFC, oral food challenge to peanut; posit., positive; negat., negative.  
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Table 4.1 Demographic and clinical features of the primary diagnostic study population (n=104).  
Values are expressed as number (percentage) or median (range).Significant p values are highlighted in bold. 















Age (years) 5.5 (1.5; 17.0) 4.0 (0.5;13.0) 5.0 (0.8; 13.5) 0.005 
Males - n (%) 32 (74.4%) 23 (63.9%) 18 (72.0%) 0.366 
History of oral exposure 
to peanut - n (%) 
26 (60.5%) 7 (19.4%) 15 (60.0%) <0.001 
SPT to peanut (mm) 9 (2; 19) 2 (0; 12) 0 (0; 0) <0.001 
Specific IgE to peanut 
(KUA/l) 
14.50 (0.14; 604.0) 0.81 (0.01; 35.70) 0.01 (0; 0.08) <0.001 
Specific IgE to Ara h 1 
(KUA/l) 
0.45 (0; 199.0) 0.06 (0; 3.79) 0.01 (0; 0.03) 0.001 
Specific IgE to Ara h 2 
(KUA/l) 
9.21 (0.05; 386.0) 0.06 (0.01; 1.84) 0.01 (0; 0.08) <0.001 
Specific IgE to Ara h 3 
(KUA/l) 
0.06 (0; 89.60) 0.05 (0; 1.36) 0.01 (0; 0.04) 0.217 
Specific IgE to Ara h 8 
(KUA/l) 
0.08 (0; 57.80) 0.01 (0; 35.80) 0.01 (0; 0.02) 0.027 
Specific IgE to Ara h 9 
(KUA/l) 
0.01 (0; 5.62) 0.02 (0; 11.0) 0.01 (0; 0.02) 0.602 
Other food allergy - n (%) 39 (90.7%) 32 (88.9%) 3 (12.0%) 1.0 
Atopic eczema - n (%) 36 (83.7%) 21 (58.3%) 12 (48.0%) 0.022 
Asthma - n (%) 13 (30.2%) 6 (16.7%) 0 (0%) 0.193 
Allergic rhinitis - n (%) 14 (32.6%) 9 (25.0%) 2 (8.0%) 0.620 
Pollen allergy - n (%) 14 (32.6%) 8 (22.2%) 1 (4.0%) 0.349 




Figure 4.3 Skin prick test to peanut (SPT), specific IgE to peanut (peanut-sIgE) and specific IgE to peanut 
components Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9, in the three patient groups.  
PA, peanut allergic; PS, peanut sensitised but tolerant; NA, non-sensitised non-allergic to peanut. The dots represent 
results for individual patients and the horizontal lines represent the median for each group. 
 
4.2 Basophils of peanut allergic children show peanut dose-
dependent up-regulation of activation markers 
The basophils of 12 (11.5%) children were "non-responders" and were necessarily excluded from 
the comparison of BAT results between groups and from the ROC curve analysis; however, they 
were taken into account when assessing the clinical application of the BAT and its impact in the 
reduction of oral food challenges.  
In peanut allergic children, basophils showed increased expression of CD63 and CD203c with 
increasing concentrations of peanut extract up to 100 ng/ml followed by a plateau, forming a bell-
112 
shaped dose-response curve in the majority of cases. The basophils from peanut sensitised but 
tolerant children did not significantly respond to peanut (p<0.001 for the comparison of the 
median basophil activation between PA and PS patients) neither did basophils from NA children 
(Figure 4.4). Similar findings were observed for SI CD203c. This difference in basophil response 
between groups was reflected in other parameters of the basophil activation test (Table 4.2).  
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Figure 4.4 Basophil activation test to peanut in the three patient groups. 
PA, peanut allergic (n=42, Fig. A and D); PS, peanut-sensitised but tolerant (n=31, Fig. B and E); NA, non-sensitised non-allergic (n=19, Fig. C and F) children. Tukey plts are represented.p value refers to the 
comparison between PA versus PS: ***p<0.001, **p<0.01 and ns, non-significant. 0 represents the negative control. Anti-IgE and fMLP are the positive controls. 
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Table 4.2 Parameters of basophil activation test (BAT) in relation to allergy versus tolerance to peanut.  
N=92.Concentrations of peanut extract are expressed in ng/ml. *p values refer to the comparison between peanut allergic and peanut sensitised but tolerant patients. Abbreviations: BAT, basophil activation 
test; PA, peanut allergic; PS, peanut sensitised but tolerant; NA, non-sensitised non-allergic; AUC ROC, area under the receiver-operating characteristic curve; SI, stimulation index; EC50, half-maximal 
effective concentration. 
BAT to peanut 
Peanut allergic 
(n=42) 
Peanut tolerant (n=50) 
p value* 
AUC ROC curve 
(95% CI) PS (n=31) NA (n=19) 
%CD63+ Peanut 0.1 0.83 (0.09, 7.18) 0.02 (0, 0.20) 0.13 (0, 0.39) <0.001 0.75 (0.65, 0.86) 
%CD63+ Peanut 1 8.14 (1.57, 32.05) 0 (0, 0.67) 0.23 (0, 0.64) <0.001 0.92 (0.86, 0.98) 
%CD63+ Peanut 10 35.88 (13.13, 60.71) 0.13 (0, 0.77) 0.25 (0.01, 0.58) <0.001 0.97 (0.94, 1.0) 
%CD63+ Peanut 100 42.12 (19.96, 68.45) 0.56 (0.11, 2.53) 0.36 (0, 0.84) <0.001 0.99 (0.97, 1.0) 
%CD63+ Peanut 1,000 36.54 (23.46, 68.5) 2.62 (0.16, 9.06) 0.49 (0, 0.74) <0.001 0.96 (0.93, 1.0) 
%CD63+ Peanut 10,000 47.42 (37.52, 67.79) 5.24 (0.83, 19.83) 0.41 (0.02, 0.80) <0.001 0.93 (0.87, 0.98) 
SI CD203c Peanut 0.1 1.14 (1.0, 1.60) 0.99 (0.93, 1.07) 0.99 (0.91, 1.04) <0.001 0.75 (0.65, 0.85) 
SI CD203c Peanut 1 1.56 (1.23, 3.03) 0.98 (0.93, 1.05) 1.0 (0.97, 1.03) <0.001 0.93 (0.87, 0.99) 
SI CD203c Peanut 10 3.23 (2.11, 5.0) 1.0 (0.96, 1.09) 1.0 (0.96, 1.03) <0.001 0.98 (0.97, 1.0) 
SI CD203c Peanut 100 4.27 (2.42, 5.36) 1.08 (1.0, 1.44) 1.0 (0.92, 1.08) <0.001 0.99 (0.98, 1.0) 
SI CD203c Peanut 1,000 4.0 (3.0, 6.6) 1.18 (1.02, 1.67) 0.97 (0.93, 1.02) <0.001 0.97 (0.93, 1.0) 
SI CD203c Peanut 10,000 4.78 (3.46, 6.51) 1.43 (1.1, 2.43) 1.0 (0.97, 1.09) <0.001 0.93 (0.87, 0.98) 
Mean CD63 Peanut 10-100 39.8 (19.7, 64.4) 0.35 (0, 1.85) 0.29 (0.4, 0.63) <0.001 0.99 (0.98, 1.0) 
Mean CD203c Peanut 10-100 3.69 (2.53, 5.09) 1.04 (0.98, 1.29) 1.0 (0.94, 1.05) <0.001 0.99 (0.99, 1.0) 
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BAT to peanut 
Peanut allergic 
(n=42) 
Peanut tolerant (n=50) 
p value* 
AUC ROC curve 
(95% CI) PS (n=31) NA (n=19) 
Mean CD63 Peanut 100-1,000 36.39 (25.52, 65.19) 2.04 (0.34, 6.07) 0.51 (0.10, 0.82) <0.001 0.98 (0.97, 1.0) 
Mean CD203c Peanut 100-1,000 4.26 (2.79, 6.29) 1.13 (1.05, 1.54) 1.0 (0.95, 1.07) <0.001 0.99 (0.97, 1.0) 
AUC CD63 Peanut 149.1 (88.6, 249.7) 9.2 (1.5, 21.2) 1.6 (0.5, 3.8) <0.001 0.98 (0.96, 1.0) 
AUC CD203c Peanut 16.9 (13.0, 22.8) 5.5 (5.1, 6.6) 5.0 (4.8, 5.3) <0.001 0.99 (0.97, 1.0) 
Maximal %CD63+ Peanut 59.5 (39.5, 76.8) 5.24 (1.6, 23.56) 0.84 (0.42, 1.53) <0.001 0.95 (0.90, 0.99) 
Maximal SI CD203c Peanut 5.5 (4.0, 7.9) 1.43 (1.2, 2.93) 1.04 (1.0, 1.12) <0.001 0.95 (0.90, 0.99) 
%CD63+ Peanut 100/aIgE 1.14 (0.71, 1.54) 0.02 (0.01, 0.13) 0.02 (0, 0.11) <0.001 0.97 (0.95, 1.0) 
%CD63+ Peanut 100/aFcɛRI 1.92 (1.42, 4.49) 0.03 (0.01, 0.21) 0.02 (0, 0.11) <0.001 0.96 (0.91, 1.0)
$
 
EC50 (ng/ml) - CD63 10 (1, 10) 300 (100, 1000)
#
 - <0.001 - 
EC50 (ng/ml) - CD203c 10 (1, 10) 200 (100, 825)
+
 - <0.001 - 
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The %CD63+ basophils in response to the negative control (p=0.958) and non-IgE-mediated 
positive control (fMLP, p=0.581) was similar across groups. The response to anti-IgE was higher 
in PA compared to PS (p=0.007). The proportion of non-responders was higher in peanut-tolerant 
(including peanut sensitised but tolerant and non-sensitised non-allergic children) compared to 
peanut allergic (11 versus 1, p=0.012) children.  
 
4.3 Optimal diagnostic cut-off values 
Peanut allergy (based on oral food challenge or 95% PPV cut-offs, n=42) and tolerance status 
(based on oral food challenge or peanut consumption, n=50) was the reference-point to evaluate 
the diagnostic performance of BAT on ROC curve analysis. The area under the ROC curve for 
each BAT parameter is represented in Table 4.2.  
The best diagnostic cut-off values (although all cut-offs performed well without statistically 
significant differences between them) were obtained for the percentage of CD63-positive 
basophils at 100 ng/ml and for the mean percentage of CD63-positive basophils at 10 and 100 
ng/ml of peanut extract (Table 4.3). These were simultaneously optimal, negative and positive 
decision levels, with 98% sensitivity, 96% specificity, 95% PPV, 98% NPV and 97% accuracy. 
The mean percentage of CD63-positive basophils at 10 and 100 ng/ml of peanut extract was the 
BAT parameter selected for further diagnostic analyses.  
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Table 4.3 Optimal cut-offs for the different parameters of basophil activation test to peanut.  
The BAT parameters of choice are highlighted in bold. *LR could not be determined as sensitivity or specificity was 100%. Numbers in the left column indicate the concentration of peanut extract in ng/ml. 
Abbreviations: aIgE, anti-IgE; aFcɛRI, anti-FcɛRI; BAT, basophil activation test; AUC ROC, area under the receiver-operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, 
negative predictive value; LR, likelihood ratio; SI, stimulation index; AUC, area under the curve. The concentrations of peanut extract in the left column are expressed in ng/ml. 
BAT parameter 























































































































































































































































































































































































































































The area under the ROC curve for BAT (considering the mean CD63 10-100) was superior to that 
for other allergy tests, namely for SPT to peanut and specific IgE to peanut and to Ara h 1, Ara h 
2, Ara h 3, Ara h 8 and Ara h 9 (Table 4.4, Figure 4.5). Ara h 2-specific IgE performed better than 
specific IgE to the other peanut components.  
 
Figure 4.5 Receiver operating characteristic curves 
Receiver operating characteristic curves for the basophil activation test (mean CD63 10-100, red), skin prick test (dark 
blue), specific IgE to peanut (green) and specific IgE to Ara h 1 (violet), to Ara h 2 (orange), to Ara h 3 (yellow), to Ara h 8 




Table 4.4 Performance of different tests in the diagnosis of peanut allergy.  
For the basophil activation test, the average percentage of CD63-positive basophils at 10 and 100 ng/ml of peanut extract (mean CD63 10-100) was considered. Non-responders were excluded as there was 
no outcome for BAT. Abbreviations: AUC ROC, area under the receiver operating characteristic curve; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR, 
likelihood ratio; SPT, skin prick test to peanut; BAT, basophil activation test. 
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4.4 Validation of diagnostic cut-off values in an independent 
population 
In order to externally validate my findings, 65 children (25 peanut allergic, 24 peanut-sensitised 
but tolerant and 16 non-sensitised non-allergic) were prospectively recruited from an independent 
population. Demographic and clinical characteristics of this validation population are represented 
in Table 4.5. They underwent the same study procedures as the primary study population. The 
majority (94%) of these children underwent oral food challenge. All positive oral food challenges 




Table 4.5 Demographic and clinical characteristics of the external validation population  
N=65. Values are expressed as number (percentage) or median (range). *p value refers to the comparison between 


















Age (years) 5.3 (1.7; 13.2) 6.0 (0.5; 15.8) 5.2 (4.8; 7.0) 0.689 
Males - n (%) 20 (80.0%) 14 (58.3%) 10 (62.5%) 0.128 
Oral exposure to peanut 
- n (%) 
8 (32.0%) 8 (33.3%) 9 (56.3%) 1.0 
SPT to peanut (mm) 9 (1; 17) 4 (0; 9) 0 (0; 0) <0.001 
Specific IgE to peanut 
(KUA/l) 
6.13 (0.15; 194.0) 1.53 (0.07; 22.20) 0.01 (0.01; 0.08) 0.021 
Specific IgE to Ara h 1 
(KUA/l) 
0.21 (0.01; 74.70) 0.08 (0.01; 11.70) 0.01 (0.01; 0.05) 0.128 
Specific IgE to Ara h 2 
(KUA/l) 
1.65 (0.01; 142.0) 0.12 (0; 7.0) 0.01 (0.01; 0.01) <0.001 
Specific IgE to Ara h 3 
(KUA/l) 
0.04 (0.01; 15.20) 0.06 (0.01; 7.28) 0.01 (0.01; 0.05) 0.864 
Specific IgE to Ara h 8 
(KUA/l) 
0.03 (0.01; 9.80) 0.04 (0.01; 62.30) 0.01 (0.01; 0.17) 0.980 
Specific IgE to Ara h 9 
(KUA/l) 
0.01 (0.01; 7.0) 0.04 (0.01; 11.90) 0.01 (0.01; 0.01) 0.084 
Other food allergy - n 
(%) 
24 (96.0%) 21 (87.5%) 6 (37.5%) 0.349 
Atopic eczema - n (%) 20 (80.0%) 18 (75.0%) 14 (87.5%) 0.742 
Asthma - n (%) 14 (56.0%) 6 (25.0%) 7 (43.8%) 0.042 
Allergic rhinitis - n (%) 19 (76.0%) 11 (45.8%) 10 (62.5%) 0.042 
Pollen allergy - n (%) 12 (48.0%) 11 (45.8%) 7 (43.8%) 1.0 





Four (6%) patients had non-responder basophils and were excluded from further analyses. 
Applying the optimal cut-off previously determined for the average percentage of CD63-positive 
basophils at 10 and 100ng/ml of peanut extract, BAT showed 100% specificity, 83.3% sensitivity, 
100% PPV, 90.2% NPV and 93.4% accuracy. BAT proved to be superior to SPT to peanut, 
specific IgE to peanut and to Ara h 2 (Table 4.6), as was observed in the primary study 
population. 
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Table 4.6 External validation of diagnostic cut-offs of BAT in comparison with other allergy tests.  
N=61, non-responders were excluded. The following optimal cut-offs were applied: for BAT, Mean CD63 10-100 ≥4.78% ; for  SPT, ≥5 mm; for peanut-specific IgE, ≥5.35 KUA/l; and for Ara h 2-specific IgE, 
≥0.53 KUA/l. Abbreviations: BAT, basophil activation test; SPT, skin prick test to peanut; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; LR+, positive 
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4.5 The use of the basophil activation test in peanut-sensitised 
children with equivocal diagnosis 
Considering the practical aspects involved in the performance of BAT (namely the use of fresh 
blood and the performance of cell stimulation and flow cytometry on the same day of blood 
collection), it did not seem feasible to apply this test to all patients with suspected peanut allergy. 
Apart from the feasibility, it would probably not offer additional value to the allergy tests currently 
used in clinical practice, such as SPT and specific IgE, which are informative in some cases. 
Therefore, I hypothesised that BAT was most useful in cases where the results of SPT and/or 
specific IgE fell in the immunological grey area (Figure 1.6) or, when considered together with the 
clinical history, were inconclusive. The utility of BAT was further assessed in the subgroup (n=44) 
of the primary study population with equivocal history and inconclusive results of SPT, peanut-
specific IgE and CRD. Table 4.7 represents the demographic and clinical features of this 




Table 4.7 Demographic and clinical features of subgroup of the primary study population with equivocal 
clinical history and inconclusive skin prick test and specific IgE results  
N=44. Values are expressed as number (percentage) or median (range). Significant p values are highlighted in bold. 








Age (years) 5.0 (2.0; 6.0) 4.0 (0.5; 13.0) 0.964 
Males - n (%) 4 (50.0%) 23 (63.9%) 0.690 
History of oral exposure to peanut - n 
(%) 
0 (0%) 7 (19.5%) 0.618 
SPT to peanut (mm) 7 (2; 9) 2 (0; 12) 0.002 
Specific IgE to peanut (KUA/l) 0.94 (0.14; 14.50) 0.81 (0.01; 35.70) 0.964 
Specific IgE to Ara h 1 (KUA/l) 0.03 (0.01; 8.67) 0.06 (0; 3.79) 0.622 
Specific IgE to Ara h 2 (KUA/l) 0.15 (0.05; 8.95) 0.06 (0.01; 1.84) 0.023 
Specific IgE to Ara h 3 (KUA/l) 0.01 (0.01; 1.62) 0.05 (0; 1.36) 0.189 
Specific IgE to Ara h 8 (KUA/l) 0.01 (0.01; 4.66) 0.01 (0; 35.80) 0.893 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.28) 0.02 (0; 11.0) 0.823 
Other food allergy - n (%) 8 (100%) 32 (88.9%) 1.0 
Atopic eczema - n (%) 5 (62.5%) 21 (58.3%) 1.0 
Asthma - n (%) 0 (0%) 6 (16.7%) 0.573 
Allergic rhinitis - n (%) 0 (0%) 9 (25%) 0.175 
Pollen allergy - n (%) 0 (0%) 8 (22.2%) 0.284 
Non atopic - n (%) 0 (0%) 0 (0%) - 
 
Three Paediatric Allergy consultants were asked to classify these 44 patients as peanut allergic or 
peanut tolerant based on the clinical history, SPT and specific IgE to peanut and to peanut 
components. In the majority of cases (46-64%) the physicians could not decide about the allergic 
status to peanut without doing an oral food challenge. They correctly diagnosed 26-36% and 
misclassified 9-16% of cases, of which 14% were false-negatives. The agreement between the 
three pairs of physicians was poor to fair with κ values of 0.16, 0.29 and 0.36. The 3 specialists 
agreed in 16 (36%) cases: 4 (9%) correctly diagnosed, 1 (2%) misclassified and 11 (25%) where 
they were unable to decide. In contrast, BAT provided 36 (82%) correct diagnoses, 2 (5%) false-
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positives, 1 (2%) false-negative and required 5 (11%) oral food challenges. The performance of 
the various allergy tests was assessed by ROC curve analyses (Figure 4.6 and Table 4.8). 
Excluding non-responders and considering optimal cut-offs, BAT had a diagnostic accuracy of 
95% (Table 4.9). This is in contrast with specific IgE to peanut, Ara h 2-specific IgE and SPT, 
whose accuracy suffered in this subgroup. 
 
 
Figure 4.6 Receiver operating characteristic curves  
Receiver operating characteristic curves for basophil activation test (red), skin prick test (blue), specific IgE to peanut 
(green) and specific IgE to Ara h 2 (orange) for (A) the whole study population (n=92) and (B) children with equivocal 
history, SPT and specific IgE to peanut and its components (n=39).  
 
 
Table 4.8 Area under the receiver operating characteristic curve for the different allergy tests considering the 
whole study population and the subgroup with equivocal diagnosis.  
Abbreviations: AUC ROC, area under the receiver operating characteristic curve; 95% CI, 95% confidence interval; SPT, 
skin prick test to peanut; BAT, basophil activation test. 
Allergy tests 
AUC ROC (95% CI) 
Whole population (n=92) Equivocal population (n=39) 
SPT 0.97 (0.93, 1.0) 0.83 (0.67, 0.98) 
Specific IgE to peanut 0.89 (0.82, 0.95) 0.49 (0.24, 0.74) 
Ara h 2-specific IgE 0.96 (0.92, 0.99) 0.73 (0.55, 0.91) 
BAT 0.99 (0.98, 1.0) 0.95 (0.87, 1.0 
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Table 4.9 Performance of different tests in the diagnosis of peanut allergy in the clinically equivocal population.  
N=39, non-responders were excluded as there was no outcome for BAT. For BAT, the average percentage of CD63-positive basophils at 10 and 100ng/ml of peanut extract was considered. *LR- could not be 
determined because sensitivity was 100%. Abbreviations: AUC ROC, area under the receiver operator characteristic curve; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; 
95% CI, 95% confidence interval; SPT, skin prick test to peanut; BAT, basophil activation test.  
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4.6 The combination of basophil activation test with other 
diagnostic tests 
The diagnostic performance of different tests was evaluated in the primary study population 
(n=104), including BAT non-responders, in three ways (Table 4.10):  
1. Considering each test on its own;  
2. Considering the results of different diagnostic tests simultaneously; and  
3. Considering BAT as a second or third sequential step in the diagnostic process, performed in 
patients where the results of single or combinations of standard allergy tests were equivocal.  
 
Table 4.10 Performance of allergy tests in the diagnosis of peanut allergy.  
N=104. Results are presented as number of patients (% of total study population). *The proportion of correct diagnoses 
was determined as ("true-positives"+"true-negatives")/n=104.
ǂ
For BAT, excluding non-responders, the proportion of 
correct diagnoses was 96.7%.**Reduction in oral food challenges was calculated in comparison with the number of oral 
food challenges following SPT and specific IgE (i.e. 36 oral food challenges); negative numbers represent a decrease and 
positive numbers an increase in the number of oral food challenges required. ***For BAT, 4.78% for the average of CD63-
positive basophils at 10 and 100ng/ml of peanut extract was used as the diagnostic cut-off point. Abbreviations: SPT, skin 
prick test to peanut; Specific IgE, peanut-specific IgE; Ara h 2, specific IgE to Ara h 2; BAT, basophil activation test; OFC, 
oral food challenges. 
















SPT  78 (75%) 1 (1%) 1 (1%) - 24 (23%) -12 (-33%) 
Specific IgE  57 (55%) 3 (3%) 3 (3%) - 41 (39%) +5 (+13%) 
Ara h 2  82 (79%) 1 (1%) 2 (2%) - 19 (18%) -17 (-46%) 
BAT***  89 (86%
ǂ
) 2 (2%) 1 (1%) 
104 
(100%) 
12 (12%) -24 (-67%) 
















SPT + Specific IgE 67 (64%) 1 (1%) 0 (0%) - 36 (35%) 0 (0%) 
Specific IgE + Ara h 2 66 (63%) 1 (1%) 1 (1%) - 36 (35%) 0 (0%) 
Specific IgE + BAT 66 (63%) 1 (1%) 2 (2%) 
104 
(100%) 
35(34%) -1 (-3%) 
SPT + BAT 77 (74%) 2 (2%) 0 (0%) 
104 
(100%) 
25 (25%) -11 (-31%) 
SPT + Ara h 2 78 (75%) 1 (1%) 0 (0%) - 25 (24%) -11 (-31%) 
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Ara h 2 + BAT 77 (74%) 1 (1%) 2 (2%) 
104 
(100%) 
24 (24%) -12 (-33%) 
SPT + Specific IgE + Ara h 2 67(64%) 1 (1%) 0 (0%) - 36 (35%) 0 (0%) 
SPT + Ara h 2 + BAT 70 (67%) 1 (1%) 0 (0%) 
104 
(100%) 
33 (33%) -3 (-8%) 
SPT + Specific IgE + BAT 63 (61%) 2 (2%) 0 (0%) 
104 
(100%) 
39 (38%) +3 (+8%) 
Specific IgE + Ara h 2 + BAT 63 (61%) 1 (1%) 1 (1%) 
104 
(100%) 
39 (38%) +3 (+8%) 
SPT + Specific IgE + Ara h 2 + BAT 60 (58%) 1 (1%) 0 (0%) 
104 
(100%) 
43 (42%) +7 (+19%) 
BAT as a second step                           
















SPT → BAT 98 (94%) 3 (3%) 2 (2%) 24 (23%) 1 (1%) -35 (-97%) 
Specific IgE → BAT 93 (89%) 5 (5%) 3 (3%) 41 (39%) 3 (3%) -33 (-92%) 
Ara h 2 → BAT 99 (95%) 2 (2%) 2 (2%) 19 (18%) 1 (1%) -35 (-97%) 
SPT + Specific IgE → BAT 97 (93%) 3(3%) 1 (1%) 36 (35%) 3 (3%) -33 (-92%) 
SPT + Ara h 2 → BAT 99 (95%) 2 (2%) 1 (1%) 38 (37%) 2 (2%) -34 (-94%) 
SPT + Specific IgE + Ara h 2 → BAT 96 (92%) 3 (3%) 1 (1%) 36 (35%) 4 (4%) -32 (-89%) 
BAT as a third step  





















Considering single tests, BAT performed best and allowed a reduction in the number of oral food 
challenges by two-thirds, followed by Ara h 2-specific IgE and SPT to peanut. Peanut-specific IgE 
on its own performed the poorest, conferring the highest number of oral food challenges and 
correctly diagnosing only 55% of patients. Considering combinations of allergy tests, it was best 
to combine two different tests as opposed to three or four tests, which led to an increase in the 
equivocal cases because tests gave contradictory results with consequent increase in the number 
of oral food challenges. All combinations of tests required an increase between 2 and 3.5-fold in 
the number of oral food challenges compared to BAT alone. 
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With a view to apply BAT in clinical practice, the role of BAT as a second or third step in the 
diagnostic work-up was assessed, which would require a smaller number of BAT and would 
probably prove most useful, as shown in Section 4.5 (Table 4.10, Figure 4.7). The 2-step strategy 
significantly reduced the number of oral food challenges, more than using Ara h 2-specific IgE as 
a second step to SPT or to peanut-specific IgE (Table 4.11.), as proposed by Dang et al
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. The 3-
step sequential strategy of SPT→Ara h 2-specific IgE→BAT (Table 4.10, Figure 4.7) further 
reduced the number of oral food challenges to zero at the expense of a slightly higher number of 
false-negative results (n=3).  
 
 
Table 4.11 Performance of Ara h 2-specific IgE as a second step in the diagnostic process, following SPT or 
specific IgE to peanut.  
N=104. Results are presented as number of patients (% of total study population). *The proportion of correct diagnoses 
was determined as ("true-positives"+"true-negatives")/n=104.  **Reduction in oral food challenges was calculated in 
comparison with the number of oral food challenges following SPT and specific IgE (i.e. 36 oral food challenges); negative 
numbers represent a decrease in the number of oral food challenges required compared to using SPT and specific IgE. 
Ara h 2-specific IgE as a second 











SPT → Ara h 2 93 (89%) 2 (2%) 3 (3%) -30 (-83%) 







Figure 4.7 Diagnosing peanut allergy using BAT sequentially in the cases where SPT, specific IgE to peanut and/or Ara h 2-specific IgE were equivocal.  
Equivocal cases are marked in bold). In this simulation, oral food challenges were done in cases where BAT was indeterminate (i.e. “non-responders”). A-C: 2-step diagnostic strategy where BAT follows 
single tests; D-F, 2-step diagnostic strategy where BAT follows combinations of tests; G, 3-step diagnostic strategy. Abbreviations: SPT, skin prick test; sIgE, specific IgE; Ara h 2, specific IgE to Ara h 2; NPV, 
negative predictive value; PPV, positive predictive value; PA, peanut allergic; PS, peanut sensitised but tolerant; NA, non-peanut-sensitised non-allergic; BAT, basophil activation test; NR, non-responders; 
OFC, oral food challenges.  
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4.7 Conclusions 
Considering SPT, peanut-specific IgE, specific IgE to peanut components and BAT, BAT has the 
best diagnostic profile. Combinations of tests offer no significant advantage to BAT alone and 
lead to an increase in the number of oral food challenges. The most accurate and cost-effective 
analysis appears to be that of using a 2-step sequential approach where SPT or Ara h 2-specific 
IgE is followed by BAT in the equivocal cases. In order to maximize safety and decrease false-
negative tests to 0%, the 2-step sequential approach can be modified to do oral food challenges 
in the cases with equivocal BAT as well as in the BAT-negative patients. One should bear in mind 




 and 2-9% 
indeterminate outcomes
121, 122
). Future studies will determine whether BAT can add to the oral 




Chapter 5 Distinct parameters of the basophil activation test 
reflect the threshold and the severity of allergic reactions to 
peanut  
Published in Santos AF et al. J Allergy Clin Immunol 2015; 135 (1):179-86 (open-access).  
Currently, there are no reliable objective biomarkers to predict the severity of future allergic 
reactions or the threshold dose at which an individual peanut allergic patient may react. Such 
markers would be very valuable in the management of peanut allergy as they could help to 
identify peanut allergic patients who are at higher risk of developing life-threatening reactions 
and/or of reacting to low amounts of the allergens. The BAT reproduces very closely the 
phenotype of peanut-sensitised patients in relation to allergy versus tolerance, as reported in the 
previous chapter 4
165
. Basophils and mast cells are the effector cells of anaphylaxis. Basophils 
seem to be particularly relevant in food-induced anaphylaxis which often occurs without elevated 
serum tryptase. This observation suggests that the BAT could be used to safely assess the 
severity and the threshold of allergic reactions to peanut, as an in vitro surrogate for oral food 
challenges.  
Different methods to express the results of the BAT, based on the allergen-induced dose-
response curve, reflect different aspects of the basophil response, as described in Section 1.7.4. 
For example, the percentage of activated basophils measures basophil reactivity, whereas the 
concentration of allergen at which basophils become activated measures basophil sensitivity to 
the allergen
78
. I hypothesised that patients with severe reactions would show greater basophil 
reactivity and that patients who respond to lower doses of peanut allergen would show greater 
basophil sensitivity.  I hypothesised that the higher percentage of basophils activated, the higher 
percentage of basophils degranulating and the higher the amount of vasoactive mediators 
released leading to more severe symptoms; and also that the threshold dose for basophil 
activation and degranulation in vitro during the BAT would correspond to the threshold dose in 
vivo during the challenges.   
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5.1 Severity and threshold study population 
One hundred and twenty four patients were submitted to oral peanut challenges. Fifty two (42%) 
patients had a positive challenge to peanut and constituted the population of interest for the 
severity and threshold study. Three PA patients had non-responder basophils and were therefore 
excluded from further analyses. The study population (Table 5.1, n=49) was aged from 1.6 to 13 
years (median age 5 years) and the majority (77%) had never ingested peanut prior to the 
challenge.  
 
Table 5.1 Characteristics of the severity and threshold study population.  
Values are expressed as number (percentage) or median (interquartile range).  
Demographic features and investigations 
Study population 
(n=49) 
Age (years) 5.4 (4.7; 5.9) 
Males - n (%) 34 (69.4%) 
Symptom score 3 (3; 4) 
Cumulative threshold dose of peanut protein (g) 0.1 (0.03; 0.63) 
SPT to peanut (mm) 9 (7; 12) 
Specific IgE to peanut (KUA/l) 5.15 (0.51; 29.78) 
Specific IgE to Ara h 1 (KUA/l) 0.11 (0.02; 2.14) 
Specific IgE to Ara h 2 (KUA/l) 1.65 (0.20; 15.20) 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.33) 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.01; 0.47) 
Serum specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 
Number of major peanut allergens bound by IgE 2 (1; 2) 
Peanut-specific IgG4 (µg/l) 190.0 (120.0; 662.5) 
Ratio of peanut-specific IgG4 to IgE 15.7 (5.7; 88.3) 
Other food allergy - n (%) 47 (95.9%) 
Atopic eczema - n (%) 40 (81.6%) 
Asthma - n (%) 19 (38.8%) 
Allergic rhinitis - n (%) 27 (55.1%) 
Pollen allergy - n (%) 14 (28.6%) 
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5.2 Allergic reactions during the peanut challenges 
5.2.1 Severity 
Symptoms during the challenge ranged from mild oral symptoms to anaphylaxis. Twenty (41%) 
patients had severe reactions (Table 5.2). Nine (18.4%) patients required the administration of 
intramuscular adrenaline and 10 (77%) required the administration of intravenous fluid boluses. 
One patient (1.9%) had a biphasic reaction with symptoms appearing about 5 hours after the 
resolution of the allergic symptoms that had developed during the challenge.  
 





1 4 (8.2%) 
2 2 (4.1%) 
3 23 (46.9%) 
4 15 (30.6%) 
5 5 (10.2%) 
 
 
Severe reactors (i.e. symptom scores 4 or 5) had comparable SPT results (p=0.102) and higher 
levels of specific IgE to peanut (p=0.010), to Ara h 1 (p=0.021) and to Ara h 2 (p=0.003) 
compared to the patients who had mild/moderate reactions (i.e. symptom scores 1, 2 or 3). A 
greater number of peanut major allergens (Ara h 1, Ara h 2, Ara h 3) recognised by patients' IgE 




Table 5.3 Characteristics of the study population according to the severity groups.  
Values are expressed as number (percentage) or median (interquartile range). *p<0.001 not indicated as these 
characteristics formed the basis to classify the patients into severity and threshold groups. Significant p values are 
highlighted in bold. Abbreviation: SPT, skin prick test. 








Age (years) 5.2 (4.4; 5.8) 5.4 (5.0; 6.2) 0.250 
Males - n (%) 19 (65.5%) 15 (75.0%) 0.542 
Symptom score 3 (3; 3) 4 (4; 5) * 
Cumulative threshold dose of 
peanut protein (g) 
0.10 (0.33; 1.38) 0.10 (0.03; 0.38) 0.884 
SPT to peanut (mm) 9 (4; 10) 10 (7; 13) 0.102 
Specific IgE to peanut (KUA/l) 1.86 (0.38; 12.85) 23.20 (5.18; 94.80) 0.010 
Specific IgE to Ara h 1 (KUA/l) 0.09 (0.01; 0.23) 0.20 (0.09; 11.58) 0.021 
Specific IgE to Ara h 2 (KUA/l) 0.68 (0.10; 2.67) 10.11 (1.48; 41.40) 0.003 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.13) 0.05 (0.01; 0.98) 0.221 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.01; 0.23) 0.03 (0.01; 1.96) 0.582 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 0.01 (0.01; 0.07) 0.818 
Number of major peanut 
allergens bound by IgE 
1.0 (0; 2.0) 2.0 (1.0; 3.0) 0.019 
Peanut-specific IgG4 (µg/l) 160 (120; 405) 380 (120; 1100) 0.235 
Ratio of peanut-specific IgG4 to 
IgE 
21.63 (5.78; 161.23) 11.26 (3.15; 76.75) 0.209 
Other food allergy - n (%) 27 (93.1%) 20 (100.0%) 0.507 
Atopic eczema - n (%) 23 (79.3%) 17 (85.0%) 0.720 
Asthma - n (%) 11 (37.9%) 8 (40.0%) 1.0 
Allergic rhinitis - n (%) 15 (51.7%) 12 (60.0 %) 0.771 
Pollen allergy - n (%) 7 (24.1%) 7 (35.0%) 0.524 
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Patients who received intramuscular adrenaline had higher specific IgE to peanut (p=0.031) and 
to Ara h 2 (p=0.011) than patients who did not require adrenaline (Table 5.4). 
Table 5.4 Demographic and clinical characteristics of study participants according to the requirement of 
intramuscular adrenaline.  
Values are expressed as number (percentage) or median (interquartile range). Significant p values are highlighted in bold. 
Abbreviation: SPT, skin prick test. 
Demographic and clinical 
features 
Adrenaline required (n=9) 
Adrenaline not required 
(n=40) 
p value 
Age (years) 5.15 (4.94; 6.31) 5.39 (4.63; 5.85) 0.786 
Males - n (%) 6 (66.7%) 28 (70.0%) 1.0 
Cumulative threshold dose of 
peanut protein (g) 
0.10 (0.03; 0.24) 0.10 (0.03; 1.62) 0.579 
SPT to peanut (mm) 10 (8; 16) 9 (5; 11) 0.111 
Specific IgE to peanut (KUA/l) 27.50 (15.93; 87.65) 2.74 (0.47; 16.53) 0.031 
Specific IgE to Ara h 1 (KUA/l) 0.13 (0.01; 3.25) 0.10 (0.02; 0.41) 0.667 
Specific IgE to Ara h 2 (KUA/l) 15.20 (9.21; 54.30) 1.09 (0.17; 6.60) 0.011 
Specific IgE to Ara h 3 (KUA/l) 0.05 (0.01; 1.10) 0.03 (0.01; 0.24) 0.333 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.02; 2.04) 0.02 (0.01; 0.28) 0.339 
Specific IgE to Ara h 9 (KUA/l) 0.02 (0.01; 0.04) 0.01 (0.01; 0.02) 0.653 
Number of major peanut 
allergens bound by IgE 
2 (1; 3) 2 (1; 2) 0.309 
Peanut-specific IgG4 (µg/l) 590 (180; 1043) 160 (120; 575) 0.135 
Ratio of peanut-specific  
IgG4 to IgE 
10.05 (1.90; 149.91) 17.62 (5.88; 88.33) 0.346 
Other food allergy - n (%) 9 (100.0%) 38 (95.0%) 1.0 
Atopic eczema - n (%) 7 (77.8%) 33 (82.5%) 0.663 
Asthma - n (%) 3 (33.3%) 16 (40.0%) 1.0 
Allergic rhinitis - n (%) 7 (77.8%) 20 (50.0%) 0.159 
Pollen allergy - n (%) 4 (44.4%) 10 (25.0%) 0.254 
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5.2.2 Threshold  
The cumulative threshold dose of peanut protein varied between 0.033 and 9.35 g (median=0.1 
g). Twenty-eight (57%) patients reacted to 0.1 g or less of peanut protein during the oral food 
challenge (Table 5.5).  
 
Table 5.5 Threshold of allergic reactions to peanut during the challenges  
N=49 
Cumulative threshold dose 
of peanut protein (g) 
Number (%)                 
of patients 
0.033 19 (39%) 
>0.033 <0.1 2 (4%) 
0.1 7 (14%) 
>0.1 <4 14 (29%) 




Patients with lower threshold had larger wheals on SPT to peanut (p=0.021) and higher levels of 
specific IgE to peanut (p=0.026) and to Ara h 2 (p=0.032) than patients who reacted to more than 
0.1 g of peanut protein (Table 5.6). Interestingly, patients with a higher cumulative peanut 




Table 5.6 Characteristics of the study population according to the threshold groups.  
Values are expressed as number (percentage) or median (interquartile range). *p<0.001 not indicated as these 
characteristics formed the basis to classify the patients into the threshold groups. Significant p values are highlighted in 
bold. Abbreviation: SPT, skin prick test. 
Demographic features and 
investigations 
Threshold groups  
according to the cumulative threshold dose 
0.1g peanut protein 
(n=28) 
>0.1g peanut protein 
(n=21) 
p value 
Age (years) 5.3 (4.8; 5.8) 5.4 (4.6; 6.1) 0.928 
Males - n (%) 18 (64.3%) 16 (76.2%) 0.533 
Cumulative threshold dose of 
peanut protein (g) 
0.03 (0.03; 0.09) 0.92 (0.37; 4.38) * 
SPT to peanut (mm) 10 (8; 13) 8 (4; 11) 0.021 
Specific IgE to peanut (KUA/l) 7.17 (1.73; 75.80) 1.33 (0.38; 12.35) 0.026 
Specific IgE to Ara h 1 (KUA/l) 0.18 (0.04; 8.67) 0.09 (0.01; 0.15) 0.051 
Specific IgE to Ara h 2 (KUA/l) 5.05 (1.06; 46.80) 0.46 (0.12; 7.36) 0.032 
Specific IgE to Ara h 3 (KUA/l) 0.04 (0.01; 0.89) 0.02 (0.01; 0.05) 0.069 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.01; 0.28) 0.02 (0.01; 2.04) 1.0 
Serum IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.04) 0.01 (0.01; 0.02) 0.856 
Number of major peanut allergens 
bound by IgE 
2 (1; 3) 1 (1; 2) 0.089 
Peanut-specific IgG4 (µg/l) 140 (120; 800) 290 (130; 660) 0.425 
Ratio of peanut-specific IgG4 to IgE 8.6 (2.3; 66.1) 48.9 (15.5; 159.4) 0.011 
Other food allergy - n (%) 28 (100.0%) 19 (90.5%) 0.179 
Atopic eczema - n (%) 25 (89.3%) 15 (71.4%) 0.146 
Asthma - n (%) 11 (39.3%) 8 (38.1%) 1.0 
Allergic rhinitis - n (%) 19 (67.9%) 8 (38.1%) 0.048 
Pollen allergy - n (%) 8 (28.6%) 6 (28.6%) 1.0 
 
Classifying patients according to the discrete threshold dose of peanut protein at the time of 
reaction yielded similar findings (Table 5.7).  
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Table 5.7 Characteristics of the study population grouped according to the discrete threshold doses of 
peanut protein on oral food challenges.  
Values are expressed as number (percentage) or median (interquartile range). *p<0.001 not indicated as these 
characteristics formed the basis to classify the patients into the threshold groups. Significant p values are highlighted in 
bold. Abbreviation: SPT, skin prick test. 
Demographic features and 
investigations 
Threshold groups 
according to the discrete threshold dose 
0.1g peanut protein 
(n=31) 
>0.1g peanut protein 
(n=18) 
p value 
Age (years) 5.4 (4.9; 5.9) 5.3 (4.5; 5.8) 0.799 
Males - n (%) 20 (65%) 14 (78%) 0.521 
Discrete threshold dose of peanut 
protein (g) 
0.03 (0.03; 0.10) 1.0 (0.46; 3.13) * 
SPT to peanut (mm) 10 (8; 13) 4 (4; 10) 0.005 
Specific IgE to peanut (KUA/l) 10.34 (1.85; 67.40) 0.80 (0.36; 6.63) 0.009 
Specific IgE to Ara h 1 (KUA/l) 0.20 (0.04; 4.61) 0.09 (0.01; 0.13) 0.031 
Specific IgE to Ara h 2 (KUA/l) 5.23 (1.10; 39.53) 0.38 (0.08; 1.26) 0.005 
Specific IgE to Ara h 3 (KUA/l) 0.04 (0.02; 0.91) 0.01 (0.01; 0.04) 0.015 
Specific IgE to Ara h 8 (KUA/l) 0.04 (0.01; 1.96) 0.02 (0.01; 0.04) 0.178 
Serum IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.08) 0.01 (0.01; 0.02) 0.612 
Number of major peanut allergens 
bound by IgE 
2.0 (1.0; 3.0) 1.0 (0.5; 2.0) 0.008 
Peanut-specific IgG4 (µg/l) 190 (120; 818) 240 (100; 648) 0.830 
Ratio of peanut-specific IgG4 to IgE 8.7 (2.9; 51.5) 83.8 (16.3; 189.5) 0.005 
Other food allergy - n (%) 31 (100%) 16 (34%) 0.130 
Atopic eczema - n (%) 28 (70%) 12 (30%) 0.058 
Asthma - n (%) 12 (63%) 7 (37%) 1.0 
Allergic rhinitis - n (%) 21 (78%) 6 (22%) 0.036 
Pollen allergy - n (%) 9 (64%) 5 (28%) 1.0 
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5.3 Basophil activation test markers of severity and threshold 
BAT parameters were assessed in relation to the severity and the threshold dose of reaction to 
peanut during the oral food challenges. Table 5.8 shows the results for the studied BAT 
parameters in the study population overall.  
 
Table 5.8 Results for the various BAT parameters in the total study population 
N=49. Values are expressed as median (interquartile range). CDsens was calculated based on the CD63 dose-response 
curve. Numbers in the left column indicate the concentration of peanut extract in ng/ml. Abbreviation: AUC CD63, area 
under the dose-response curve considering the percentage of CD63-positive basophils; BAT, basophil activation test; 
EC50, half-maximal effective concentration.  
BAT to peanut Study population 
%CD63+ Peanut 0.1 0.63 (0; 3.05) 
%CD63+ Peanut 1 2.38 (0.90; 15.44) 
%CD63+ Peanut 10 18.16 (4.45; 51.90) 
%CD63+ Peanut 100 21.78 (8.44; 51.88) 
%CD63+ Peanut 1,000 23.53 (7.70; 43.37) 
%CD63+ Peanut 10,000 34.36 (12.32; 55.44) 
Mean %CD63 Peanut 10-100 16.94 (6.29; 52.38) 
AUC CD63 Peanut 86.96 (46.82; 207.38) 
Maximal %CD63+ to peanut 39.90 (15.20; 67.39) 
%CD63+ peanut/anti-IgE 0.82 (0.32; 1.32) 
EC50 (ng/ml) - CD63 10 (1; 10) 
CDsens 12.97 (1.96; 85.91) 
 
5.3.1 Severity of allergic reactions to peanut is associated with greater allergen-specific 
basophil reactivity 
Patients with severe reactions to peanut during the oral food challenge had a higher proportion of 
CD63-positive basophils at concentrations of peanut extract ranging from 0.1 to 10,000 ng/ml 
compared to peanut allergic patients with mild/moderate reactions (p=0.003-0.049; Figure 5.1 and 
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Table 5.9 BAT parameters associated with the severity of allergic reactions to peanut.  
Values are expressed as median (interquartile range). CDsens was calculated based on the CD63 dose-response curve. 
Numbers in the left column indicate the concentration of peanut extract in ng/ml. Significant p values are highlighted in 
bold. Abbreviation: AUC CD63, area under the dose-response curve considering the percentage of CD63-positive 
basophils.  







%CD63+ Peanut 0.1 0.36 (0; 3.05) 1.03 (0.16; 3.22) 0.215 
%CD63+ Peanut 1 2.13 (0.36; 8.12) 8.60 (1.68; 34.41) 0.016 
%CD63+ Peanut 10 6.65 (2.15; 31.73) 37.04 (12.80; 70.71) 0.009 
%CD63+ Peanut 100 17.11 (2.60; 44.28) 48.44 (16.24; 68.79) 0.003 
%CD63+ Peanut 1,000 18.56 (3.37; 35.18) 34.33 (20.31; 59.27) 0.049 
%CD63+ Peanut 10,000 25.86 (5.74; 44.68) 52.79 (28.92; 58.93) 0.012 
Mean %CD63 Peanut 10-100 13.26 (2.56; 38.05) 41.31 (10.23; 67.36) 0.012 
AUC CD63 Peanut 66.44 (27.64; 164.91) 159.14 (78.84; 240.42) 0.016 
Maximal %CD63+ to peanut 27.74 (9.99; 56.23) 59.49 (31.47; 75.85) 0.025 
%CD63+ peanut/anti-IgE  0.53 (0.15; 0.85) 1.32 (0.92; 1.55) <0.001 
EC50 (ng/ml) - CD63 10 (1; 100) 10 (1; 10) 0.058 
CDsens 5.37 (0.99; 50.66) 32.59 (11.62; 87.97) 0.023 
 
 
The best basophil markers for the severity of allergic reactions were the ratio of the percentage of 
CD63-positive basophils at 100 ng/ml of peanut to the percentage of CD63-positive basophils 
following stimulation with anti-IgE (CD63 peanut/anti-IgE, p<0.001; Figure 5.2) and the 
percentage of CD63-positive basophils at 100 ng/ml of peanut extract (p=0.008). The latter 
marker was previously identified as optimal for the diagnosis of peanut allergy
165
 and was the best 
discriminator of the patients who had severe reactions requiring the administration of 
intramuscular adrenaline (Table 5.10).  
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Figure 5.2 Best BAT parameter associated with the severity of allergic reactions. 
The best BAT parameter to distinguish between patients with severe versus non-severe reactions to peanut was the ratio 





























Table 5.10 BAT parameters according to the requirement of intramuscular adrenaline.  
Values are expressed as median (interquartile range). CDsens was calculated based on the CD63 dose-response curve. 
Numbers in the left column indicate the concentration of peanut extract in ng/ml. Significant p values are highlighted in 
bold. Abbreviation: AUC CD63, area under the dose-response curve considering the percentage of CD63-positive 
basophils.  
BAT parameters Adrenaline required (n=9) 
Adrenaline not required 
(n=40) 
p value 
%CD63+ Peanut 0.1 3.31 (1.98; 12.96) 0.33 (0; 1.18) 0.001 
%CD63+ Peanut 1 5.65 (8.60; 45.65) 1.95 (0.67; 9.42) 0.001 
%CD63+ Peanut 10 59.63 (37.04; 73.93) 10.69 (2.46; 35.16) 0.002 
%CD63+ Peanut 100 68.01 (45.09; 74.66) 17.59 (6.08; 46.41) <0.001 
%CD63+ Peanut 1,000 49.65 (35.13; 64.49) 20.31 (3.54; 34.33) 0.002 
%CD63+ Peanut 10,000 57.30 (39.34; 64.54) 27.43 (6.66; 49.64) 0.007 
Mean %CD63 Peanut 10-100 62.27 (35.72; 72.63) 13.67 (5.32; 41.26) 0.003 
AUC CD63 Peanut 223.95 (131.91; 276.69) 76.74 (31.88; 183.94) 0.001 
Maximal %CD63+ to peanut 70.31 (62.68; 80.26) 31.91 (11.29; 58.14) 0.001 
%CD63+ peanut/anti-IgE 1.34 (0.99; 1.45) 0.64 (0.20; 1.21) 0.010 
EC50 (ng/ml) - CD63 1.0 (1.0; 10.0) 10.0 (1.0; 100.0) 0.066 






5.3.2 Basophil sensitivity indicates the threshold of allergic reactions to peanut 
The dose-response for peanut-induced basophil activation of patients with lower cumulative 
peanut threshold on oral food challenge was shifted to the left compared to the dose-response of 
patients with a higher cumulative peanut threshold (Figure 5.3).  
 
Figure 5.3 Peanut-dose-response of basophil activation in patients with low versus high threshold of 
reactivity to peanut.  
 
Peanut allergic patients with lower threshold on oral food challenge had higher basophil sensitivity 
as expressed by a higher CDsens (p=0.005) and a correspondingly lower EC50 (p=0.019; Table 
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Table 5.11 BAT parameters associated with the threshold of allergic reactions to peanut.  
Values are expressed as median (interquartile range). CDsens was calculated based on the CD63 dose-response curve. 
Numbers in the left column indicate the concentration of peanut extract in ng/ml. Significant p values are highlighted in 
bold. Abbreviation: AUC CD63, area under the dose-response curve considering the percentage of CD63-positive 
basophils.  
BAT to peanut 
Threshold groups 
0.1g peanut protein    
(n=28) 
>0.1g peanut protein 
(n=21) 
p value 
%CD63+ Peanut 0.1 1.07 (0.14; 3.34) 0.36 (0; 1.43) 0.140 
%CD63+ Peanut 1 3.08 (1.41; 39.38) 1.76 (0.68; 4.85) 0.090 
%CD63+ Peanut 10 19.33 (4.67; 71.52) 15.54 (2.15; 36.12) 0.163 
%CD63+ Peanut 100 23.60 (8.73; 58.03) 21.78 (1.99; 49.36) 0.505 
%CD63+ Peanut 1,000 22.86 (7.70; 38.88) 24.57 (3.30; 55.36) 0.818 
%CD63+ Peanut 10,000 36.08 (10.96; 54.47) 34.36 (10.40; 58.37) 0.888 
Mean %CD63 Peanut 10-100 10.18 (5.16; 16.09) 20.41 (4.36; 43.42) 0.419 
AUC CD63 Peanut 92.96 (34.24; 231.34) 86.96 (52.84; 196.60) 0.671 
Maximal %CD63+ to peanut 47.59 (15.12; 74.75) 34.66 (13.08; 62.81) 0.303 
%CD63+ peanut/anti-IgE 0.79 (0.44; 1.26) 0.83 (0.09; 1.35) 0.716 
EC50 (ng/ml) - CD63 1.0 (1.0; 32.5) 10.0 (10.0; 10.0) 0.019 





Figure 5.4 Best BAT parameter associated with the threshold of allergic reactions  
The best BAT parameter to distinguish between patients with low versus high threshold of reactivity to peanut was CDsens 
determined using the CD63 dose-response curve. **p<0.01. 
 
 
5.3.3 Logistic regression analyses to assess different parameters of severity and 
threshold 
As various parameters other than BAT varied with the severity and the threshold of allergic 
reactions to peanut (Table 5.9 and Table 5.11), logistic regression analyses were conducted to 
assess which parameters were independently associated with severity and threshold (Table 
5.12). Following multivariable analyses, only the basophil activation markers were retained for 
severity and for threshold meaning that the BAT alone was more discriminative in predicting the 
severity (CD63 peanut/anti-IgE, p=0.001) and the threshold (CDsens, p=0.020) of allergic reactions 
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Table 5.12 Univariable and multivariable analyses of factors associated with the severity and threshold of 
allergic reactions to peanut.  
*All variables were re-tested by forward multivariable logistic regression and only variables contributing to the model 
(p<0.05) were retained. CDsens refers to CDsens calculated using the CD63 dose-response curve. 
Variable 
Severe allergic reaction Low threshold of reactivity 
OR (95% CI) p value OR (95% CI) p value 
Univariable analysis 
%CD63+ peanut/anti-IgE 0.111 (0.026; 0.478) 0.001 - - 
CDsens - - 1.027 (1.004; 1.050) 0.020 
SPT - - 1.231 (1.033; 1.466) 0.020 
Specific IgE to peanut 1.014 (1.0; 1.029) 0.056 1.022 (1.0; 1.045) 0.053 
Ara h 1-specific IgE 1.031 (0.985; 1.079) 0.186 1.016 (0.975; 1.058) 0.459 
Ara h 2-specific IgE 1.034 (0.999; 1.070) 0.054 1.036 (0.994; 1.080) 0.090 
Ara h 3-specific IgE - - 3.391 (0.590; 19.501) 0.171 
Number of major peanut 
allergens bound by IgE  
2.342 (1.144; 4.791) 0.020 1.712 (0.896; 3.272) 0.104 
Ratio peanut-sIgG4/IgE - - 0.999 (0.997; 1.001) 0.283 
Allergic rhinitis - - 3.431 (1.049; 11.222) 0.041 
Multivariable analysis* 
%CD63+ peanut/anti-IgE 0.111 (0.026; 0.478) 0.001 - - 




5.4 Basophil activation test cut-offs for severity and threshold  
The ratio of the percentage of CD63-positive basophils following stimulation with 100 ng/ml of 
peanut extract to the percentage of CD63-positive basophils following stimulation with anti-IgE 
was chosen as the BAT parameter to reflect the severity of allergic reactions. A ratio greater or 
equal to 1.3 increased the proportion of severe reactors by 3-fold (relative risk (RR) =3.4; 95% 
CI=1.8-6.2) compared to patients with less than 1.3 for the ratio of %CD63+ peanut/anti-IgE 
(p=0.001, Figure 5.5). 
 
Figure 5.5 Proportion of patients with severe reactions according to the 75th percentile of basophil reactivity 
 Basophil reactivity was measured by %CD63+ peanut/anti-IgE. **p<0.01. 
 
Patients with CDsens greater or equal to 84.0 were two times more likely to react to low amounts of 
peanut (RR=1.9; 95%CI=1.3-2.8) compared to patients with lower values of CDsens and thus with 
a higher threshold of reactivity to peanut (p=0.014, Figure 5.6.).  
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Figure 5.6 Proportion of patients with lower threshold of reactivity to peanut according to the 75th percentile 
of basophil sensitivity  




BAT cut-offs to estimate the severity (Figure 5.7 and Table 5.13) and the threshold (Figure 5.8 
and Table 5.14) of peanut allergic reactions were also determined by ROC curve analyses.  
 
Figure 5.7 Receiver operating characteristic (ROC) curve for the use of %CD63+ peanut/anti-IgE for 
estimation of the severity of allergic reactions to peanut during challenges.  
AUC (95% CI)=0.81 (0.68; 0.91) 
 
Table 5.13 Negative, optimal and positive cut-offs for the use of the ratio between the proportion of CD63-
positive basophils following stimulation with peanut and with anti-IgE for estimation of the severity of allergic 













































Figure 5.8 Receiver operating characteristic (ROC) curve for the use of CDsens for the estimation of the 
threshold of allergic reactions to peanut during challenges. 
[AUC (95% CI)=0.75 (0.60; 0.87)] 
 
 
Table 5.14 Negative, optimal and positive cut-offs for the use of CDsens for the estimation of the threshold of 
allergic reactions to peanut during challenges. 
 
 
5.5 Correlation between severity and threshold 
Clinically, symptom score and threshold dose were not correlated (Rs= -0.067, p=0.645, Table 
5.15). However, the basophil markers of severity (CD63 peanut/anti-IgE) and of threshold (CDsens) 
were strongly correlated (Rs=0.60; p<0.001,).  
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Table 5.15 Correlations between severity (as measured by symptom score) and threshold (as measured by 
cumulative threshold dose) of allergic reactions to peanut and different diagnostic tests.  
N=44. Spearman correlation coefficient and p values are indicated. Significant correlations are highlighted in bold. CDsens 
was calculated based on the CD63 dose-response curve. Abbreviation: SPT, skin prick test. 
 Symptom score Cumulative threshold dose 
Symptom score - 
rs= -0.067 
p=0.645 




































































5.6 Classification of the severity of allergic reactions to peanut using 
different severity scores 
The severity of allergic reactions to peanut was classified according to severity scores other than 
the one described by Ewan et al
148
 (Table 5.3 and Table 5.9), namely the one described by 
Mueller et al
172
 (Table 5.16), the one described by Brown et al
173
 (Table 5.17), the one described 
by Sampson et al
174
 (Table 5.18) and the one described by Van der Zee et al
175
 (Table 5.19). The 
comparison of severity groups defined according to the different criteria showed similar although 
not perfectly overlapping results, with SPT, specific IgE to peanut and to Ara h 2 and number of 
allergens as well as markers of basophil reactivity being associated with severity considering the 




Table 5.16 Demographic, clinical and BAT parameters between severe and non-severe reactors classified 
according to the severity score adopted by Mueller et al
172
.  
Values are expressed as number (percentage) or median (interquartile range). Significant p values are highlighted in bold. 
CDsens was calculated based on the CD63 dose-response curve. Numbers in the left column indicate the concentration of 
peanut extract in ng/ml.  Abbreviations: SPT, skin prick test; AUC CD63, area under the dose-response curve considering 
the percentage of CD63-positive basophils.  







Age (years) 5.2 (4.0; 5.8) 5.4 (5.0; 6.2) 0.176 
Males - n (%) 17 (65%) 17 (74%) 0.552 
Cumulative threshold dose of 
peanut protein (g) 
0.08 (0.03; 1.15) 0.10 (0.03; 0.50) 0.594 
SPT to peanut (mm) 9 (4; 10) 10 (7; 13) 0.045 
Specific IgE to peanut (KUA/l) 1.81 (0.36; 12.03) 15.35 (4.17; 61.65) 0.017 
Specific IgE to Ara h 1 (KUA/l) 0.09 (0.01; 0.28) 0.17 (0.06; 7.99) 0.051 
Specific IgE to Ara h 2 (KUA/l) 0.73 (0.09; 2.95) 7.31 (0.57; 33.48) 0.011 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.18) 0.04 (0.01; 0.89) 0.340 
Specific IgE to Ara h 8 (KUA/l) 0.02 (0.01; 0.14) 0.03 (0.01; 2.01) 0.324 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 0.01 (0.01; 0.04) 0.395 
Number of major peanut 
allergens bound by IgE 
1.0 (0; 2.0) 2.0 (1.0; 3.0) 0.024 
Peanut-specific IgG4 (µg/l) 150 (115; 363) 335 (128; 928) 0.151 
Ratio of peanut-specific IgG4 to 
IgE 
19.93 (5.64; 147.66) 12.64 (5.09; 77.76) 0.342 
Other food allergy - n (%) 24 (92%) 23 (100%) 0.491 
Atopic eczema - n (%) 21 (81%) 19 (83%) 1.0 
Asthma - n (%) 11 (42%) 8 (35%) 0.770 
Allergic rhinitis - n (%) 14 (54%) 13 (57%) 1.0 







%CD63+ Peanut 0.1 0.3 (0; 3.0) 1.0 (0.1; 3.3) 0.225 
%CD63+ Peanut 1 2.2 (0.4; 10.8) 3.8 (1.5; 31.8) 0.062 
160 
%CD63+ Peanut 10 7.7 (2.2; 37.8) 27.5 (9.1; 70.3) 0.050 
%CD63+ Peanut 100 17.6 (2.8; 45.1) 34.7 (9.7; 68.0) 0.021 
%CD63+ Peanut 1,000 19.9 (3.5; 36.7) 29.9 (10.1; 52.1) 0.131 
%CD63+ Peanut 10,000 23.7 (6.0; 44.3) 45.4 (27.1; 58.7) 0.025 
Mean %CD63 Peanut 10-100 13.4 (4.7; 43.0) 26.6 (8.1; 62.3) 0.075 
AUC CD63 Peanut 69.4 (22.1; 192.4) 115.8 (66.4; 223.9) 0.032 
Maximal %CD63+ to peanut 26.8 (10.6; 61.5) 54.5 (30.5; 75.1) 0.060 
%CD63+ peanut/anti-IgE 0.53 (0.15; 0.82) 1.18 (0.92; 1.53) <0.001 
EC50 (ng/ml) - CD63 10 (1; 100) 10 (1; 10) 0.103 





Table 5.17 Demographic, clinical and BAT parameters between severe and non-severe reactors classified 
according to the severity score adopted by Brown et al
173
.  
Values are expressed as number (percentage) or median (interquartile range). Significant p values are highlighted in bold. 
CDsens was calculated based on the CD63 dose-response curve. Numbers in the left column indicate the concentration of 
peanut extract in ng/ml.  Abbreviations: SPT, skin prick test; AUC CD63, area under the dose-response curve considering 
the percentage of CD63-positive basophils. 







Age (years) 4.0 (3.1; 5.3) 5.4 (4.9; 5.9) 0.030 
Males - n (%) 6 (75%) 28 (68%) 1.0 
Cumulative threshold dose of 
peanut protein (g) 
0.24 (0.04; 3.79) 0.10 (0.03; 0.38) 0.472 
SPT to peanut (mm) 5 (4; 9) 9 (7; 13) 0.030 
Specific IgE to peanut (KUA/l) 0.41 (0.21; 2.75; 6.23 (1.09; 31.32) 0.027 
Specific IgE to Ara h 1 (KUA/l) 0.02 (0.01; 0.17) 0.13 (0.03; 3.16) 0.074 
Specific IgE to Ara h 2 (KUA/l) 0.03 (0.01; 0.20) 3.53 (0.43; 19.19) 0.002 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.16) 0.03 (0.01; 0.47) 0.716 
Specific IgE to Ara h 8 (KUA/l) 0.01 (0.01; 0.04) 0.03 (0.01; 0.47) 0.170 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 0.01 (0.01; 0.03) 0.573 
Number of major peanut 
allergens bound by IgE 
1.0 (0; 2.0) 2.0 (1.0; 3.0) 0.035 
Peanut-specific IgG4 (µg/l) 140 (83; 468) 215 (128; 703) 0.337 
Ratio of peanut-specific IgG4 to 
IgE 
98.17 (5.20; 705.56) 14.20 (5.74; 77.76) 0.259 
Other food allergy - n (%) 6 (75%) 41 (100%) 0.024 
Atopic eczema - n (%) 6 (75%) 34 (83%) 0.628 
Asthma - n (%) 2 (25%) 17 (42%) 0.458 
Allergic rhinitis - n (%) 2 (25%) 25 (61%) 0.117 







%CD63+ Peanut 0.1 0 (0; 0.3) 1.0 (0.2; 3.2) 0.011 
%CD63+ Peanut 1 1.1 (0; 2.2) 3.1 (1.3; 16.5) 0.070 
162 
%CD63+ Peanut 10 3.0 (0; 16.2) 22.7 (4.9; 59.5) 0.025 
%CD63+ Peanut 100 10.2 (0.1; 38.6)  26.4 (8.9; 56.2) 0.045 
%CD63+ Peanut 1,000 10.5 (0.3; 30.7) 25.7 (9.0; 48.4) 0.043 
%CD63+ Peanut 10,000 18.7 (0.8; 36.7) 40.7 (15.7; 57.5) 0.033 
Mean %CD63 Peanut 10-100 9.1 (0; 28.5) 21.2 (7.0; 59.1) 0.055 
AUC CD63 Peanut 69.4 (4.3; 129.4) 89.1 (48.5; 211.1) 0.123 
Maximal %CD63+ to peanut 25.6 (1.2; 49.2) 42.9 (17.1; 69.7) 0.088 
%CD63+ peanut/anti-IgE  0.20 (0; 1.08) 0.87 (0.47; 1.34) 0.035 
EC50 (ng/ml) - CD63 10 (3; 78) 10 (1; 10) 0.699 






Table 5.18 Demographic, clinical and BAT parameters between severe and non-severe reactors classified 
according to the severity score adopted by Sampson et al
174
.  
Values are expressed as number (percentage) or median (interquartile range). Significant p values are highlighted in bold. 
CDsens was calculated based on the CD63 dose-response curve. Numbers in the left column indicate the concentration of 
peanut extract in ng/ml.  Abbreviations: SPT, skin prick test; AUC CD63, area under the dose-response curve considering 
the percentage of CD63-positive basophils. 






Age (years) 5.3 (4.6; 5.9) 5.4 (4.9; 5.8) 0.578 
Males - n (%) 18 (64%) 16 (76%) 0.533 
Cumulative threshold dose of 
peanut protein (g) 
0.08 (0.03; 0.78) 0.1 (0.3; 0.63) 0.627 
SPT to peanut (mm) 9 (6; 10) 10 (7; 13) 0.306 
Specific IgE to peanut (KUA/l) 1.97 (0.38; 13.68) 18.35 (2.08; 83.75) 0.029 
Specific IgE to Ara h 1 (KUA/l) 0.09 (0.01; 0.26) 0.18 (0.02; 8.67) 0.099 
Specific IgE to Ara h 2 (KUA/l) 0.90 (0.19; 2.81) 9.21 (0.29; 37.10) 0.040 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.16) 0.04 (0.01; 0.94) 0.386 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.01; 0.28) 0.03 (0.01; 1.93) 0.639 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 0.01 (0.01; 0.04) 1.0 
Number of major peanut allergens 
bound by IgE 
1.0 (1.0; 2.0) 2.0 (1.0; 3.0) 0.062 
Peanut-specific IgG4 (µg/l) 180 (120; 405) 380 (120; 1100) 0.301 
Ratio of peanut-specific IgG4 to 
IgE 
21.63 (5.78; 161.26) 11.26 (3.15; 76.75) 0.218 
Other food allergy - n (%) 26 (93%) 21 (100%) 0.500 
Atopic eczema - n (%) 24 (86%) 16 (76%) 0.470 
Asthma - n (%) 11 (39%) 8 (38%) 1.0 
Allergic rhinitis - n (%) 15 (54%) 12 (57%) 1.0 







%CD63+ Peanut 0.1 0.3 (0; 3.1) 1.0 (0.2; 3.1) 0.189 
%CD63+ Peanut 1 1.9 (0.3; 9.0) 5.5 (1.7; 33.5) 0.012 
164 
%CD63+ Peanut 10 7.7 (2.1; 34.7) 34.5 (10.7; 70.6) 0.024 
%CD63+ Peanut 100 18.2 (2.4; 44.3) 47.7 (12.5; 68.5) 0.009 
%CD63+ Peanut 1,000 19.9 (3.3; 35.7) 33.8 (13.0; 56.9) 0.066 
%CD63+ Peanut 10,000 26.8 (5.5; 45.1) 51.0 (34.4; 58.8) 0.021 
Mean %CD63 Peanut 10-100 13.4 (2.3; 40.3) 37.6 (8.5; 65.7) 0.029 
AUC CD63 Peanut 71.5 (26.3; 176.7) 148.0 (63.1; 234.9) 0.031 
Maximal %CD63+ to peanut 31.05 (9.37; 58.18) 59.34 (26.07; 75.59) 0.043 
%CD63+ peanut/anti-IgE 0.54 (0.14; 1.02) 1.10 (0.78; 1.46) 0.003 
EC50 (ng/ml) - CD63 10 (1; 100) 10 (1; 10) 0.164 






Table 5.19 Demographic, clinical and BAT parameters between severe and non-severe reactors classified 
according to the severity score adopted by Van der Zee et al
175
.  
Values are expressed as number (percentage) or median (interquartile range). Significant p values are highlighted in bold. 
CDsens was calculated based on the CD63 dose-response curve. Numbers in the left column indicate the concentration of 
peanut extract in ng/ml.  Abbreviations: SPT, skin prick test; AUC CD63, area under the dose-response curve considering 
the percentage of CD63-positive basophils. 






Age (years) 5.3 (4.3; 5.8) 5.4 (4.9; 6.1) 0.379 
Males - n (%) 18 (64%) 16 (76%) 0.533 
Cumulative threshold dose of 
peanut protein (g) 
0.10 (0.03; 1.62) 0.10 (0.03; 0.37) 0.885 
SPT to peanut (mm) 9 (4; 10) 10 (8; 13) 0.041 
Specific IgE to peanut (KUA/l) 1.81 (0.38; 9.93) 25.30 (5.34; 98.70) 0.003 
Specific IgE to Ara h 1 (KUA/l) 0.07 (0.01; 0.18) 0.22 (0.10; 20.30) 0.005 
Specific IgE to Ara h 2 (KUA/l) 0.54 (0.09; 2.20) 11.0 (1.79; 54.30) 0.001 
Specific IgE to Ara h 3 (KUA/l) 0.03 (0.01; 0.04) 0.05 (0.01; 0.94) 0.111 
Specific IgE to Ara h 8 (KUA/l) 0.03 (0.01; 0.04) 0.03 (0.01; 1.93) 0.835 
Specific IgE to Ara h 9 (KUA/l) 0.01 (0.01; 0.02) 0.01 (0.01; 0.04) 1.0 
Number of major peanut allergens 
bound by IgE 
1.0 (0; 2.0) 2.0 (1.0; 3.0) 0.006 
Peanut-specific IgG4 (µg/l) 160 (120; 443) 350 (123; 1043) 0.190 
Ratio of peanut-specific IgG4 to 
IgE 
34.15 (6.47; 167.78) 10.05 (2.52; 66.05) 0.087 
Other food allergy - n (%) 26 (93%) 21 (100%) 0.500 
Atopic eczema - n (%) 22 (79%) 18 (86%) 0.714 
Asthma - n (%) 10 (36%) 9 (43%) 0.768 
Allergic rhinitis - n (%) 14 (50%) 13 (62%) 0.563 







%CD63+ Peanut 0.1 0.3 (0; 2.5) 1.0 (0.2; 3.2) 0.135 
%CD63+ Peanut 1 1.9 (0.3; 5.1) 13.0 (1.7; 36.4) 0.005 
166 
%CD63+ Peanut 10 6.1 (2.1; 24.3) 39.6 (13.4; 71.3) 0.002 
%CD63+ Peanut 100 13.3 (2.4; 41.8) 49.2 (17.1; 69.2) 0.001 
%CD63+ Peanut 1,000 14.6 (3.3; 33.9) 35.2 (20.7; 58.2) 0.023 
%CD63+ Peanut 10,000 23.7 (5.5; 45.1) 51.0 (30.7; 58.8) 0.014 
Mean %CD63 Peanut 10-100 12.5 (2.3; 31.8) 45.0 (11.4; 69.1) 0.003 
AUC CD63 Peanut 64.3 (26.3; 133.3) 170.3 (80.8; 258.4) 0.005 
Maximal %CD63+ to peanut 26.80 (9.37; 50.60) 59.63 (32.44; 78.09) 0.008 
%CD63+ peanut/anti-IgE  0.53 (0.14; 0.83) 1.29 (0.92; 1.54) <0.001 
EC50 (ng/ml) - CD63 10 (1; 100) 5.5 (1; 10) 0.026 
CDsens 4.83 (0.93; 23.93) 39.82 (12.12; 99.10) 0.009 
 
Logistic regression analyses classifying the severity of allergic reactions according to the other 
severity scores and according to the need for adrenaline corroborated my findings using the 
severity classification adopted by Ewan et al
148
 (Table 5.20), except for the logistic regression 
analyses using the classification by Brown et al where the p value for %CD63+ peanut/anti-IgE 
was above the cut-off for statistical significance (p=0.057).  
 
Table 5.20 Results of multivariable analyses of factors associated with the severity of allergic 
reactions to peanut classified using different severity classification systems.  
Significant p values are highlighted in bold.  
Classification  of 
severity 
Variable OR (95% CI) p value 
Mueller
172
 %CD63+ peanut/anti-IgE 0.121 (0.025; 0.592) 0.002 
Sampson
174
 %CD63+ peanut/anti-IgE 0.062 (0.016; 0.244) 0.009 
Van Der Zee
175





Basophils are effector cells of food-induced anaphylaxis. Allergen-induced basophil reactivity and 
sensitivity in vitro indicates the severity and threshold of allergic reactions to peanut during oral 
peanut challenges, respectively. Basophil reactivity (assessed by the ratio of the percentage of 
CD63-positive basophils at 100 ng/ml of peanut to the percentage of CD63-positive basophils 
following stimulation with anti-IgE) is associated with severity and basophil sensitivity (measured 
by CDsens) is associated with threshold of allergic reactions to peanut. Patients with a ratio of the 
percentage of CD63-positive basophils at 100 ng/ml of peanut to the percentage of CD63-positive 
basophils following stimulation with anti-IgE greater or equal than 1.3 were 3 times more likely to 
have severe allergic reactions to peanut. Patients with CDsens greater or equal than 84.0 were 2 
times more likely to react to low amounts of peanut. The basophil activation test may therefore be 
used as an in vitro surrogate for oral food challenges to estimate the severity and the threshold of 
allergic reactions and to improve the management of patients with peanut allergy.  
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Chapter 6 Additional applications of the basophil activation test 
 
The basophil activation test (BAT) can have applications beyond the diagnosis of allergy and the 
characterisation of the immune response to allergens. During my PhD, I participated in 
collaborative projects with colleagues within King's College London in which I used the BAT to 
detect the biological activity of peanut protein in complex mixtures such as house dust extracts 
and to detect the ability of auto-antibodies present in the serum of asthmatic patients to induce 
basophil degranulation. I also investigated signalling pathways during peanut-induced basophil 
activation.  
 
6.1 Determination of the biological activity of peanut protein in 
house dust 
Published in Brough HA, Santos AF et al. J Allergy Clin Immunol 2013; 132(3):630-8 and included 
in this thesis with permission from Elsevier. 
Understanding how children become sensitised to peanut may lead to the development of 
strategies to prevent peanut allergy. Exposure to peanut can occur through various routes: in 
utero, via breast milk, via dietary gastrointestinal exposure or via environmental exposure through 
the skin or through inhalation. Epicutaneous exposure, particularly in children with abraded skin 
due to eczema, may play an important role in peanut sensitisation
88, 176
. Environmental exposure 
to peanut has been identified as a risk factor for the development of peanut allergy. Applying a 
food frequency questionnaire to children with peanut allergy, children with egg allergy who are at 
high-risk of developing peanut allergy and low-risk non-allergic controls and all their household 
members, Fox et al
145
 demonstrated a dose-response relationship between the household peanut 
consumption, which is an indirect marker of environmental peanut exposure, and the risk of later 
development of peanut allergy. In a follow-on study, Brough et al
177
 quantified the peanut protein 
in house dust samples using a polyclonal peanut ELISA and observed that peanut protein levels 
in the environment were positively correlated to peanut consumption in the home. Quantifying 
peanut protein in the home environment raised the question as to whether peanut allergens in 
house dust maintained their biological activity.  
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Functional in vitro assays that closely resemble in vivo allergic reactions have been used in 
previous studies to verify the allergenic potential of peanut proteins, i.e. their ability to trigger mast 
cell and basophil activation and degranulation, both pure and in complex mixtures
46, 178
. 
Mediators, such as β-hexosaminidase and histamine, released by rat basophilic leukaemia cells 
and stripped-human basophils passively sensitised with plasma from allergic patients have been 
measured following stimulation with allergen
179
. More recently, assays evaluating the expression 
of activation markers on the surface of basophils of allergic patients by flow cytometry, similar to 
the BAT described in the previous chapters, have been used to assess the allergenicity of 
foods
180
 and have been shown to be a sensitive and specific tool to detect low amounts of peanut 
in food matrices
181
. I hypothesised that BAT would be useful in verifying the biological activity of 
peanut proteins in household dust samples. 
 
6.1.1 Peanut protein in house dust is able to activate basophils from peanut allergic 
children 
Three children mono-allergic to peanut and 3 non-allergic children were recruited to test the ability 
of peanut allergens contained in house dust samples to elicit basophil activation. Two of the 
patients with peanut allergy were sensitised to the 3 major peanut allergens (Ara h 1, Ara h 2, and 
Ara h 3), and 1 patient was sensitised to Ara h 1 and Ara h 2. None of these patients were 
sensitised to any other food or airborne allergens, as assessed by SPT. Extracted dust samples 
with high or low peanut protein content were tested using blood from children with peanut allergy 
and non-allergic children, forming 5 pairs of dust sample–patient experiments.  
Dust samples containing peanut protein levels of less than 0.375 ng/ml did not induce significant 
basophil activation neither in children with peanut allergy (medians below 1% of CD63-positive 
basophils, Figure 6.1.A) nor in non-allergic children (medians below 2.7% of CD63-positive 
basophils, Figure 6.1. C). In contrast, dust samples containing high concentrations of peanut 
protein resulted in dose-dependent activation of basophils from peanut allergic (Figure 6.1.B) but 
not from non-allergic children (Figure 6.1.D). The proportion of CD63-positive basophils was 
significantly higher in children with peanut allergy at peanut concentrations ranging between 1 




Figure 6.1 Activation of basophils from peanut mono-allergic or non-allergic patients by dust samples. 
Activation of basophils was induced by serial dilutions of dust samples containing low (A and C) or high (B and D) peanut 
protein in peanut-monoallergic (A and B) or non-allergic (C and D) patients (n=5 pairs of sample-patient experiments). 
Quartiles and minimum and maximum percentages of CD63-positive basophils are displayed. High peanut dust extracts 
were dilution-adjusted to the maximum same concentration of peanut protein (10 μg/ml) and then underwent serial 
dilutions for comparability of dose-response, and low peanut dust samples were prepared by using the same dilution 
factor. Basophil activation for each concentration of peanut was compared between allergic and non-allergic children (i.e., 
A vs. C and B vs. D). **p<0.01. 
 
The threshold for basophil activation was 1 ng/ml using basophils from the 3 selected donors with 
peanut allergy (Figure 6.1.B versus Figure 6.1.D). Basophils of allergic and non-allergic patients 
showed comparable spontaneous basophil activation (p=0.690) and CD63 expression induced by 
anti-IgE (p=0.222) and N-formyl-methionyl-leucyl-phenylalanine (p=0.841) - Table 6.1. In children 
with peanut allergy, the dose-response of basophil activation by dust samples was comparable 
with the dose-response to similar concentrations of the independent peanut standard. Basophils 
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of non-allergic patients were not activated by the peanut standard up to 10 µg/ml of peanut 
protein. 
Table 6.1 Basophil activation of peanut allergic and non-allergic children  
Basophil activation is expressed as median (interquartile range) of the percentage of CD63-positive basophils stimulated 
with high-peanut-containing dust samples or the peanut standard or controls. Abbreviations: RPMI, Roswell Park Memorial 
Institute medium (negative control); fMLP, Formyl-Methionyl-Leucyl-Phenylalanine. 
Peanut protein 
(ng/ml) 
Peanut allergic children Non-allergic children 
Dust samples Peanut standard Dust samples Peanut standard 
0.1 1.6 (0; 4.3) 2.0 (1.0; 25.1) 0.1 (-0.3; 0.8) 0 (0; 0.1) 
1 7.8 (4.4; 9.6) 1.0 (0.62; 77.0) 0.6 (0.3; 0.9) 0.1 (0; 0.3) 
10 31.2 (14; 36.6) 13.5 (9.1; 77.0) 2.8 (0.7; 3.7) 0.5 (0; 1.4) 
100 51.7 (26.6; 56.1) 26.8 (20.1; 58.9) 1.3 (0.9; 5.1) 0 (0; 0.5) 
1,000 43.3 (33.3; 59.5) 27.8 (27.4; 52.8) 4.6 (3.1; 6.2) 0.4 (0; 1.4) 
10,000 64.4 (46.2; 78.2) 44.8 (38.8; 45.3) 7.2 (6.2; 9.0) 1.1 (0; 2.6) 
Controls Peanut allergic children Non-allergic children 
RPMI 0.9 (0.87; 0.95) 1.5 (0.85; 1.75) 
Anti-IgE 22.0 (17.6; 63.7) 12.0 (9.6; 35.5)   




BAT is a useful tool in determining the allergenicity and the biological activity of peanut proteins, 
in complex mixtures, such as house dust. The peanut protein in the dust samples tested retained 
the ability to interact with immune cells, causing activation and degranulation of basophils from 
peanut allergic children. This suggests that peanut protein present in house dust may be an 
important source of allergenic protein that is biologically active and therefore could be implicated 
in allergic sensitisation. For example, peanut protein in house dust may be able to interact with 
dendritic cells present in the abraded and inflamed skin of patients with eczema leading to allergic 
sensitisation to peanut, which in turn can lead to peanut allergy. 
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6.2 Determination of the ability of auto-anti-IgE antibodies to 
activate peripheral blood basophils 
Published in Chan YC, Ramadani F, Santos AF, et al.  J Allergy Clin Immunol 2014; 134 (6): 
1394-1401 (open-access). 







. By cross-linking IgE or aggregating FcεRI receptors, some of these 
auto-antibodies are able to activate mast cells and basophils and this activation is independent of 
allergens. Different methods have been used to measure the serum levels (e.g. ELISA-based 
methods) and to determine the function of such antibodies, including the autologous serum skin 
test
182
, the basophil histamine release test
185
 and, more recently, the basophil activation test using 
flow cytometry
186
. However, the levels of the auto-antibodies present in the serum do not 
necessarily reflect their inflammatory activity
187
. Furthermore, these auto-antibodies are also 
present in the serum of healthy individuals and may not have any pro-inflammatory activity.  
Asthma develops in non-atopic individuals and exacerbations can happen independently of 
allergen exposure. One possible mechanism involved in the elicitation of basophil and mast cell 
degranulation that can initiate the exacerbation of asthmatic symptoms independently of allergen 
is the presence of auto-antibodies anti-IgE or anti-FcεRI. Two hypotheses were considered to 
explain the involvement of IgE in asthma, independent of allergen: 1. IgG anti-IgE antibodies were 
elevated in the serum of asthmatics irrespective of atopic status compared with controls; and 2. 
some IgG anti-IgE antibodies were able to activate mast cells and basophils whereas others had 
a regulatory role and inhibited allergen-induced effector cell activation.  
 
6.2.1 Naturally occurring IgG anti-IgE antibodies are detectable in the serum of 
asthmatic patients 
Serum samples of atopic asthmatics (AA), non-atopic asthmatics (NAA) and non-atopic non-
asthmatic controls (NAC) were tested for IgG anti-IgE antibodies using an in-house custom ELISA 
using omalizumab as a standard to calibrate the ELISA
184
. Ten serum samples (6 from NAA and 4 
from AA) showed concentrations of serum IgG anti-IgE above the upper limit of the 95% 
confidence interval of the measurements in NAC (Figure 6.2.). There were no significant 
differences in the levels of anti-IgE antibodies between the 3 groups of patients (Table 6.2).   
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Figure 6.2 Concentrations of IgG anti-IgE autoantibodies in sera from non-atopic controls (NAC), non-atopic 
asthmatic subjects (NAA), and atopic asthmatic subjects (AA). 
The dotted line shows 95% confidence limit of the range in controls. Samples marked # were used in later experiments. 
 
Table 6.2 Concentration of IgG anti-IgE antibodies in the serum  
Range is indicated per group. 
 Non-atopic controls Non-atopic asthmatics Atopic asthmatics 
Serum IgG anti-IgE 
antibodies (ng/ml) 
22-223 11-1761 39-1070 
 
 
6.2.2 Some serum samples containing IgG anti-IgE auto-antibodies induce basophil 
activation 
The serum samples were also tested on a BAT. Basophils from an atopic donor were incubated 
with different test serum samples or with autologous serum or buffer (as negative controls) or with 
polyclonal goat anti-human IgE or monoclonal mouse anti-human FcεRI or fMLP (as positive 
controls) and basophil activation was assessed by flow cytometry (Figure 6.3, Figure 6.4, Figure 
6.5).  
Sera from 2 NAA (NAA17 and NAA18) and 3 AA (AA5, AA8, AA14) subjects were able to induce 
basophil activation. However, this activity did not equate with elevated IgG anti-IgE antibody 
concentration. For example, serum sample from AA8 activated basophils but the levels of auto-
anti-IgE were below the defined reference line; conversely, serum samples from NAA2, NAA16 




Figure 6.3 Basophil activation in response to the negative and to the positive controls. 
 
Figure 6.4 Basophil activation induced by serial dilutions of a serum sample of an asthmatic patient with 
elevated levels of IgG anti-IgE antibodies as determined by ELISA. 
 
 
Figure 6.5 Basophil activation induced by serum samples of non-atopic controls (NAC), non-atopic 
asthmatics (NAA) and atopic asthmatics (AA).  
The dotted line indicates the detection threshold (defined as 3 standard deviations above the mean percentage of CD63-
positive basophils following incubation with autologous serum, i.e. >2.67% CD63-positive basophils). Samples marked # 




6.2.3 IgG depletion from serum samples abolished the observed activatory effect 
Depletion of IgG from the serum samples that were able to cause basophil activation reduced this 
effect, confirming that basophil activation was due to the presence of IgG antibodies (p=0.041, 
Figure 6.6). 
 
Figure 6.6 Serum samples causing basophil activation were depleted of IgG and re-tested on the basophil 
activation assay.  
Basophil activation was reduced following incubation with IgG-depleted samples (n=5), *p<0.05.  
 
6.2.4 IgG anti-IgE antibodies modify allergen-induced basophil activation by inhibiting 
the allergen-IgE interaction 
To further examine the effect of serum samples on allergen-induced basophil activation, PBMCs 
from the same donor used in previous experiments were incubated with the serum samples, anti-
IgE or autologous serum and then stimulated with house dust mite allergen Der p 2. Serum 
samples from two asthmatic subjects (NAA16 and AA12) inhibited Der p 2-induced basophil 
activation. Depletion of IgG (Figure 6.7. A) or IgE-binding proteins (Figure 6.7. B) abolished this 
effect and purification of IgE-binding proteins retained the inhibitory activity (Figure 6.7.C and D).  
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Figure 6.7 Antibody levels and basophil activation following IgG depletion and depletion or purification of  
IgE-binding proteins.  
A. Total IgG concentration in 2 test sera ex vivo and following IgG depletion. B. IgE-binding proteins ex vivo and following 
depletion and isolation of IgE binding proteins. C and D. Effects of sera ex-vivo and following IgG depletion (C) and 
removal and purification of IgE binding proteins (D) on Der p  2-induced basophil activation induced by Der p 2 (30 ng/ml). 
Bars represent the mean/standard deviation of 3 independent experiments. *p<0.05 and ***p<0.001. 
 
To confirm the inhibitory activity of the sera, cells from the basophilic cell line RBL-SX38 were 
sensitised with recombinant IgE specific for the grass allergen Phl p 7 and stimulated with 
recombinant Phl p 7. Pre-incubation with serum samples from NAA16 or AA12 significantly 
reduced binding of recombinant allergen to IgE but not of allergen-specific IgE to RBL-SX38 cells, 
indicating that IgG anti-IgE antibodies modify allergen-induced basophil activation by inhibiting the 




Figure 6.8 Modification of allergen-induced basophil activation by anti-IgE antibodies 
A. Binding of recombinant Phl p 7-specific IgE to FcεRI on RBL-SX38 cells. B. Binding of Phl p 7 to IgE-sensitised RBL-
SX38 cells. C and D. Changes in binding of Phl p 7-specific IgE (C) and changes in binding of Phl p 7 (D) on RBL-SX38 
cells sensitised with Phl p 7-specific recombinant IgE and pre-incubated with sera, followed by stimulation with 
recombinant Phl p 7 compared with no serum control. Bars represent the mean/standard deviation of 3 independent 
experiments. **p<0.01 and ***p<0.001. 
 
6.2.5 Conclusions 
IgE-specific auto-antibodies were detectable in atopic and non-atopic asthmatic subjects and 
controls. They bound to IgE regardless of whether or not IgE was bound to its high-affinity 
receptor. Some of these auto-antibodies activated basophils, whereas others inhibited allergen-
induced basophil activation. Activatory anti-IgE auto-antibodies could cause clinical symptoms of 
asthma independently of allergen exposure and could explain some phenotypes of asthma 
classified as non-atopic. Inhibitory IgG anti-IgE auto-antibodies may contribute to a natural 
regulatory mechanism that could conceivably influence the severity and presence or absence of 
clinical expression of IgE-mediated diseases, including asthma and food allergy, and the 
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outcomes of therapeutic processes such as allergen immunotherapy and therapy with exogenous 
IgG anti-IgE.  
 
6.3 Basophil intracellular signalling 
Cross-linking of IgE molecules bound to FcεRI by allergens initiates a cascade of intracellular 
events downstream of the high affinity IgE receptor leading to basophil degranulation, including 
phosphorylation of intracellular signalling molecules, both activatory (such as Syk and p38MAPK) 
and inhibitory (such as SHP and SHIP) - Figure 1.2.  
I aimed to determine the patterns of phosphorylation of some of these intracellular signalling 
molecules that accompany the expression of basophil activation markers and to confirm that 
phosphorylation of some of these intracellular signalling molecules and the expression of 
activation markers on the surface of basophils can be simultaneously assessed by flow cytometry.  
 
6.3.1 Up-regulation of CD63 is accompanied by the phosphorylation of Syk and p38 
MAPK 
Stimulation of basophils from peanut allergic patients with peanut extract resulted in the 
phosphorylation of Syk and p38-MAPK (Figure 6.9) 
 
Figure 6.9 Peanut-induced phosphorilation of Syk and p38-MAPK 
Stimulation of basophils with 1000ng/ml of peanut extract resulted in up-regulation of phosphorylated Syk (A) and 
phosphorylated p38-MAPK (B). Histograms represent the isotype control (grey), the negative control (blue) and cells 




A time course was performed to identify the kinetics of phosphorylation of these two activatory 
signalling molecules. The maximum expression of phosphorylated Syk and p38MAPK was 
detected at 3 minutes (Figure 6.10.A and B). The phosphorylation of these signalling mediators 




Figure 6.10 Peanut-induced expression of phosphorylated Syk, phosphorylated p38MAPK and CD63 at 
different time-points.  
Expression of phosphorylated Syk (A, C), phosphorylated p38MAPK (B, D) and CD63 (E) following stimulation with 1000 
ng/ml of peanut extract at different time points. Figures C and D represent histograms of MFI for P-Syk-PE and P-p38-
MAPK-PE at the various time-points studied: 1 minute (light violet), 3 min (dark violet), 5 minutes (green), 10 minutes 
(blue), 20 minutes (orange) and 30 minutes (red). 
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 Phosphorylation of p38MAPK and up-regulation of CD63 developed in the same proportion of 




Figure 6.11 Expression of CD63 on the cell surface and of phosphorylated p38MAPK intracellularly in 
basophils of a peanut allergic patient after stimulation with 1000ng/ml of peanut extract for 30 minutes. 
 
6.3.2 Conclusions 
Intracellular and surface markers can be independently and simultaneously assessed by flow 
cytometry. Combined analysis of basophil intracellular signalling molecules and activation 
markers may complement studies on immune mechanisms involving basophils. A kinetic analysis 
of basophil signalling showed that Syk and p38-MAPK phosphorylation occurred early with a 
maximum expression at 3 minutes following stimulation with allergen and preceded the up-
regulation of activation markers. This corresponds to the signalling pathway downstream of FcεRI 
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Chapter 7 Disentangling the discrepancy between clinical 
allergy and sensitisation to peanut 
Published in Santos AF et al. IgG4 inhibits peanut-induced basophil and mast cell activation in 
peanut tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 2015 (in 
press, open-access). 
The discrepancy between allergic sensitisation and clinical food allergy creates diagnostic 
difficulties and a fundamental gap in our knowledge about the mechanisms of food allergy and 
tolerance. I have used peanut allergy as a model of IgE-mediated food allergy. Specific IgE to Ara 
h 2 is particularly discriminative in identifying PA patients
43, 44
; however, examples can be found of 
peanut tolerant patients who have high levels of Ara h 2-specific IgE and conversely of PA 
patients who test negative to Ara h 2 and the other major peanut allergens
188
.  
Basophils and mast cells are effector cells of acute allergic reactions to foods, including 
anaphylaxis. As reported in chapter 4, the whole blood BAT has high accuracy in the diagnosis of 
peanut allergy and correlates very closely with the clinical phenotype of IgE-sensitised patients, 
i.e. allergic versus tolerant patients, better than specific IgE levels to peanut, to Ara h 2 or to any 
of the other peanut components
165
. Similar in vitro systems using passive sensitisation of 
basophils or mast cells with patients' plasma can be used to test the ability of allergen-specific IgE 
antibodies present in the plasma to elicit effector cell activation and degranulation in response to 
allergen.  
Two non-mutually exclusive hypotheses were addressed to explain the discrepancy between 
allergic sensitisation and clinical allergy to peanut, as described in Section 1.13. The first 
hypothesis was that the levels and the specificity of IgE are different between allergic and tolerant 
patients. The second hypothesis was that sensitised but tolerant patients have an inhibitor that 
blocks the function of IgE. Given that natural tolerance to peanut is allergen-specific and long-
lasting, the IgE inhibitor is likely to be a food-specific antibody of an isotype other than IgE, such 
as IgG4. IgG4 has been shown to increase in patients who naturally outgrow IgE-mediated food 
allergy, such as cow's milk allergy
102, 103
, and in patients who are submitted to immunotherapy to 
foods
110, 112
 or to immunotherapy to respiratory allergens
108, 109
. Whether IgG4 can play an 
inhibitory role in the allergen-IgE interaction in sensitised but otherwise tolerant patients is 




, and was therefore the main suspect of being the IgE inhibitor in PS 
patients.  
 
7.1 IgG4 study population 
Two hundred and twenty eight children, 108 peanut allergic and 110 peanut tolerant (77 PS and 
43 NA), were included in this analysis. PS patients included 6 children (3% of total and 8% of PS) 
who had outgrown peanut allergy. PA children were slightly older (median 6 years-old) and more 
frequently had asthma (39.8%) and allergic rhinitis (59.3%) than PS children (median 4 years-old, 
18.2% with asthma and 31.2% with allergic rhinitis). The other demographic and clinical features 
were similar between the two groups (Table  7.1). 
 
Table 7.1 Demographic and clinical features of the study population 
N=228. Number (percentage) or median (interquartile range) are represented. 
*
p values refer to the comparison between 
peanut allergic and peanut sensitised but tolerant patients. 















Age (years) 6.0 (5.0; 10.0) 4.0 (1.5; 7.5) 5 (5.0; 7.0) <0.001 
Males - n (%) 74 (68.5%) 47 (61.0%) 30 (69.8%) 0.185 
Other food allergy - n (%) 94 (87.0%) 67 (87.0%) 9 (20.9%) 0.582 
Atopic eczema - n (%) 71 (65.7%) 46 (59.7%) 18 (41.9%) 0.248 
Asthma - n (%) 43 (39.8%) 14 (18.2%) 8 (18.6%) 0.001 
Allergic rhinitis - n (%) 64 (59.3%) 24 (31.2%) 12 (27.9%) <0.001 
Pollen allergy - n (%) 51 (47.2%) 25 (32.5%) 9 (20.9%) 0.075 
Non atopic - n (%) 0 (0%) 0 (0%) 14 (32.6%) - 
 
In parallel, samples from an independent population of 19 peanut allergic patients that had been 
submitted to peanut oral immunotherapy (POIT) at Addenbroke's Hospital in Cambridge, as part 
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of the STOP I trial, were tested. Samples were collected before and between 6 to 24 months after 
treatment (Table 7.2).  
 
Table 7.2 Time to follow-up and peanut protein tolerated before and after peanut oral immunotherapy in the 
participants in the STOP I trial.  
Abbreviations: ID, identification; OIT, oral immunotherapy.  
Subject ID 
Peanut protein 
tolerated pre-OIT (g) 
Time to follow up 
at post-OIT visit 
Peanut protein 
tolerated post-OIT (g) 
POIT1 0.200 24 months 0.80 
POIT2 0.031 24 months 0.80 
POIT3 0.556 24 months 0.80 
POIT4 0.256 12 months 6.46 
POIT5 0.006 12 months 0.83 
POIT6 0.006 24 months 0.80 
POIT7 0.031 18 months 0.80 
POIT8 0.081 18 months 0.80 
POIT9 0.006 24 months 0.80 
POIT10 0.081 18 months 0.80 
POIT11 0.256 24 months 0.80 
POIT12 0.001 12 months 6.25 
POIT13 0.001 12 months 6.57 
POIT14 0.006 6 months 2.49 
POIT15 0.256 24 months 0.80 
POIT16 0.006 24 months 0.80 
POIT17 0.001 6 months 0.025 
POIT18 0.031 12 months ~ 5.6 




7.2 Passive sensitisation basophil and mast cell assays reproduced 
in vitro patients' clinical reactivity to peanut  
As described in chapter 4, the whole blood basophil activation test to peanut reproduced very 
closely the clinical phenotype (i.e. peanut allergic or peanut tolerant) of peanut-sensitised 
patients
161
. Similar experiments were performed in which LAD2 cells or IgE-stripped primary 
basophils from healthy donors were sensitised with plasma from PA, PS or NA patients prior to 
stimulation with peanut extract. Mast cells sensitised with plasma from PA patients, but not from 
PS or NA patients, showed a dose-dependent activation in response to peanut.  Figure 7.1 
represents the activation of LAD2 cells sensitised with plasma from PA, PS or NA patients, and 
stimulated with peanut extract, expressed as percentage of CD63-positive cells. The same 
findings were found for the percentage of CD107a+ LAD2 cells and with primary human basophils 
(Figure 7.2).  
 
Figure 7.1 Peanut-induced activation of mast cells sensitised with plasma from peanut allergic, peanut-
sensitised but tolerant and non-sensitised non-allergic patients. 
PA (n=6), PS (n=5), NA (n=2). Mean and standard error are represented. p value refers to the comparison between PA 
and PS for each concentration of peanut extract. **p<0.01 





































Figure 7.2 Peanut-induced activation of basophils sensitised with plasma from peanut allergic, peanut-
sensitised but tolerant and non-sensitised non-allergic patients  
N=15, 5 per group. Abbreviations: PA, peanut allergic; PS, peanut-sensitised but tolerant; NA, non-sensitised non-allergic. 
LAD2 cells were stimulated with 10 ng/ml of peanut extract. To correct for the variability in cell reactivity among basophil 
donors, the percentage of CD63-positive basophils is expressed as the ratio between the maximal reactivity to peanut 
extract with tested plasma and the maximal reactivity to peanut extract with plasma from a peanut allergic subject used as 
an internal control in all experiments. Horizontal lines represent the median for each group. p values correspond to the 
comparison between PA and PS patients and between PA and NA patients. The comparison between PS and NA groups 
was non-significant **p<0.01. 
 
7.3 Differences in peanut-specific IgE between peanut allergic and 
peanut sensitised but tolerant individuals 
 
7.3.1 Levels of specific IgE to peanut and to peanut components only partially explained 
differences in clinical reactivity to peanut between peanut allergic and peanut 
sensitised but tolerant individuals 
PA patients showed higher levels of specific IgE to peanut (p<0.001) and to Ara h 1 (p<0.001), 
Ara h 2 (p<0.001) and Ara h 8 (p=0.019) than PS patients (Table 7.3). However, there was a 



























Table 7.3 Skin prick test to peanut and serum specific IgE levels to peanut and to peanut components. 
 N=228, except if otherwise indicated.
*
Median (interquartile range) are indicated. p values refer to the comparison between 





















Skin prick test to 
peanut (mm) 
















Peanut 13.30 (2.26; 98.70) 1.83 (0.48; 5.20) 0.01 (0.01; 0.02) <0.001 
Ara h 1
x
 0.44 (0.04; 31.13) 0.11 (0.01; 0.34) 0.01 (0.01; 0.01) <0.001 
Ara h 2
x
 6.04 (0.90; 54.55) 0.08 (0.03; 0.25) 0.01 (0.01; 0.04) <0.001 
Ara h 3
+
 0.12 (0.02; 2.41) 0.06 (0.02; 0.34) 0.01 (0.01; 0.01) 0.075 
Ara h 8
¬
 0.08 (0.01; 2.09) 0.01 (0.01; 0.23) 0.01 (0.01; 0.01) 0.019 
Ara h 9
#
 0.01 (0.01; 0.08) 0.02 (0.01; 0.25) 0.01 (0.01; 0.01) 0.169 
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Figure 7.3 Specific IgE to peanut and to peanut components in peanut allergic, peanut sensitised but tolerant 
and non-sensitised non-allergic children.  
N=228 for peanut-specific IgE; n=222 for specific IgE to Ara h 1 and Ara h 2; n=221 for specific IgE to Ara h 3; n=220 for 
specific IgE to Ara h 8; n=219 for specific IgE to Ara h 9. Horizontal lines represent the median for each group. 




7.3.2 Profiles of IgE sensitisation to peanut allergens did not distinguish all cases of 
peanut allergic and peanut-sensitised but tolerant patients 
There was no obvious relationship between the profiles of IgE sensitisation to peanut allergens 
and clinical reactivity (Table 7.4). The majority (67.8%) of PA patients were sensitised to more 
than one peanut allergen (Ara h 1, Ara h 2 and/or Ara h 3) whereas PS patients were more likely 
to be sensitised to one or none of the peanut major allergens (60.5%). Although there was a 
substantial overlap between PA and PS patients, there were two unique patterns of sensitisation, 
one per group: all patients sensitised simultaneously to Ara h 1 and to Ara h 2 were PA and all 
patients monosensitised to Ara h 1 were PS. Table 7.5 shows the prevalence of sensitisation to 
the five tested peanut allergens.  
 
Table 7.4 Profiles of IgE sensitisation to major peanut allergens in peanut allergic and in peanut-sensitised 
but tolerant children.  
Only patients with IgE results for all peanut components were included. N=103 PA and 76 PS. The percentage of patients 

















 but tolerant (%) 
p value 
Ara h 1 2 & 3 48.5 23.7 0.001 
Ara h 1 & 2 15.5 0 <0.001 
Ara h 2 & 3 1.9 3.9 0.355 
Ara h 1 & 3 1.9 11.8 0.007 
Ara h 1 0 15.8 <0.001 
Ara h 2 26.9 21.1 0.234 
Ara h 3 1.0 3.9 0.203 
No Ara h 1 2 3 3.8 19.7 0.001 
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Table 7.5 Prevalence of sensitisation to the peanut components in peanut allergic and peanut-sensitised but 
tolerant patients.  
Only patients with IgE results for all peanut components were included. N=103 PA and 76 PS. Sensitisation was defined 
as a level of specific IgE ≥0.10 KUA/l. The number and percentage of patients per group are represented. Significant p 
values are highlighted in bold. 
Prevalence of 
sensitisation 




Ara h 1 69 (64%) 39 (51%) 0.096 
Ara h 2 97 (90%) 37 (48%) <0.001 
Ara h 3 55 (51%) 33 (43%) 0.299 
Ara h 8 46 (43%) 23 (30%) 0.091 
Ara h 9 23 (21%) 25 (33%) 0.092 
 
 
7.4 High ratio of peanut-specific IgG4 to IgE was associated with 
peanut tolerance 
 
7.4.1 Peanut-specific IgG4 was higher in peanut-sensitised but tolerant patients 
compared to peanut allergic patients 
One hundred and one patients (65 PA, 27 PS, 9 NA) with detectable peanut-specific IgG4 were 
randomly selected to be tested for IgG4 to individual peanut components. Considering this group 
of 101 patients, the levels of peanut-specific IgG4 were 1.6-fold higher in PS than in PA patients 
(p=0.012, Figure 7.4 and Table 7.6). However, there were no significant differences between the 
levels of specific IgG4 to peanut components in PA and PS patients (Figure 7.4 and Table 7.6), 
except for Ara h 2-specific IgG4 that was higher in PA patients (p=0.034).  
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Figure 7.4 Specific IgG4 to peanut and peanut components in peanut allergic and peanut tolerant children, 
including peanut sensitised but tolerant and non-sensitised non-allergic children  
N=101. Horizontal lines represent the median for each group. p values that were significant are indicated. Abbreviations: 
PA, peanut allergic; PS, peanut-sensitised but tolerant; NA, non-sensitised non-allergic. *p<0.05. 
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Table 7.6 Serum specific IgG4 levels to peanut and to peanut components in peanut allergic and peanut 
tolerant patients.  
N=101. Median and interquartile range are represented. 
*
p value refers to the comparison between peanut allergic and 
peanut sensitised but tolerant patients. Significant p values are highlighted in bold. 
  
 
The levels of peanut-specific IgA were also measured in the serum of 205 patients (105 PA, 66 
PS and 34 NA) where sample was available. Peanut-specific IgA was detectable (≥1000 μg/l) in 
only 35 (17%) of these patients (28 PA, 5 PS and 2 NA) and ranged between 1.04 mg/l and 42.2 
mg/l.  The comparison between PA and PS did not reveal statistically significant differences 
(p=0.903 - Table 7.7). 
 
Table 7.7 Serum peanut-specific IgA levels in peanut allergic, peanut sensitised but tolerant and non-
sensitised non-allergic patients with detectable serum peanut-specific IgA.  
Median and interquartile range are represented. Abbreviations: PA, peanut allergic; PS, peanut-sensitised but tolerant; 
NA, non-sensitised non-allergic. *p value corresponds to the comparison between PA and PS. 
 PA (n=28) PS (n=5) NA (n=2) p value* 
Peanut-specific 
IgA (mg/l) 


















Peanut 400 (160; 960) 650 (430; 2140) 160 (100; 580) 0.023 
Ara h 1 20 (10; 60) 20 (10; 80) 10 (0; 30) 0.684 
Ara h 2 30 (10; 100) 10 (0; 40) 10 (0; 70) 0.034 
Ara h 3 40 (20; 100) 80 (30; 190) 30 (20; 250) 0.074 
Ara h 8 20 (0; 50) 40 (10; 100) 10 (0; 50) 0.068 
Ara h 9 10 (0; 60) 30 (10; 1040) 10 (0; 20) 0.065 
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7.4.2 The ratio of peanut-specific IgG4 to IgE was significantly higher in peanut-
sensitised but tolerant patients 
Overall, the levels of specific IgG4 to peanut and to peanut components could not explain the 
clinical differences between PA and PS patients. I hypothesised that the relative amounts rather 
than absolute amounts of IgE and IgG4 could explain the differences in clinical phenotype and 
determined the ratios of IgG4 to IgE to peanut and to Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 
9. The ratio of specific IgG4 to IgE directed to peanut was 8 times higher in PS compared to PA 
patients (p<0.001, Figure 7.5). The differences between PS and PA patients were even greater in 
the ratio of IgG4 to IgE to the major peanut allergens, namely Ara h 1 (18.8-fold, p=0.05), Ara h 2 
(100-fold, p=0.004) and Ara h 3 (7-fold, p=0.016).  
 
Figure 7.5 Ratio of IgG4 to IgE to peanut and to peanut allergens in peanut allergic and peanut sensitised 
but tolerant children.  
N=65 PA and 27 PS. Median and interquartile range are represented. Abbreviations: PA, peanut allergic; PS, peanut-
sensitised but tolerant. Significant p values are highlighted in bold.  
 
The observed differences in the ratio of peanut-specific IgG4 to IgE between PA and PS patients 
could be due to differences in IgE rather than differences in the ratio itself. After adjusting for 
specific IgE levels by analysis of covariance using ranks, the differences in the ratio of peanut-
specific IgG4 to IgE between PA and PS patients remained significant (p=0.001). Similarly, using 
a multivariate logistic regression model, log base 10 transformed IgG4 (p=0.004) and IgE 
(p<0.001) were both significantly associated with peanut allergy. A relative importance analysis 
showed that IgE accounted for 64% of the models explanatory power in predicting PA versus PS 
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patients, and IgG4 explained the remaining 36%. PA patients tended to have higher levels of IgE 
to peanut and to peanut major allergens whereas PS patients showed a predominance of IgG4 
over IgE (Figure 7.6).   
 
Figure 7.6 Distribution of IgE and IgG4 levels in peanut allergic, peanut sensitised but tolerant and non-
sensitised non-allergic children.  
N=101. Log base 10 of IgE and IgG4 levels are represented. Abbreviations: PA, peanut allergic; PS, peanut-sensitised but 
tolerant; NA, non-sensitised non-allergic. 
 
In PA patients submitted to POIT (n=19), the levels of peanut-specific IgE were similar before and 
after treatment but the levels of peanut-specific IgG4 and the ratio of peanut-specific IgG4 to IgE 
were significantly higher post-immunotherapy (Table 7.8).  
Table 7.8 Levels of specific IgE and IgG4 to peanut in peanut allergic patients submitted to peanut oral 
immunotherapy before and after treatment. 
N=19. Median and interquartile range are represented. Significant p values are highlighted in bold. 
 Pre-POIT Post-OIT p value 
Peanut-specific IgE (KUA/l) 27.30 (5.71; 100.0) 10.50 (2.83; 85.90) p=0.573 
Peanut-specific IgG4 (µg/l) 580 (270; 1510) 7200 (1210; 21200) p<0.001 
Ratio IgG4/IgE 16.77 (4.12; 96.80) 170.64 (30.95; 585.75) p=0.001 
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7.4.3 Peanut-specific IgG4/IgE ratio was inversely correlated with basophil activation in 
response to peanut 
In order to assess whether the ratio of IgG4 to IgE had a functional consequence in the ability of 
peanut extract to elicit basophil activation in vitro, the subgroup of patients for whom peanut-
specific IgG4 had been determined and for whom whole blood basophil activation test to peanut 
had been performed were selected. Patients with non-responder basophils and patients with IgE 
below 0.10 KUA/l, were excluded. The peanut-specific IgG4 to IgE ratio was inversely correlated 
with basophil activation in response to peanut using Spearman correlation coefficient (Rs=-0.686, 
p<0.001, n=55) - Figure 7.8. 
 
 
Figure 7.7 Peanut-specific IgG4/IgE ratio was inversely correlated with basophil activation in response to 
peanut.  
Red circles represent peanut allergic patients and blue circles represent peanut sensitised but tolerant patients (n=55). 
Variables are represented in a logaritmic scale base 10. Basophil activation is expressed as the mean percentage of 




7.5 IgG4 inhibits peanut-induced basophil and mast cell activation in 
peanut tolerant children sensitised to peanut major allergens 
 
7.5.1 Plasma from peanut-sensitised tolerant (but not from non-sensitised non-allergic) 
patients were able to inhibit peanut-induced basophil and mast cell activation 
similar to plasma of peanut allergic patients submitted to peanut oral 
immunotherapy 
 
The observations described in the previous section 7.4. suggested that IgG4 was likely to have an 
inhibitory role over IgE. I hypothesized that this would be most relevant to PS patients with IgE 
directed to the major peanut allergens Ara h 1, Ara h 2 and Ara h 3 that would otherwise be 
predictive of peanut allergy. The ability of plasma from these patients to inhibit mast cells and 
basophils sensitised with plasma from a reference PA patient also sensitised to Ara h 1, Ara h 2 
and Ara h 3 was tested (Table 7.9). Samples from patients submitted to POIT (Table 7.8) and 
from NA patients (with and without detectable serum peanut-specific IgG4) were used as controls.  
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Table 7.9 Profiles of sensitisation of the peanut-sensitised but tolerant patients selected for the inhibition studies and of the peanut allergic patients used as a reference to assess 
inhibition of mast cell activation. 
 *These PS patients were also tested in the mast cell activation assay shown in Figure 7.1. 
Participant 
ID 
Specific IgE (KUA/l) Specific IgG4 (µg/l) 
Peanut Ara h 1 Ara h 2 Ara h 3 Ara h 8 Ara h 9 Peanut Ara h 1 Ara h 2 Ara h 3 Ara h 8 Ara h 9 
PS1 9.31 0.88 0.42 0.27 0.22 11.9 760 30 20 40 40 3570 
PS2* 97.1 88.30 82.30 1.61 0.20 43.90 6090 700 10700 60 4 1040 
PS3* 128 15.20 0.67 5.62 0.26 0.25 3360 80 30 1450 20 20 
PS4* 35.7 0.08 1.84 0.71 1.01 8.48 3940 80 60 110 90 2770 
PS5 5.21 0.36 0.24 0.2 0.01 11 600 90 40 80 50 1900 
PS6* 5.18 0.96 0.52 0.68 0.01 0.02 1130 0 810 410 0 0 
PS7* 3.16 1.79 0.26 0.17 6.06 0.22 650 40 10 100 80 960 
PS8 0.71 0.13 0.28 0.12 0.08 0.1 70 0 0 0 0 0 
PS9 2.09 0.21 0.24 0.32 0.85 0.02 320 0 0 10 0 10 
PS10 22.2 11.7 0.59 1.21 0.01 0.01 4300 480 4720 620 0 0 
PS11 3.95 0.3 0.16 0.35 62.3 0.22 2440 130 30 1410 2740 10 
PS12 0.49 0.19 0.38 0.2 0.16 0.23 580 10 120 60 0 30 
PA 255 84.4 125 1.8 0 0 100 30 20 10 0 10 
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Peanut-induced mast cell and basophil activation was inhibited in the presence of plasma from 
PS patients with IgE directed to the peanut major allergens, Ara h 1, Ara h 2 and Ara h 3. The 
results using LAD2 cells or primary human basophils that had been treated with lactic acid to 
remove IgE before sensitisation with the reference plasma sample from the peanut allergic patient 
were comparable (Figure 7.8). One sample of a peanut allergic patient was used as a reference 
for the mast cell assays and another sample of a peanut allergic patient (also with high levels of 
peanut-specific IgE and IgE to Ara h 1, Ara h 2, Ara h 3, Ara h 8 and Ara h 9) was used for the 
basophil assays (see Section 2.3.5.5. and Section 2.3.6.2.). 
 
Figure 7.8 Plasma from peanut-sensitised but tolerant patients inhibits peanut-induced activation of mast 
cells and basophils sensitised with plasma from a peanut allergic patient. 
Peanut-induced activation of mast cells (A) and basophils (B) sensitised with plasma from a peanut allergic patient (red) in 
the presence of plasma from peanut-sensitised but tolerant patients (pink, n=7 in A and n=9 in B). p values correspond to 
the comparison between groups for each concentration of peanut extract. *p<0.05 **p<0.01 ***p<0.001. 
 
Samples of peanut allergic patients submitted to peanut oral immunotherapy were also able to 
inhibit peanut-induced activation of mast cells and basophils previously sensitised with a 
reference plasma sample from a peanut allergic patient or with plasma from the peanut allergic 





Figure 7.9 Plasma from peanut allergic patients collected post-oral immunotherapy inhibit peanut-induced 
activation of mast cells and basophils sensitised with plasma from a reference peanut allergic patient or 
plasma from peanut allergic patients collected pre-oral immunotherapy.  
Peanut-induced activation of mast cells (A) and basophils (B) sensitised with a reference plasma from a peanut allergic 
patient (A) or with plasma samples of peanut allergic patients submitted to POIT collected before the start of the treatment 
(B) is inhibited in the presence of post-treatment plasma from patients who underwent peanut oral immunotherapy (A, n=3 
and B, n=5).  Red bars refer to activation of cells sensitised with plasma from a reference peanut allergic patient (A) or 
plasma from peanut allergic patients before POIT (B) and purple bars refer to activation of the cells sensitised with plasma 
from a reference peanut allergic patient (A) or plasma from peanut allergic patients before POIT (B) in the presence of 
plasma from peanut allergic patients submitted to POIT. In B, pairs of plasma samples from the same peanut allergic 
patient before and after POIT were used in each experiment. p values correspond to the comparison between groups for 
each concentration of peanut extract. *p<0.05. 
 
Plasma samples of non-sensitised non-allergic patients were not inhibitory, regardless of whether 
they had detectable peanut-specific IgG4. Once again, the results of passive sensitisation 
experiments using the mast cell line and primary human basophils were comparable (Figure 
7.10).   
 
Figure 7.10 Plasma from non-sensitised non-allergic patients does not inhibit peanut-induced activation of 
mast cells and basophils sensitised with plasma from a peanut allergic patient. 
Peanut-induced activation of mast cells (A) and basophils (B) sensitised with plasma from a peanut allergic patient (red) in 
the presence of plasma from non-sensitised non-allergic patients (blue) N=3 in A and n=3 in B. The differences between 
groups for each concentration of peanut extract were not statistically significant.  
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In summary, peanut-induced activation of mast cells and basophils sensitised with a reference 
plasma sample from a peanut allergic patient was inhibited in the presence of plasma from PS 
patients with IgE to the major peanut allergens and in the presence of plasma from patients 
submitted to POIT but not in the presence of plasma from NA patients (Figure 7.11.).   
 
Figure 7.11 Inhibition of peanut-induced mast cell activation in the presence of plasma from peanut-
sensitised but tolerant patients, from patients submitted to peanut oral immunotherapy and from non-
sensitised non-allergic patients.  
PS, n=12; POIT, n=19; NA, n=3. Cells were stimulated with 10 ng/ml of peanut extract. Horizontal lines represent the 
median for each group of patients. Inhibition was tested against the same plasma of a peanut allergic patient. %Inhibition 
= (%CD63+ of cells sensitised with PA plasma-%CD63+ of cells sensitised with PA plasma in presence of test 
plasma)/%CD63+ of cells sensitised with PA plasma. 
 
The basophil and mast cell inhibition experiments were performed in the presence of plasma to 
assess the inhibitory effect of plasma components. The hypothesized inhibitory mechanisms may 
happen at the extracellular cellular level by competition with IgE for binding to the allergen and/or 
at the cellular level by co-cross-linking with IgE. If both mechanisms co-exist a correlation with 
symptoms is expected both in the presence of plasma and in plasma-free conditions; although 
inhibition may possibly be higher in the presence of plasma where the two mechanisms may 
occur concomitantly. Figure 7.12 represents the results of passive sensitisation experiments in 
which the inhibitory activity of the plasma was assessed in the presence of plasma and in plasma-
free conditions, i.e. with and without a washing step following sensitisation with plasma from PS 
or NA patients and before stimulation with peanut extract. In these experiments, receptor-bound 
IgE was stripped of basophils from a healthy atopic donor (non-sensitised and non-allergic to 
peanut). These stripped basophils were subsequently sensitised with plasma from a PA patient. 
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Sensitised cells were then washed and sensitised with plasma from a PS patient (pink) or with 
plasma from a NA patient (blue) or with buffer (red), before stimulation with peanut extract or the 
positive controls or the negative control. As expected, untreated basophils from the healthy donor 
were not activated by peanut extract but, when stripped of IgE and sensitised with plasma from a 
PA patient, did show marked activation after peanut stimulation. The addition of PS plasma to the 
basophils previously sensitised with PA plasma markedly inhibited activation in response to 
peanut stimulation (Figure 7.12.A); however, this inhibition did not occur if PS plasma was 
washed before peanut stimulation (Figure 7.12.B). These results support the role of a component 
in the plasma of PS patients that is able to reduce peanut-induced basophil activation. The effect 
of a possible intracellular mechanism resulting from co-cross linking of IgE and an inhibitory 
antibody is not apparent. 
 
 
Figure 7.12. Modification of peanut-induced activation of basophils sensitised with plasma from a peanut 
allergic patient by plasma from peanut-sensitised but tolerant patient. 
IgE was stripped of basophils from a healthy atopic donor (non-peanut allergic, no peanut-specific IgE) and the basophils 
were sensitised with plasma from a peanut allergic patient. Subsequently, plasma from a peanut sensitised but tolerant 
patient (pink) or from a non-sensitised non-allergic patient (blue) or media (red) were added to the basophils before 
stimulation with peanut extract or the positive controls (figure 7.12.A). In figure 7.12.B, the same steps were taken; 
however, basophils were washed before stimulation with the peanut extract. Abbreviations: CPE, crude peanut extract; 
aIgE, anti-IgE; fMLP, formyl-methionyl-leucyl-phenylalanine. 
 
7.5.2 Removal of IgG4 antibodies partially restored peanut-induced mast cell activation 
Plasma samples of twelve PS patients with IgE to the 3 major peanut allergens Ara h 1, Ara h 2 
and Ara h 3  and with detectable peanut-specific IgG4 (Table 7.9), that had shown the ability to 
inhibit peanut-induced basophil and mast cell activation were selected, as well as nine plasma 
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samples from PA patients submitted to POIT (Table 7.8). Selected samples were depleted of 
IgG4 or mock-depleted, as confirmed by ELISA (Figure 7.3) and ImmunoCAP (Table 7.10). The 
inhibitory capacity of IgG4-depleted and mock-depleted samples was tested in the inhibition of 
mast cell activation assay using cells sensitised with plasma from PA patients who had the same 
IgE sensitisation pattern as PS samples, namely Ara h 1, Ara h 2 and Ara h 3 (Table 7.9).  
 
Figure 7.13 IgG4 ELISA of IgG4 and mock-depleted plasma samples. 
Total IgG4 levels of plasma samples of 12 peanut-sensitised but tolerant patients (PS) and of 9 patients submitted to 



















































































2 0 0 0
4 0 0 0
6 0 0 0
M o c k










Table 7.10 Peanut-specific IgG4 ImmunoCAP of IgG4 and mock-depleted plasma samples. 
Levels of specific IgG4 (µg/ml) to peanut in plasma samples from peanut-sensitised but tolerant patients (PS, n=12) and 
patients submitted to peanut oral immunotherapy (POIT, n=9) following depletion of IgG4, as assessed by ImmunoCAP. 
Abbreviation: nd, not detectable 
 Mock-depleted IgG4-depleted 
PS1 0.24 nd 
PS2 0.62 nd 
PS3 0.25 nd 
PS4 0.49 nd 
PS5 0.19 0.03 
PS6 0.01 nd 
PS7 0.10 nd 
PS8 nd nd 
PS9 0.02 nd 
PS10 0.46 nd 
PS11 0.28 nd 
PS12 0.11 nd 
POIT1 1.99 nd 
POIT2 2.29 nd 
POIT3 1.10 nd 
POIT5 0.27 nd 
POIT8 2.22 nd 
POIT10 2.31 nd 
POIT12 0.29 nd 
POIT14 1.58 0.05 
POIT17 nd nd 
 
As the method adopted for IgG4 depletion required a 1 in 10 dilution of the plasma sample, pilot 
experiments were performed in which plasma samples of interest were tested in the mast cell 
inhibition assay diluted 1 in 10 to confirm that the diluted samples could still inhibit peanut-induced 
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Figure 7.14 Peanut-induced activation of mast cells sensitised with plasma from a reference peanut allergic 
patient in the presence of plasma of peanut-sensitised but tolerant patients diluted 1:10. 
PA, Peanut-induced activation of mast cells sensitised with a reference peanut allergic plasma (red); PA+PS,  Peanut-
induced activation of mast cells sensitised with a reference peanut allergic plasma in the presence of plasma from peanut-
sensitised but tolerant patients, undiluted (dark pink) and diluted 1:10 (light pink). 
 
IgG4 and mock-depleted samples were then re-tested in the mast cell inhibition assay using 
LAD2 cells sensitised with the reference plasma from a peanut allergic patient. IgG4 depletion 
from PS samples partially restored peanut-induced mast cell activation (p=0.007). Figure 7.15 










Figure 7.15 Inhibition of peanut-induced activation of mast cells sensitised with plasma from a peanut allergic 
patient in the presence of mock-depleted plasma samples or IgG4-depleted plasma samples from peanut-
sensitised but tolerant patients  
Median inhibition=75% versus 30%, respectively; p=0.007, n=12. %Inhibition = (%CD63+ of cells sensitised with PA 
plasma-%CD63+ of cells sensitised with PA plasma in presence of test plasma)/%CD63+ of cells sensitised with PA 
plasma.Horizontal lines represent the median for each group of patients. **p<0.01. 
P A + P S  1 : 1 0  ( n = 6 )
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Reduction of mast cell inhibition was also observed when testing IgG4-depleted post-POIT 










Figure 7.16 Inhibition of peanut-induced activation of mast cells sensitised with plasma from a PA patient in 
the presence of mock-depleted plasma samples or IgG4-depleted plasma samples from patients who 
underwent peanut oral immunotherapy  
Median inhibition=80% versus 52% respectively; p=0.04, n=9. %Inhibition = (%CD63+ of cells sensitised with PA plasma-
%CD63+ of cells sensitised with PA plasma in presence of test plasma)/%CD63+ of cells sensitised with PA plasma. 
Horizontal lines represent the median for each group of patients. *p<0.05. 
 
7.6 Conclusions 
At the population level, peanut allergic patients have higher levels of peanut-specific IgE to 
peanut and are more likely to have IgE directed to Ara h 2 and to the other peanut major 
allergens. At the individual level, peanut allergic and peanut tolerant patients can have 
comparable levels of specific IgE to peanut. Inhibition of IgE activity by allergen-specific IgG4 is a 
mechanism of peanut tolerance in patients with elevated specific IgE to peanut and its major 
peanut allergens. The clinical phenotype of individual peanut-sensitised patients is probably a 
result of the combination of different characteristics of the patient's pool of peanut-specific IgE 




Chapter 8 Discussion 
 
During my PhD, I have developed and validated a BAT to peanut as a novel biomarker of peanut 
allergy and as a biomarker to estimate the severity and threshold of allergic reactions to peanut. 
The BAT showed to be far superior in diagnosing peanut allergy than tests that detect the 
presence of peanut-specific IgE. As an in vitro surrogate of oral food challenge, BAT estimated 
the severity and the threshold of allergic reactions to peanut. The gating strategy used to identify 
basophils had a critical role in the enhanced performance of the basophil activation test. I have 
also used this assay in independent projects that detected the biological activity of peanut 
allergens in household dust samples and assessed the ability of auto-IgE antibodies present in 
the serum of asthmatic patients to degranulate mast cells and basophils. As a result of my MRC 
Early Career Award, having validated the BAT, I developed a novel mast cell assay using the 
LAD2 cell line to test the ability of samples from allergic and tolerant patients to elicit mast cell 
activation and inhibition, respectively. Finally, I have used these basophil and mast cell assays to 
explore the mechanisms underlying the discrepancy between the presence of IgE and clinical 
reactivity to peanut. I demonstrated that in some patients the absence of clinical allergy despite 
the presence of IgE is explained by peanut-specific IgE directed against irrelevant minor 
allergens. In other patients, with IgE directed to major peanut allergens, IgG4 can block the 
function of IgE preventing activation and degranulation of effector cells, mast cells and basophils.  
 
8.1 The strategy adopted to gate on basophils has implications for 
the diagnostic accuracy of the basophil activation test 
The BAT can be used to diagnose allergic disease and to study its underlying immunological 
mechanisms. The methodology used to identify basophils has important consequences for the 
outcome of the test. In chapter 3, I showed that CD123 is down-regulated following basophil 
activation and hence gating strategies that depend on this marker lead to the loss-to-analysis of 
activated basophils and to the underestimation of basophil activation. Using CD203c in addition to 
CD123/HLA-DR or CD203c in isolation proved superior to gating on CD123/HLA-DR, reducing 
the number of false-negatives and false-positives and improving the diagnostic accuracy from 91 
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to 97%. These results show that when BAT is used as an allergy test, the gating strategy adopted 
has important diagnostic implications in the assessment of individual patients.  
Basophils have been identified with CD123 and HLA-DR in previous studies, using flow cytometry 
and other techniques
189
, and CD123 expression was reported to be stable with the atopic status 
of the patient and following basophil activation
66, 69, 187
. In my study, the MFI of CD123-FITC was 
comparable between atopic and non-atopic patients, but there was a decrease in the MFI of 
CD123-FITC following basophil activation. This is in contrast to previous studies
66, 69, 187
 and is 
probably related to differences in the study population (e.g. adults versus children), in the disease 
models studied (e.g. patients with respiratory versus food allergies) and in the study design (e.g. 
basophils stimulated with allergen in vivo versus in vitro, which can have different kinetics). With 
respect to HLA-DR, basophils were HLA-DR-negative and were consistently distinct from HLA-
DR-positive cells under all conditions. These findings are consistent with previous reports
66
 and 




The combined use of the three basophil identification markers, CD203c/CD123/HLA-DR, proved 
superior to using CD123/HLA-DR alone. The diagnostic performance of BAT to peanut between 
identifying basophils as CD123+/HLA-DR- cells or as CD203c+/HLA-DR- cells was compared. 
The latter gating strategy resulted in a greater area under the ROC curve (0.99 versus 0.96) and 
improved the diagnostic accuracy (97% versus 91 %) of BAT. Furthermore, considering the 
minimum number of basophils of 500 as an exclusion criterion, 15% of patients would be 
inevaluable using CD123+/HLADR-. The consequences of the adopted gating strategy are 
clinically relevant as the BAT is used to diagnose peanut allergy in individual patients. An 
example is illustrated in Figure 3.6, in which, with basophils gated as CD123+/HLA-DR-, BAT 
would be considered negative at the diagnostic concentrations of 10 and 100 ng/ml. In fact, BAT, 
in this case, was clearly positive when basophils were selected using the 3 markers' strategy. A 
false-negative would have serious consequences, as it could lead to liberalization of peanut 
consumption, risking potentially severe allergic reactions. The loss-to-analysis of cells and/or the 
underestimation of basophil activation have important implications for the final outcome of the test 
and thus for the diagnosis of individual patients. The same applies to other clinical applications of 
BAT, such as monitoring of treatment, and to mechanistic experiments. Using the final gating 
strategy (SSC
low
/ CD203c+/HLA-DR-), the contamination with other immune cells was minimal; 
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therefore, there did not seem to be particular advantage in using a lineage negative antibody 
mixture to exclude other immune cells before gating on the CD203c+/HLA-DR- basophils.  
Identifying basophils with CD203c alone led to comparable outcome in terms of numbers of 
basophils and basophil activation markers to using CD203c+/HLA-DR- and was also superior to 
using CD123+/HLA-DR-, as represented in Table 3.3. CD203c is a basophil specific marker in 
whole blood. Expression of CD203c is constitutive but is increased in patients with atopic eczema 
and food allergy 
104, 192
, as previously described in terms of histamine release
193
 suggesting it is a 
marker of underlying basophil activation, possibly reflecting ongoing piecemeal degranulation. 
This enhances the separation of CD203c+ basophils from the other blood cells in a population of 
highly atopic children
165
, like the one studied here. The majority of patients in our study had 
eczema and other food allergies in addition to suspected peanut allergy and this represents a 
population where CD203c would be constitutively expressed at a higher level compared to other 
children, allowing a clear differentiation between basophils and other cells. The conjugation to the 
bright fluorochrome phyco-erythrin may have also contributed to optimal identification of cells 
expressing CD203c. SSC
low
/CD203c+ is an alternative basophil identification strategy that has the 
advantage of serving also as an activation marker, enabling BAT to be performed as a 2-colour 
(preferred) or even as a single colour BAT, which would make BAT easier and less expensive to 
perform.  
Despite the number of studies evaluating BAT as a diagnostic or clinical tool, the clinical and 
research applications of BAT are still surrounded by some controversy with regards to the 
preferred gating strategy to identify basophils by flow cytometry. Herein I compared different 
strategies for identifying basophils using CD123 and their clinical implications and demonstrated 
the down-regulation of CD123 following basophil activation. The performance of BAT soon after 
blood collection and the consistent use of live cells for flow cytometry on the same day 
contributed to the validity of the results. However, my study population consisted mostly of highly 
atopic children enrolled in a study examining the use of BAT in the diagnosis of peanut allergy
165
. 
Therefore, although my results would apply to other paediatric populations of patients with 
suspected peanut allergy, a similar validation would need to be conducted for application to other 
populations, such as non-atopic or older patients being assessed for other conditions such as 
drug allergy. While assessing changes in basophil identification markers, I discovered that in a 
subset of patients, basophils down-regulate CD123, the low affinity subunit of the IL-3 receptor, 
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upon activation. This phenomenon was patient-specific rather than specific for atopic or allergic 
status. In the patients where this was observed, the down-regulation occurred only in conditions 
where basophils were activated and correlated with the degree of activation, as expressed by 
CD63 and CD203c. IL-3 is predominantly produced by T cells and is able to induce basophils to 
release histamine and up-regulate CD203c and CD63 in the absence of allergen
194, 195
. It can also 
act synergistically with allergen or other stimulants to increase basophil activation and histamine 
release
70, 167, 194
. The response to this priming effect is variable between basophil donors and 
requires different concentrations of IL-3
186
. Some research groups have used exogenous IL-3 to 
prime basophils in the BAT
70, 167, 196
.  However, basophils secrete IL-3 themselves in response to 
IgE-mediated activation for autocrine priming, which has been suggested to be a possible 
mechanism underlying the hyper-reactive nature of the basophils of allergic patients
197
. The 
basophil intracellular pathways down-stream of the IL-3 and the IgE receptors seem indeed 
connected
195
. Future studies should test the hypothesis that down-regulation of CD123, which is 
part of the IL-3 receptor, is a negative regulatory mechanism to avoid further cell activation.  
 
8.2 The basophil activation test improved the diagnosis of peanut 
allergy  
In order to arrive at a correct diagnosis of peanut allergy or tolerance, a considerable proportion of 
peanut-sensitised patients seen in Allergy clinics need to undergo an oral food challenge. 
Specialised centres have become over-whelmed with increasing numbers of oral food challenge 
requests; and over-diagnosis of peanut allergy due to over-reliance on allergy tests alone is 
common. Diagnostic cut-off levels have been determined for peanut allergy in some centres
127-131
. 
However, there is a large immunological grey area between 95% PPV and 95% NPV cut-offs for 
SPT, peanut-specific IgE and Ara h 2-specific IgE (Figure 1.6). If one applies a single cut-off value 
based on the ROC curve point-of-inflexion, the diagnostic accuracy of these tests suffers. In BAT, 
the ROC curve optimal cut-off acted simultaneously as positive and negative cut-off with no 
"immunological grey area", allowing for a significant reduction in the number of oral food 
challenges, even amongst difficult patients with conflicting history and results of SPT and specific 
IgE to peanut and peanut components. Unlike for these other tests, BAT allowed the use of the 
ROC point-of-inflexion as a single cut-off value while maintaining a 97% diagnostic accuracy. 
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This is the first study to prospectively validate BAT in an independent population and to evaluate 
its diagnostic performance on its own, in combination and sequentially with other allergy tests as 
well as its impact on the number of oral food challenges
74, 143, 198
. I studied a large population, 
including not only sensitised but also non-sensitised non-allergic patients. Although peanut-
induced basophil activation would not be expected in the absence of peanut-specific IgE, it was 
important to demonstrate the specificity of BAT in NA patients. BAT maintained a good 
performance in an independent population, prospectively recruited to validate the diagnostic cut-
offs. In 44 children with evidence of sensitisation and equivocal allergy test results, three 
specialist doctors were in poor agreement regarding diagnosis and were unable to decide in the 
majority of cases whether or not they were peanut allergic without doing an oral food challenge. In 
contrast, BAT performed very well with 95% diagnostic accuracy in this particularly challenging 
subgroup.  
One of the strengths of the diagnostic study is that participants were carefully clinically 
phenotyped, the vast majority by oral food challenge. In the primary study population, twenty-
three patients were assumed to have peanut allergy, based on SPT and/or peanut-specific 
IgE≥95%PPV cut-offs (previously validated in our clinic's patient population
129
) and recent clear-
cut allergic reactions to peanut reported in the clinical history. This assumption represents a 
potential weakness of the study; however, given the extremely high probability that such patients 
would react clinically, it was decided on clinical and ethical grounds not to challenge them. The 
majority of patients that were challenged underwent DBPCFC (48/61), but 4 children younger 
than 1 year of age and another 9 older children underwent open oral food challenges. The 
majority (7/9) of older children undergoing open oral food challenges had negative challenges 
(open oral food challenge is the gold-standard for peanut tolerance) and the two who had a 
positive oral food challenge had objective unequivocal signs of an allergic reaction immediately 
after peanut ingestion, consistent with the new Practall guidelines' criteria for a positive oral food 
challenge
119
. In 5 patients (4.6%), the oral food challenges were inconclusive, which highlights the 
fact that, although DBPCFC is the gold-standard, it is not fool-proof in the diagnosis of peanut 
allergy
120
. BAT may prove particularly useful in cases where an oral food challenge cannot be 
performed or is indeterminate. In the external validation population, 94% of patients were 
challenged and all positive oral food challenges were DBPCFC.  
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It should be noted that a single day challenge protocol was used, in which placebo and active 
doses were interspersed (Table 2.1, Section 2.2.3.1.). This is not in keeping with the recent 
Practall guidelines
119
 but is in keeping with the LEAP study recommended challenge procedure to 
peanut (registered at http://ClinicalTrials.gov with the identification number NCT00329784)
8, 199
. 
This is done for pragmatic reasons as a large number of children travel from further afield in the 
United Kingdom and it is difficult for them to stay for a 2-day oral food challenge. On the rare 
occasion that a child reacts following a placebo dose then a 2-day DBPCFC is performed in which 
placebo doses are administered on one day and active doses on the other day. Only 2 out of 52 
patients with positive challenges in the severity and threshold study initially reacted following 
placebo on a mixed active-placebo one-day protocol and both these patients had their diagnosis 
of peanut allergy subsequently confirmed using a 2-day DBPCFC.  
The main limitation of the use of BAT for diagnosis was that a proportion of patients had non-
responsive basophils, rendering BAT uninterpretable. The proportion of non-responders found 
(11.5% in the primary study population and 6.2% in the external validation population) was similar 
to that previously described
104, 143, 200, 201
. This is analogous to situations where SPT cannot be 
interpreted because of a negative histamine control or where peanut-specific IgE cannot be 
interpreted in the light of a high polyclonal IgE production or indeed where an oral food challenge 
is inconclusive. Importantly, these are not misdiagnosed patients but cases where BAT is 
uninterpretable and the diagnostic work-up needs to be taken further, namely by doing an oral 
food challenge. The fact that non-responders were almost exclusively (92%) peanut-tolerant 
patients raises the question of whether basophil unresponsiveness through the IgE-mediated 
pathway could be a mechanism underlying peanut tolerance.  
An important consideration is the composition of allergen extracts. In this study, different peanut 
extracts were used for different tests and could have accounted for differences in the results of 
SPT, specific IgE and the BAT and in their ability to diagnose peanut allergy. Nevertheless, the 
same ALK-Abelló peanut extract from the same batch was used for all the basophil and mast cell 
in vitro assays; the same manufacturer was used for the SPT performed in all patients; and the 
specific IgE assays from Thermofisher are well-standardised. Furthermore, all extracts contained 
the peanut major allergens (see section 2.3.3). The fact that the same manufacturer was used for 
SPT and BAT may have contributed to the observed closer performance between these two tests 
compared to the serologic tests.  
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There are a number of other considerations when considering applying BAT in clinical practice. 
BAT needs to be performed on live cells, soon after blood collection, and requires expensive flow 
cytometry equipment and appropriately trained staff. Appropriate standardisation of the laboratory 
procedure, flow cytometry and data analysis would be required for a wider application of the test. 
The development of automated methods and the use of simplified equipment are desirable for 
routine clinical application of the BAT.  
Following the evaluation of the diagnostic performance of the BAT and the other allergy tests by 
ROC curve analysis, the utility of the different allergy tests in the diagnosis of peanut allergy in 
clinical practice, and their impact on the reduction of oral food challenges, comparing this with the 
current strategy adopted in our clinic of combining SPT and specific IgE to peanut was assessed. 
Very few studies have addressed the utility of combinations of allergy tests and this deficiency 
has been highlighted as an unmet clinical need in the NIAID-sponsored food allergy guidelines
3
. 
This was assessed in three ways: considering each test on its own, considering the results of 
different diagnostic tests simultaneously, and considering BAT as a second or third sequential 
step in the diagnostic process, performed in patients where the results of single or combinations 
of standard allergy tests were equivocal. For these analyses, the entire primary study population 
was considered, including patients with non-responder basophils, and interpreted the results of 
the different tests by applying conventional diagnostic cut-offs
44, 129
. The results of tests when 
interpreted individually were considered equivocal if they fell between the negative and the 
positive conventional cut-offs for SPT, peanut-specific IgE
129
 and Ara h 2-specific IgE
44
 or when 
different allergy tests gave contradictory results. The change in the number of oral food 
challenges was compared with the strategy of combining SPT and specific IgE currently adopted 
in our clinic to decide about the need for oral food challenge. 
The impact of BAT was different in the three scenarios considered: single tests, combination of 
tests, and BAT as a sequential step in the diagnostic process (Table 4.10). Considering single 
tests, BAT performed best, followed closely by Ara h2-specific IgE and SPT, even when patients 
with non-responder basophils were taken into account. Peanut-specific IgE performed the poorest 
and required the highest number of oral food challenges. BAT is a unique test as it is a functional 
test and does not present any "immunological grey area" for the patients for whom there is an 
outcome. The same cut-off (based on the ROC point of inflexion 4.78%) that allowed confirmation 
of peanut allergy with 95% certainty also allowed the exclusion of the diagnosis with 98% 
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certainty. The positive likelihood ratio (LR+) of the elected cut-offs of BAT was 24.4 for the point of 
inflexion which is above the level of 10 at which a test is clinically useful
133
, resulting in a high 
post-test probability irrespective of the pre-test probability. Conversely, the negative likelihood 
ratio of BAT was extremely low, which proves very useful in excluding the diagnosis of peanut 
allergy given a negative test result.  
Surprisingly, the use of different combinations of tests provided little, if any, advantage compared 
to BAT alone, with a uniform reduction in the percent of correct diagnoses and a significant 
increase in the number of oral food challenges required. Disappointingly, the combination of tests 
did not result in a consistent decrease in the number of false-negative outcomes. When 
combining results of different diagnostic tests before deciding about the need for oral food 
challenge, the best outcome was to combine two tests among SPT, Ara h 2-specific IgE and BAT. 
Adding more tests (i.e. considering the results of 3 or 4 tests) did not significantly reduce and 
often increased the number of oral food challenge because in the cases where the tests gave 
contradictory results, oral food challenges were required. Combining two allergy tests compared 
to BAT alone decreased the false-negative cases by 2% (SPT + BAT) or decreased the false-
positive cases by 1% (Ara h 2-specific IgE + BAT), depending on the specific combination. In 
particular, adding Ara h 2-specific IgE to SPT and specific IgE to peanut did not improve the 
diagnosis. Adding specific IgE to peanut to other tests resulted in no change or in an increase in 
the number of oral food challenge, further putting into question the diagnostic value of specific IgE 
to peanut when other tests are available.  
Performing BAT as a sequential step reduced the number of BAT tests required (Table 4.10, 
Figure 4.7) and had a major impact in reducing the number of oral food challenges regardless of 
the test performed as first line. For instance, performing BAT following SPT or following Ara h 2-
specific IgE allowed a 97% reduction in the number of oral food challenges compared to the 
combination of SPT and peanut-specific IgE (the routine clinical reference-point in our clinic) and 
a 92% reduction compared to BAT alone. However, this was at the expense of 2 or 3 false-
negative outcomes. To prevent any false-negative cases from occurring as a result of this 
sequential test approach, all the BAT-negative patients would require oral food challenges in 
addition to the patients with equivocal BAT. Even in this more conservative scenario the total 
number of oral food challenges required would be significantly reduced by 64% (SPT followed by 
BAT) or 69% (Ara h 2-specific IgE followed by BAT) compared to combining SPT and peanut-
214 
specific IgE. The decision on whether to increase the number of oral food challenges or of BAT, 
both reducing the possibility of false-negative tests, would depend on a cost-benefit analysis. I 
believe that SPT followed by BAT is better than Ara h 2-specific IgE followed by BAT for practical 
reasons (SPT provides immediate results while Ara h 2-specific IgE followed by BAT would 
require 2 separate blood collections) and given regional differences in the patterns of sensitisation 
to peanut allergens
39
. The 3-step diagnostic strategy further reduced the number of BAT required 
and eliminated the need for oral food challenges but this was at the expense of a higher false-
negative rate, not from BAT but from SPT and Ara h 2-specific IgE.  
A sequential approach was previously proposed by Dang et al
44
 to test the accuracy and practical 
applicability of Ara h 2-specific IgE in the diagnosis of peanut allergy. The exact same approach 
of considering Ara h 2-specific IgE as a second step in the diagnosis of peanut allergy in cases 
where SPT or specific IgE to peanut were equivocal was applied to our own study population. 
BAT correctly diagnosed a higher proportion of patients, resulted in a lower number of false-
negative diagnosis and a greater reduction in the number of oral food challenges, compared to 
Ara h 2-specific IgE. One possible explanation for the superiority of BAT compared to Ara h 2-
specific IgE as a diagnostic test is that BAT is a functional assay that takes into account the 
combined ability of different IgE molecules, when cross-linked by different peanut allergens 
present in the extract, to trigger basophil degranulation. This includes both high and low affinity 
IgE antibodies directed to major and minor peanut allergens (not only Ara h 2 and some of which 
were not tested on ImmunoCAP). Besides, Ara h 2 is not always the most dominant peanut 
allergen in all geographical locations
39
. Even in areas where Ara h 2 is dominant, such as the 
United States, Australia and the United Kingdom, studies have reported cases of peanut allergy in 
which patients test negative to all available peanut components
43, 44, 135
. Also in this study, there 
was one case of a peanut allergic child with detectable IgE to peanut extract but undetectable 
specific IgE to Ara h 2 and to the other peanut components. 
 
8.3 Estimating the severity and the threshold of allergic reactions to 
peanut with the basophil activation test 
Current management of peanut allergy relies on allergen avoidance and the prescription of auto-
injectable adrenaline to patients deemed to be at risk of anaphylaxis. Knowing whether individual 
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patients are at risk of reacting to low amounts of the allergen or of developing severe reactions 
would improve the care for patients with peanut allergy. Apart from resembling very closely the 
clinical phenotype of patients in terms of clinical reactivity to peanut
165
, BAT reflected the severity 
and the threshold of allergic reactions to peanut. Allergen-specific basophil reactivity (as 
measured by CD63 peanut/anti-IgE) and basophil sensitivity (as measured by CDsens) were 
identified as biomarkers of severity and threshold of allergic reactions to peanut during oral food 
challenge.  
This was a prospective study of a well-characterised population of peanut allergic patients that 
were submitted to oral food challenge regardless of the presence of clinical risk factors for severe 
reactions and of the SPT and specific IgE results. In most previously published studies, patients 
with a history of anaphylaxis, current asthma and/or with specific IgE levels above the 95% 
positive predictive value cut-off were often excluded, thereby limiting the spectrum of the disease 
severity studied
202
. Different severity scores have been adopted in different studies, some 
including both symptom score and the eliciting dose. The severity score adopted here had 
previously been validated
148, 203
 and does not include the dose that caused a reaction as the aim 
was to assess these two factors, severity and threshold, independently. Indeed, distinct BAT 
parameters reflected the severity and the threshold of allergic reactions. The best parameter to 
predict severity was the ratio between basophil specific activation in response to allergen and 
basophil non-specific activation in response to anti-IgE. The response of basophils of allergic 
patients to allergen has been reported to be greater than to anti-IgE or anti-FcεRI
192, 200
. In a 
previous study of cow's milk allergic children, the ratio between the percentage of CD63-positive 
basophils in response to cow's milk and to anti-FcεRI was higher in patients with persistent cow's 
milk allergy compared with patients who outgrew their allergy and was correlated with the severity 
of the reaction during challenges
200
.  
In contrast to a study recently published
204
, in which BAT showed no correlation with severity but 
only with threshold, in the present study, BAT informed not only about threshold but also about 
severity of allergic reactions during oral food challenge. Although different severity scores were 
primarily used, in both studies findings were confirmed with other severity scores; thus the 
severity scores used were unlikely to have accounted for the discrepancy between study results. 
These differences might be explained by the adopted oral food challenge protocol. In the cited 
study, oral food challenges were performed over 2 days, with 2-hour intervals between doses up 
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to a cumulative dose of 4.443g of peanut protein
204
. In the present study, oral food challenges 
were performed on a single day with 20-minute intervals between doses and the cumulative dose 
for children older than 3 years was 9.35g
205
. These factors could have contributed to the greater 
severity of reactions during the oral food challenge observed, enabling to identify a biomarker for 
severity. Stronger correlations for threshold were found, logistic regression analyses were 
performed and cut-offs both for severity and threshold were determined in this study
205
. 
Limitations related to the design and performance of the challenges need to be taken into 
consideration, namely the fact that the lowest dose of peanut protein given was 0.033g for high-
risk patients and 0.1g for most patients which is above the published estimated doses calculated 
to cause objective symptoms in 10% of the peanut allergic population (ca. 3mg peanut protein); 
and the fact that challenges were performed with interspersed doses which resulted in variable 
time interval between active doses in different patients. With regards to the assessment of the 
severity of allergic reactions, there may have been some variation in symptom scoring by different 
researchers undertaking the challenges. A list of subjective symptoms and objective signs to be 
ticked by the operator would have been preferable compared to free text for the description of the 
allergic reactions that was used in the case report form.  
SPT and serum specific IgE to peanut have been tested as biomarkers of the severity of allergic 
reactions to peanut. Previous studies showed contradictory results, some finding that SPT and 
serum specific IgE predicted the development of anaphylaxis
26, 206-208
 and others failing to find any 
association between the allergy test results and severity of allergic reactions
24, 202
. In my study, 
patients with severe reactions had higher levels of specific IgE to peanut, to Ara h 1 and to Ara h 





 by patients’ IgE and with increased intensity of bands on immunoblotting as a 
surrogate for antibody affinity and avidity
209
. My study corroborates these findings as patients with 
severe reactions had IgE directed to a larger number of peanut major allergens compared with 
patients with mild/moderate reactions. Interestingly, patients with a higher ratio of peanut-specific 
IgG4 to IgE reacted at higher doses of peanut, supporting the hypothesis that IgG4 competes with 
IgE for binding to the allergen, blocking its effect and preventing degranulation of basophils at low 
concentrations of peanut extract. One of the advantages of BAT is that it is a functional assay that 
takes into account all these factors, including levels, specificity, diversity and affinity of allergen-
specific IgE and even possible interference by other allergen-specific antibodies, which together 
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are responsible for allergen-induced effector cell activation. Therefore, BAT has a greater 
potential to reflect the allergic reaction as it happens in vivo than methods that test these IgE 
parameters separately. This is reflected in my data where, following multivariable analyses, BAT 
parameters proved to be more predictive of severity and threshold of allergic reactions than the 
other tests. 
A relationship between severity and threshold has previously been suggested
212
 with patients who 
react to lower doses being more at risk of developing severe symptoms. In my study and 
others
204, 213
, the clinical parameters of severity and threshold were not correlated. However, a 
strong correlation was found for the respective basophil parameters. This discrepancy could be 
due to the fact that during the BAT the "in vitro challenge" can proceed to higher doses whereas 
in vivo oral food challenges are typically stopped with the first allergic symptoms and signs. The 
severity of allergic reactions during oral food challenges may have been different if a large dose of 
allergen had been consumed at once. The fact that basophil activation can be tested at high 
doses of allergen, regardless of disease severity, is another clear advantage of BAT as a 
biomarker of disease severity compared to oral food challenges. 
The BAT markers identified for severity and threshold of reactions during oral food challenge with 
peanut may not reflect the severity and threshold of allergic reactions in the wider community. 
Hourihane et al
208
 showed that the challenge score correlated with the most recent reaction but 
not with the most severe reaction in the community, suggesting that patients’ reactivity to peanut 
changes over time. Co-factors that can increase the severity of allergic reactions (e.g. 
uncontrolled asthma, viral infections, menstruation, exercise, consumption of alcohol or drugs and 
psychological factors) may be present in the community and are usually controlled during oral 
food challenge. Similarly, variation in the threshold may occur as the eliciting doses during oral 
food challenge can be underestimated, e.g. because the patient feels safe during the oral food 
challenge, but can also be overestimated, e.g. because mild symptoms would remain unnoticed in 
a community setting
175
. Severity and eliciting dose during challenges have not been reproducible 
in other studies, highlighting the limitations of this approach
214, 215
. 
The utility of BAT as a marker for severity and threshold of allergic reactions is to provide 
additional information to the patients. This information should be interpreted in the context of the 
clinical history and the presence of other risk factors. The management of patients should 
continue to be based on patient education and the importance of an emergency treatment plan 
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and appropriate training cannot be over-emphasised, regardless of the magnitude of the allergy 
test results, including BAT. However, BAT can identify patients who are at risk of reacting to small 
amounts of the allergens and of developing severe symptoms who require special attention. 
Further validation of these objective BAT markers in different populations repeated at different 
time points may allow us to identify the subset of high-risk peanut allergic children who may 
require closer monitoring as well as the subgroup of children whose allergy to peanut may be 
spontaneously resolving. Identification of high-risk groups should not be based only on the 
biological markers but also on psycho-social, demographic, behavioural and clinical parameters.  
 
8.4 Additional applications of the basophil activation test 
Being an in vitro surrogate for IgE-mediated reactions, the basophil activation test has an 
immense potential apart from its use for the diagnosis of allergic disease.  
 
8.4.1 Determination of biological activity of allergens using the basophil activation test 
Previous observational evidence demonstrated that sensitisation to peanut may occur through the 
skin
88
. Household peanut consumption, which is a marker for environmental peanut exposure, 
was identified as a risk factor for the development of peanut allergy
145
 and was positively 
correlated with peanut protein levels in the home environment
213
. Following on from these 
findings, I determined that peanut protein in house dust was biologically active and able to 
activate basophils from peanut allergic children
213
. 
The presence of biologically active peanut protein detectable in dust supports the concept that 
environmental peanut exposure can lead to peanut allergic sensitisation. To give more weight to 
the notion that peanut in dust can sensitise young children, the aim was to confirm that the peanut 
levels that were measured in house dust were biologically significant in peanut allergic patients. 
The ability of peanut protein in dust to cause allergen-specific activation of basophils from children 
with peanut allergy was indeed demonstrated. Peanut protein in household dust induced a dose-
dependent activation of basophils from children with peanut allergy, resulting in a bell-shaped 
dose-response curve typical of allergen-induced basophil activation, comparable with the dose-
response to similar concentrations of an independent peanut standard. These observations are 
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highly suggestive of a peanut-specific basophil response. Given that these children were solely 
allergic to peanut and neither sensitised nor allergic to any other food or airborne allergen, 
basophil activation was very unlikely to have been caused by allergens other than peanut present 
in the dust samples (e.g., house dust mite or grass and tree pollen allergens). The allergen-
specific response was further confirmed by the fact that activation was not observed when 
basophils from non-allergic children were stimulated with the high peanut level–containing dust 
samples. Furthermore, the inability of dust samples with negligible levels of peanut to cause 
basophil activation in both children with peanut allergy and non-allergic children excludes non–
allergen-specific basophil activation. Taken together, these findings confirm that peanut allergens 
in house dust are able to interact with immune cells, such as basophils. I supposed that, being 
biologically active, peanut allergens in house dust are not only able to activate mast cells and 
basophils but also to be captured by dendritic cells and presented to T cells in the context of a 
Th2-driven immune response leading to allergic sensitisation. 
 
8.4.2 In vitro basophil and mast cell assays as surrogates for in vivo tests for 
autoimmunity 
In a collaborative project, using a novel quantitative calibrated ELISA method, a subset of 
asthmatics were identified as having circulating anti-IgE antibodies in higher levels compared with 
non-atopic non-asthmatic controls, irrespective of their atopic status. These anti-IgE antibodies 
were not present in all asthmatics studied and did not distinguish atopic and non-atopic 
asthmatics. Furthermore, their levels were not always associated with their function. Some of 
these anti-IgE antibodies were able to elicit basophil activation whilst others interfered with the 
allergen-IgE interaction resulting in inhibition of allergen-induced basophil activation.  
Activatory anti-IgE auto-antibodies could be responsible for asthma exacerbations in patients with 
intrinsic asthma or in patients with allergic asthma when asthma exacerbations develop 
independently of allergen exposure. Inhibitory anti-IgE auto-antibodies could explain the poor 
correlation between their levels and their function in some patients
216, 217
. It could also explain why 
some patients with allergen-specific IgE do not respond clinically when exposed to allergens and 
why some asthmatics do not improve when treated with omalizumab. The vigorous IgG4 
response to allergen-specific immunotherapy could potentially include anti-IgE antibodies. The 




; however, inhibitory auto-antibodies could also be implicated. Similarly, inhibitory 
anti-IgE antibodies could be involved in the natural development of food tolerance and in 
resolution of existing food allergies, but this requires further studies. 
Of note, the activities of these auto-anti-IgEs are quite different from those of omalizumab, the 
monoclonal antibody anti-IgE used therapeutically. Firstly, they seem to bind to different portions 
of the IgE molecule. Previous studies suggest that the majority of anti-IgE auto-antibodies 
recognize the Cε2 or Cε4 domains of IgE, and not the Cε3 domain to which omalizumab binds and 
which is thought to be inaccessible when the IgE is bound to its high- or low-affinity receptors. 
Secondly, they have different mechanisms of action. Omalizumab exerts its clinical effects by 
preventing binding of IgE to its high- and low-affinity receptors, and does not appear to reduce the 
intrinsic sensitivity of basophils to activation. On the contrary, recent experiments by MacGlashan 
and colleagues suggest that sequestration of IgE during omalizumab therapy renders basophils 
hypersensitive to activation by cross-linking of reduced surface-bound IgE molecules, at least 
partly by resetting of FcεRI coupled intracellular signalling
219, 220
. The auto-anti-IgE antibodies 
studied here were either activatory or inhibitory. The former induced basophil and mast cell 
degranulation by cross-linking of receptor-bound IgEs, similar to what happens following exposure 
to allergen. The latter seemed to exert their effect by interfering with the allergen-IgE interaction, 
i.e. by preventing binding of allergen to IgE they prevent mast cell and basophil activation.  
 
8.4.3 Basophil intracellular signalling 
It is possible to assess the phosphorylation of intracellular signalling mediators at the same time 
as assessing the up-regulation of activation markers on the surface of basophils by flow 
cytometry. It is important to ensure that, despite permeabilisation of the cell membrane, CD63 
which is present on the membrane of intracellular granules is not detected on the surface of 
resting cells. Although this marker is present on the surface of granules inside the cell, it only 
becomes expressed on the plasma membrane at the cell surface after basophil activation. Flow 
cytometry allows the study of intracellular signalling in a heterogeneous mixture of blood cells, as 
opposed to western blotting which requires cell purification. Using flow cytometry, I assessed the 
phosphorylation of activatory intracellular signalling molecules down-stream of FcεRI, such as Syk 
and p38MAPK, and simultaneously assessed changes in the expression of activation markers in 
basophils, such as CD63. Studying cell signalling is valuable in addressing the mechanisms of 
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effector cell activation and inhibition. Ideally, I would also have liked to assess the changes in 
phosphorylation of the inhibitory mediators such as SHIP; however, there are no appropriate 
monoclonal antibodies available for use in flow cytometry.   
 
8.5 Mechanisms of peanut allergy and peanut tolerance: differences 
in IgE or IgE inhibition? 
Peanut-specific IgE does not equate to clinical peanut allergy. The majority of peanut-sensitised 
patients are peanut-tolerant, i.e. are able to eat age-appropriate amounts of peanut without 
developing an allergic reaction. It is possible that different mechanisms underpin tolerance to 
peanut in different subgroups of PS patients. In some cases, the absence of clinical reactivity in 
PS patients is due to the specificity of IgE for peanut proteins which are not able to cause 
degranulation of effector cells leading to systemic reactions; for example, PS patients with IgE 
that does not recognise any of the major peanut allergens and binds only to Ara h 8 or Ara h 9 in 
the cohort studied here.  In other cases, particularly of PS patients with IgE directed to the major 
peanut allergens (such as Ara h 1, Ara h 2 and Ara h 3) that are known to be able to elicit effector 
cell activation and degranulation
46, 47
, and would otherwise be a strong predictor of peanut allergy, 
inhibition of IgE by blocking antibodies may underlie the absence of allergic symptoms following 
peanut ingestion. In this study, I showed that plasma of PS patients were able to inhibit IgE-
mediated peanut-induced basophil and mast cell activation, to a similar extent as plasma from 
patients submitted to POIT, and that this effect was partially mediated by IgG4. These findings 
suggest that oral tolerance to foods is in part mediated by IgG4 in a subset of patients that 
produce IgE antibodies and may also explain why there are so many more sensitised than allergic 
individuals. 
Using passive sensitisation mast cell and basophil assays, previous findings in a whole blood 
basophil activation assay
165
 were reproduced and it was confirmed that the factors responsible for 
allergen-induced effector cell activation and unresponsiveness in PA and PS patients are present 
in the plasma. Other evidence supports a role for plasma rather than cellular intrinsic factors in 
clinical reactivity to peanut. Clinically, PS patients who are able to eat peanut without any 
problems are often allergic to other foods and airborne allergens. This indicates that their 
basophils and mast cells are functional and able to respond to allergens. Experimentally, 
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basophils from PA and PS patients have similar IgE receptor expression on their surface and are 
able respond to IgE-mediated stimulants other than allergen
156, 221
. Therefore, intrinsic differences 
in cell reactivity between PA and PS children seem an unlikely explanation for the discrepancy 
between allergy and sensitisation.  
The use of LAD2 cells in the passive sensitisation assays offered additional advantages 
compared to using primary human basophils. Firstly, being a cell line, LAD2 cells are readily 
available as they are stable in culture for long periods of time. Secondly, as they maintain their 
characteristics over time, LAD2 cells constitute a source of standardised effector cells, enabling 
the comparison of the effect of plasma from different patients, namely PA, PS, NA and patients 
undergoing peanut immunotherapy, in a reliable and consistent way. Finally, being mast cells, 
LAD2 cells allow the study of the other type of effector cells involved in the immediate phase of 
acute allergic reactions, apart from basophils. These mast cell assays may become particularly 
useful tools to explore the mechanisms of peanut allergy and tolerance (as they allow the study of 
the role of different serological components, namely of different antibody isotypes, in IgE-
mediated peanut-induced mast cell reactivity) and also to assess the response to 
immunomodulatory treatment for peanut and other food allergies and allergic diseases as a 
biomarker for clinical improvement, in the future.  
At the population level, the median serum levels of peanut-specific IgE were higher in PA 
compared to PS patients. This has been documented in different studies and has formed the 
basis of the development of diagnostic cut-offs for peanut-specific IgE
128, 129
. However, at the level 
of the individual, there was a substantial overlap between PA and PS patients. As described in 
section 4.5, a subgroup of peanut-sensitised patients with equivocal diagnosis showed no 
statistically significant differences in the levels of specific IgE to peanut components between PA 
and PS patients, except for Ara h 2
165
. PA patients were more likely to have IgE directed to Ara h 
2 alone or to Ara h 2 in combination with the other peanut major allergens compared to PS 
subjects, and had higher levels on average. However, some PA patients did not have detectable 
IgE to Ara h 2 and conversely some PS patients had Ara h 2-specific IgE above the cut-offs that 
have been identified as being associated with a high probability of clinical peanut allergy
44, 165
. 
Various examples of PA and PS patients with the same IgE sensitisation pattern to peanut 
allergens but with opposite clinical outcomes could be found in this cohort and are shown in 
Tables 7.4 and 7.9. Taken together these observations demonstrate that the levels and specificity 
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of peanut-specific IgE do not account for the differences in allergic reactivity to peanut in all cases 
of PA and PS patients.  
The hypothesis of a peanut-specific antibody counteracting the ability of peanut-specific IgE to 
activate and degranulate basophils and mast cells becomes particularly plausible in cases where 
peanut-specific IgE is high and/or when it is directed to peanut allergens that are known to be 
potent elicitors of effector cell activation, such as Ara h 1, Ara h 2 and Ara h 3. In these cases, 
IgG4 antibodies, and possibly peanut-specific antibodies of other isotypes, block IgE either by 
competing with IgE for binding to the peanut allergens or by inhibiting an activatory response at 
the cellular level by co-cross linking of IgE and ITIM-associated receptors, to which the inhibitory 
antibodies bind
222
. In my study, peanut-specific IgG4 levels were higher in PS compared to PA 
patients but the levels of IgG4 to peanut components were similar between the two groups, 
except for Ara h 2. Also in a previous study of egg allergic children, specific IgG4 levels to 
ovomucoid or ovalbumin were not significantly different between baked egg-allergic and tolerant 
children. My findings regarding IgG4 were similar in PS samples and samples of patients 
submitted to POIT. This is consistent with other POIT studies
110, 223, 224
 where IgG4 has been 
reported to increase substantially with treatment and is thought to have a role as a blocking 
antibody. In some PA and NA patients with detectable peanut-specific IgG4 these antibodies are 
likely to be directed to non-allergenic components of peanut or to different epitopes of peanut 
allergens compared to IgE and thus have no ability to block the effect of IgE. In PA patients, this 
results in IgE-mediated effector cell reactivity whereas in NA patients tolerance results from the 
absence of peanut-specific IgE in the first instance. Furthermore, in NA subjects, the absence of 
inflammatory response against the allergens and the fact that B cells are not affinity matured are 
likely to result in IgG4 antibodies of low affinity that are not able to block IgE. 
The relative amounts of IgG4 compared to IgE, rather than absolute antibody levels, is likely to be 
an important factor driving IgE inhibition. The ratio of IgG4 to IgE to peanut was significantly 
higher in PS compared to PA patients, indicating that the excess of peanut-specific IgG4 in 
relation to IgE could block peanut-specific IgE and contribute to the absence of clinical reactions 
to peanut in PS patients. In the literature, IgE/IgG4 ratios are usually reported and are often not 
corrected for the fact that the levels of IgE and IgG4 are usually measured in different units (IgE in 
KUA/l and IgG4 in mg/l)
166, 225, 226
. I have calculated IgG4/IgE ratios considering the absolute 
amounts of these immunoglobulins in nanograms present in the serum of each patient at any 
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given moment which more accurately reflects the balance between the two types of antibodies 
that potentially have opposite effects. The ratio of IgG4/IgE to the peanut major allergens was 
also higher in PS, particularly to Ara h 2 which is believed to be the most potent elicitor of effector 
cell degranulation and consequently of allergic reactions to peanut
46
. My findings are consistent 
with previous observations in patients submitted to POIT where the increase in specific IgG4 was 
greatest for Ara h 2-specific IgG4 compared with IgG4 directed to the other peanut allergens
227
 or 
where the increase in Ara h 2-specific IgG4 matched the sensitisation profile of existing IgE
114
. 
These observations support the concept that Ara h 2 is a dominant allergen in peanut allergy and 
that IgG4 responses associated with clinical improvement tend to counteract existing IgE 
responses.  
The role of IgG4 in IgE inhibition in PS and POIT samples was confirmed by depleting this 
antibody subclass from patients' plasma and observing an overall increase in peanut-induced 
mast cell activation. The fact that IgG4-depletion had only a partial effect suggests that other 
antibody isotypes could also have an inhibitory effect on IgE. For example, peanut-specific IgA 
antibodies could contribute to the competition with IgE for binding to peanut allergens and 
contribute to the overall IgE inhibitory effect; however, in this population serum peanut-specific 
IgA was only detectable in a minority of patients and did not show any differences between PA 
and PS groups. This, however, does not exclude a possible role for secretory IgA at mucosal 
surfaces which is not present in significant levels in the plasma. Although in a mouse model of 
anaphylaxis, circulating IgA rather than enteric IgA were able to suppress IgE-mediated 
anaphylaxis
228
, in a previous study of grass pollen immunotherapy, IgA isolated from the serum of 
treated patients did not show blocking activity
229
. Peanut-specific antibodies of other isotypes 
could also have some blocking effect but have not been measured in this study as there are 
currently no validated assays to quantify absolute levels of such allergen-specific antibodies.  
There are other factors that may be explored in order to obtain a complete understanding of the 
mechanisms by which IgE and allergen may or may not be able to elicit effector cell activation that 
is responsible for the clinical manifestations of allergic disease. These include the role of IgE 
affinity as well as the specific epitopes to which IgE binds
230
. It is possible that two IgE molecules 
that are specific for the same peanut allergen recognize different epitopes in the allergen 
molecule or bind to the same epitope with different affinities leading to more or less potent 
effector cell activation. The determination of IgE and IgG4 binding to linear peanut peptides with 
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the aim to identify the dominant IgE and IgG4 epitopes on peanut allergens is an ongoing project 
described in Section 8.6.4. With regards to IgE affinity, preliminary experiments were performed 
using surface plasmon resonance to measure affinity of IgE for the purified peanut allergen Ara h 
2 and compare it between plasma samples of PA and PS patients.  However these experiments 
were not pursued due to the various technical limitations of this approach. Firstly, these 
experiments were restricted by the low concentration of allergen-specific IgE in plasma samples, 
of which there was limited volume; secondly, the patients' polyclonal IgE response had varying 
specific activity (i.e. proportion of IgE that is allergen-specific); and finally, non-specific binding of 
plasma proteins to the sensor chip surface prevented the detection of genuine allergen binding by 
surface plasmon resonance. IgG depletion from plasma prior to surface plasmon resonance and 
the use of different chemical methods to remove the proteins bound to the sensor chip did not 
resolve the latter problem.  An alternative approach would be to purify IgE and run purified IgE 
over the cell containing the IgG4-Fc(sFcεRIα)2 fusion protein; however, this would require large 
volume of samples, which were not available from the most interesting cases of peanut sensitised 
but tolerant infants and young children. Another alternative approach would be to use monoclonal 
antibodies generated from single peripheral blood B cells (described in section 8.6.4.). 
Monoclonal IgE antibodies bound to the IgG4-Fc(sFcεRIα)2 fusion protein or captured by anti-IgE 
antibodies previously coupled to the sensor chip would be ideal to study the affinity of IgE for Ara 
h 2. This way the issues of low concentration of allergen-specific IgE, polyclonality of the IgE 
response, low volume of samples and unspecific binding to the cell surface would be obviated. 
Christensen et al
231
, using a panel of recombinant monoclonal anti-Der p 2 IgE antibodies with 
defined epitope specificity, clonality and affinity in different combinations, showed very elegantly 
that greater specific IgE concentration, greater specific activity to Der p 2 and greater epitope 
diversity increased basophil reactivity whereas greater affinity increased basophil sensitivity. 
Arguably, in individual peanut-sensitised patients, the clinical phenotype results from a 
combination of characteristics of the existing pool of peanut-specific IgE antibodies directed to a 
certain allergen, as well as of the inhibitory activity of IgG4 and possibly other immunoglobulin 
isotypes. Additionally, intrinsic differences in the IgG4 molecules relating to affinity and epitope 





In summary, both differences in IgE and IgE inhibition can explain the discrepancy between 
allergic sensitisation and clinical allergy to peanut. In the population studied, patients submitted to 
immunotherapy fit the "desensitisation" profile described in Section 1.8.1.; whereas PS patients 
can correspond to the "stable sensitisation", "post-allergic sensitisation" or even the "antenatal 
sensitisation" or the "pre-allergic sensitisation" profiles. In any case, the clinical phenotype, of 
allergy or tolerance, is likely to result from a combination of relative amounts, specificity, affinity 
and clonality of IgE antibodies as well as of possible inhibitory antibodies such as IgG4, specific 
for the allergen.  
 
8.6 Future perspectives 
8.6.1 Application of the basophil activation test to participants in the LEAP and LEAP-On 
studies 
The LEAP study is a randomised controlled trial aimed to assess whether early introduction of 
peanut prevents the development of peanut allergy
8
, as described in section 2.1.2. The primary 
outcome is the prevalence of peanut allergy, determined by oral food challenge, at the age of 60 
months (5 years). In a follow-on study (the LEAP-On study), participants in both arms of the LEAP 
study will avoid peanut for 1 year and will undergo another oral food challenge at the age of 72 
months (6 years). The LEAP-On study addresses the question as to whether early introduction of 
peanut induces transient desensitisation or long-term tolerance raised by the fact that some 
infants were already sensitised when peanut was introduced in their diet at the start of the study. 
Participants in the LEAP and LEAP-On studies have been assessed at recruitment, at 12, 30, 60 
and 72 months of age and blood samples have been collected at all these time points. Following 
the validation of BAT to peanut during my PhD, BAT has been performed in the LEAP and LEAP-
On studies (2 time-points) under my direct supervision in real-time on the day when participants 
undergo the oral food challenge. This is supported by funding obtained from the Immune 
Tolerance Network and the National Institute of Allergy and Infectious Diseases, in the United 
States of America.  
The performance of the basophil activation test using samples collected from participants in the 
LEAP and LEAP-On studies will further the scientific achievements reported in the present PhD 
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thesis. The data analyses at the end of the LEAP and at the end of the LEAP-On studies will allow 
accomplishing the following objectives: 
1. Further validate the BAT as a diagnostic marker for peanut allergy as it correlates very closely 
with disease expression at the level of the individual;  
2. In secondary analyses, BAT may be used as a surrogate marker of peanut allergy versus 
tolerance, i.e. as a secondary endpoint, in study participants where standard clinical methods 
have failed, namely in children who refused an oral food challenge or whose oral food challenge 
had an indeterminate outcome; 
3. Validate the use of BAT to predict the severity and the threshold of allergic reactions to peanut 
during DBPCFC; 
4. Assess the results of BAT and the other immunologic outcomes (such as IgE, IgG4 and 
IgG4/IgE ratios) in relation to the study intervention. It would be of interest to relate the results of 
BAT directly with the other immunologic parameters.  
The compared analyses of the results of BAT at the two time-points, both at the end of the LEAP 
and at the end of LEAP-On studies, will help to describe immunologically whether early peanut 
consumption induces transient desensitisation (in which case an increase in basophil reactivity 
over time will be seen, with a shift in the dose-response to the left towards lower concentrations of 
peanut between v60 – v72) or long-term oral tolerance (in which case, there will be no significant 
change in the results of BAT between the two time-points) - Figure 8.1. 
 
Figure 8.1 Basophil activation test in the LEAP and LEAP-On studies. 
Examples of hypothetical peanut dose-response curves of CD63 expression in patients in the LEAP (continuous blue line) 




8.6.2 Validation of other tests for the diagnosis of peanut and other food allergies 
A novel mast cell degranulation assay using the LAD2 mast cell line was developed, where cells 
were sensitised with plasma from PA, PS or NA patients and the expression of activation markers 
following stimulation with allergen was assessed by flow cytometry. This experimental system 
reflected in vitro the clinical reactivity or tolerance to peanut and reproduced what happened when 
basophils in patients’ whole blood are stimulated with peanut proteins. The mast cell activation 
test (MAT) may be valuable in the diagnosis of peanut allergy. I aim to test the samples of the 
patients recruited for the BAT study to further validate this potential diagnostic test. I will define 
diagnostic cut-offs for MAT to peanut and relate the results of MAT to the results previously 
obtained for BAT. The MAT has important additional value to BAT both for the diagnosis of food 
allergy and for mechanistic studies. For diagnosis, the MAT has the advantage of not requiring 
the use of fresh blood samples and thus allowing testing patients whose samples were collected 
at centres located far from the laboratory as well as testing in parallel samples that were collected 
at different time points. For mechanistic studies, the passive sensitisation design allows to study 
the functionality of antibodies and other serological factors mediating effector cell response.  
The use of the basophil activation test as a diagnostic test for peanut allergy can be applied to 
other food allergies, namely cow's milk, egg, seed and tree nut allergies. The performance of 
these tests will be compared to oral food challenge (the gold-standard) and specific diagnostic 
cut-off values will be generated for each food. I anticipate that the BAT will have diagnostic value 
and will enable to reduce the need for oral food challenges to accurately diagnose these food 
allergies. Similarly, a MAT could be developed to other food allergens in parallel with the 
validation of BAT.  
BAT and MAT may be applied to future immunomodulatory studies in patients with existing 
peanut allergy as a biomarker for clinical improvement, namely in patients undergoing allergen-
specific immunotherapy (e.g. oral, sublingual, and epicutaneous) and other treatments such as 
omalizumab or herbal formulas.  
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8.6.3 Improving the management of peanut allergy 
The BAT informed about the severity and the threshold of allergic reactions to peanut: patients 
with severe symptoms on oral food challenge had higher basophil reactivity (as measured by the 
percentage of CD63-positive basophils in response to peanut and to anti-IgE) and patients who 
reacted to lower doses of peanut on oral food challenge had higher basophil sensitivity (as 
measured by a lower effective dose of allergen on the BAT).The use of the BAT to predict the 
severity and the threshold of allergic reactions to peanut and to other foods requires validation in 
other patient populations before it can be translated to clinical practice.  
Future studies on the stability of BAT over time and during different periods of the year (e.g. hay 
fever season, asthma exacerbations) would also be informative. While BAT parameters may not 
completely distinguish between those patients with severe reactions who respond to a low 
threshold of reactivity and those with milder reactions and a higher threshold dose, they may 
prove to be far more accurate in discriminating changes in the clinical threshold and severity in 
the same individual over time. It has already been shown that BAT to peanut, egg and milk 
decreases in patients who have undergone oral immunotherapy
110, 111, 232
. It would be of great 
value to look at the stability of BAT over time in untreated patients and at the change in BAT 
parameters in patients undergoing oral immunotherapy to foods and comparing this to post-
treatment challenge outcome measures. 
 
8.6.4 Further unravelling the mechanisms of peanut allergy and tolerance 
A complete understanding of the mechanisms by which IgE and allergen may or may not elicit 
effector cell activation, that is ultimately responsible for clinical manifestations of allergic disease, 
requires a molecular approach. A combination of specificity, diversity and affinity of allergen-
specific IgE antibodies seems to determine allergen-induced basophil activation. IgE of PA and 
PS patients may recognise different peanut allergen epitopes, with different location, which may 
have different numbers of repeats (in oligomeric allergens) and/or combinations in the allergen 
molecule. This could result in effector cell activation in the case of PA and not in the case of PS 
patients. PS patients have higher relative titres of IgG4 antibodies compared to IgE and their IgE 
and IgG4 epitopes match, enabling an efficient blocking effect. The affinity of IgE and IgG4 for the 
allergens may also be important. 
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In future studies, I aim to identify and compare IgE and IgG4 epitopes on peanut allergens by 
testing existing plasma samples from PA and PS patients in this cohort on a microarray of linear 
synthetic overlapping peptides covering the complete protein sequences of all known peanut 
allergens. Using molecular modelling methods, I will determine the location of specific IgE and 
IgG4 epitopes in the known three-dimensional structure of the allergen molecules and will 
compare the epitopes recognised by IgE and IgG4 antibodies between PA and PS patients. 
Finally, I will determine the clinical relevance of these epitopes experimentally using peanut 
allergens mutated at specific sites and a combination of well-characterised monoclonal 
recombinant IgE and IgG4 antibodies on the basophil and mast cell assays.  
Allergen-specific monoclonal IgE and IgG4 antibodies can be generated from blood samples by 
single B cell cloning
151
. Thus, peanut-specific monoclonal antibodies can be engineered using 
blood samples of PA and PS patients. Allergen-specific monoclonal IgG4 antibodies can also be 
generated from monoclonal IgE antibodies by modification of the DNA encoding for the constant 
region of the heavy chain that is assembled into an expression vector using a published method 
developed by investigators at King's College London with whom I have collaborated
233
. Testing 
various combinations of monoclonal peanut-specific IgE antibodies generated from blood cells of 
PA or PS patients with known epitope specificity, affinity and clonality, in the mast cell activation 
assay will allow me to understand how the characteristics of the antibodies change effector cell 
activation. Similarly, testing monoclonal peanut-specific IgG4 antibodies generated from 
monoclonal peanut-specific IgE antibodies or from blood cells of PS patients in the inhibition of 
mast cell activation assay will allow me to understand the mechanism by which IgG4 inhibits IgE 
and how the various characteristics of the IgG4 antibodies can modify IgE inhibition. 
IgG4 can inhibit the IgE-allergen interaction either by competition for binding to the allergen 
and/or by co-cross-linking of IgE and IgG4 on the surface of effector cells and consequent 
elicitation of the inhibitory signalling downstream the FcγRII and the FcεRI receptors. The 
clarification of the mechanism by which IgG4 inhibits IgE would require inhibition of basophil or 
mast cell activation assays with a combination of removal of plasma and blockage of FcγRII 
receptors before stimulation with allergen with simultaneous analyses of the expression of 
activation markers and intracellular activatory and inhibitory signalling molecules, such as Syk 
and SHIP, for example. If the IgG4 mechanism was purely competition with IgE for binding to the 
allergen, effector cell activation would be higher when the plasma is removed, blockage of FcγRII 
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would not make any difference and there would be no significant phosphorylation of SHIP 
following stimulation with allergen. On the contrary, if the mechanism of IgG4 consists on 
inhibition of the intracellular signalling pathway downstream the FcεRI receptor as a result of co-
cross-linking, removal of the plasma would not make a difference in effector cell activation 
whereas blockage of FcγRII potentiates this activation and there is increased phosphorylation of 
SHIP following stimulation with allergen. There is also the possibility that both mechanisms 
coexist, i.e. that competition with IgE for binding to the allergen and intracellular inhibition happen 
simultaneously.  In this case, the results of the described hypothetical experiments described (i.e. 
removal of plasma, blockage of FcγRII and intracellular signalling) would be a combination of the 
expected results for each of the possible mechanisms, as described above.   
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8.7 Final conclusions 
 The basophil activation test diagnosed peanut allergy with 97% accuracy (98% sensitivity, 
96% specificity, 95% positive predictive value and 98% negative predictive value) and allowed 
a reduction in the number of oral food challenges of two thirds (66%). 
  In an independent population, prospectively recruited for external validation, the basophil 
activation test had 100% specificity, 83% sensitivity, 100% positive predictive value and 90% 
negative predictive value in the diagnosis of peanut allergy. 
 The basophil activation test proved particularly useful in cases where conventional allergy 
tests failed to diagnose peanut allergy and would otherwise need an oral food challenge to 
clarify their allergic status. Used as a second step in the diagnostic process and performed 
only in selected cases, the basophil activation test maintained a high diagnostic accuracy 
(95%) and further reduced the required number of oral food challenges by 97%.  
 The basophil activation test can be used as an in vitro surrogate for oral food challenges to 
estimate the severity and the threshold of allergic reactions to peanut and improve the 
management of patients with peanut allergy.  
 Patients with severe reactions had a higher proportion of activated basophils in the basophil 
activation test than patients with milder symptoms. The dose of peanut protein to which the 
basophils reacted in the basophil activation test was associated with the dose at which 
patients reacted on oral food challenges. This information should be interpreted in light of the 
presence of other risk factors and can help identifying high-risk patients who require closer 
monitoring and intensified education.  
 The basophil activation test may also be useful as a sensitive method to detect the presence 
of allergens and its biological activity in complex mixtures, such as foods or environmental dust 
samples. 
 The basophil activation test may also be useful to test the function of auto-antibodies directed 
to IgE or its high affinity receptor.  
 Although immediate-type food allergy is an IgE-mediated disease, there is a great discrepancy 
between the levels of allergen-specific IgE and clinical allergy. IgE levels to individual peanut 
allergens could not explain the discrepancy between peanut allergy and peanut sensitisation 
as there was a large overlap between peanut allergic and peanut tolerant patients.  
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 The levels of IgG4 to peanut and to individual peanut allergens were mostly comparable 
between peanut allergic and peanut-sensitised but tolerant children. However, the ratio of 
specific IgG4 to IgE was significantly higher in peanut-sensitised but tolerant compared to 
peanut allergic children, suggesting that the excess of IgG4 specific for peanut allergens may 
play a role in the absence of effector cell response characteristic of peanut tolerance.  
 Plasma samples from peanut-sensitised but tolerant children inhibited peanut-induced 
activation of basophils and mast cells sensitised with plasma from peanut allergic patients. 
Depletion of IgG4 antibodies from plasma samples of peanut-sensitised but tolerant patients 
with IgE directed to the major peanut allergens partially restored mast cell activation, 
supporting the hypothesis that IgG4 plays a role in IgE inhibition in tolerant but sensitised 
patients.  
 An improved understanding of the immune mechanisms underlying the dysregulation of oral 
tolerance in allergic patients and particularly of the mechanisms underlying its regulation in 
patients that are tolerant despite allergen-specific IgE will contribute to definitive treatment and 
prevention strategies for food allergy, particularly in children. For example, it could lead to the 
development of hypoallergenic allergen molecules with retained immunogenicity and modified 
IgE epitopes that could be safely and effectively used for immunotherapy, or to the 
development of epitope-specific IgG4 monoclonal antibodies that could be used to treat allergy 
or even to prevent the development of allergy in sensitised patients. The known anti-
inflammatory properties of IgG4
234
 make it a particularly interesting vehicle for a biological 
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